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OPIATES AND HYPOTHALAMIC MONOAMINERGIC REGULATION OF LH
RELEASE IN THE RAT
S U M M A R Y
Monoaminergic regulation of LH release appears to be 
influenced by the endogenous opioid peptides. Specific opioid 
receptors exist within the central nervous system and are 
richly concentrated within the hypothalamus. The present 
study was undertaken to investigate the effects of specific 
opiate agonists on hypothalamic monoaminergic activity.
In the first set of experiments, various opioid receptor 
agonists or their antagonist, naloxone, were administered 
intracerebroventricularly (icv) to short-term orchidectomized 
rats and blood samples were collected at pre-determined 
intervals. The animals were decapitated either at 20 minutes 
or at two-hours post-treatment, and the hypothalamus was 
surgically isolated.
In the second set of experiments, rats were treated with 
specific opioid receptor agonists, or their antagonist, 
during the early afternoon of pro-oestrus prior to the 
preovulatory LH surge. The animals were decapitated after an 
interval of two hours and the brains removed. Trunk blood was 
collected for LH measurement by radioimmunoassay. In one 
group of animals, the whole hypothalamus was dissected out; 
in another group, specific hypothalamic regions of the 
hypothalamus were isolated by a micropunch technique. 
Homogenates of either the whole or of specific hypothalamic
ii
regions were prepared and concentrations of noradrenaline 
(NA), adrenaline (ADR), dopamine (DA), serotonin (5-HT) and 
its metabolite 5—hydroxyindoleacetic acid (5-HIAA) were 
measured using high performance liquid chromatography coupled 
to an electrochemical detector. NA and DA turnover rates 
were estimated by the blockade of the synthesis of these two 
amines using the enzyme-blocker alpha-methy1-para -tyrosine. 
5-HT turnover was measured by obtaining the ratio between 
5-HT and 5-HIAA.
The results are detailed below:
Table 1. Effects of opiates on plasma LH and the hypothalamic 
monoamine turnover in short-term orchidectomized rats.
Hypothalamic Turnover 
NA/DA/5-HT
< X ES 22 3  > ✓ < S3 —  S> >
0/0/0 
—/+/0 
- / o / -  
0/+/0
+ Increase, - Decrease, 0 No effect.
<r'* Number of observations.
It was observed that the opiates, in general, caused a 
decrease in NA and 5—HT turnover and an increase in DA 
turnover in the hypothalamus of the short-term 
orchidectomized rat. The changes in hypothalamic DA turnover 
were not consistently associated with changes in LH levels.
Drugs Receptor LH
Properties
opiate 
Naloxone antagonist
Morphine mu-agonist
Cyclazocine kappa agonist
SKF 10,047 sigma agonist
Table 2. Effects of opiates on plasma LH and monoamine 
turnover in the whole or specific regions of the hypothalamus 
in pro-oestrous rats.
Drugs LH W.H. SCH MPO AHA ME ARN VMH
Naloxone + +/0/0 0/0/0 +/ + /0 0/0/0 0/+/0 0/+/0 0/0/0
Morphine - 0/+/0 - / o / o -/o/o - /o/o 0/0/- 0/+/0 -/o/-
Tifluadom -
< 1-.: —  o g o n  1 m  t  >
+/0/— - / o / - 0/ + /0 0/0/- 0/0/0 0/0/0 -/+/-
S K F 1 0,047 0 0/0/0 - / o / - -/ +  /0 0/0/- 0/0/- — / +/0 0/+/0
+ Increase, - Decrease, 0 No effect . (W.H. — Whole Hypothalamus)
(Number of observations, 5-24 animals in each group)
In the hypothalamic regions studied, opiate agonists 
either decreased or had no effect on NA turnover whereas the 
antagonist naloxone had the opposite effect. Surprisingly, DA 
turnover was increased by both the opiates and by their 
antagonist, naloxone. 5-HT turnover was significantly 
decreased by the opiates in most of the regions studied, but 
was unaffected by naloxone.
In conclusion, there exists a heterogenous group of 
opioid receptors within the hypothalamus which modulate 
monoamine neurotransmitters controlling LH release.
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U M T I S O I D I I I I C T r i l C D M
1The Central Control of Reproductive Processes
The understanding of the neuroendocrine mechanisms that 
control reproduction is complicated because of the 
involvement of several different neuronal systems within the 
brain. An attempt has been made here to briefly review the 
current understanding of the neuronal mechanisms involved in 
the release of LH. This includes the participation of the 
opioid, monoaminergic and gonadotrophin-releasing hormone 
(GnRH) neuronal systems and their interrelationship in 
controlling LH secretion. Before studying the actual 
involvement of these systems in the neuroendocrine regulation 
of LH, the anatomy of the hypothalamus and ventricular system 
of the brain will be briefly considered.
The Hypothalamus and Neuroendocrine Regulation
It has become increasingly evident that a major 
component of endocrine regulation lies within the brain, 
principally in the hypothalamus which has an immense 
anatomical and functional specialization (see Figure 1).
Hypothalamic neurones are formed from the ventral 
portion of the embryonic diencephalon. Once formed in the 
subventricular proliferative zone, hypothalamic neurones 
migrate to their final position and differentiate to form the 
nuclei of the adult hypothalamus. The hypothalamus develops 
ventrally to the dorsal thalamic and ventral thalamic 
derivatives of the diencephalon. It forms the lateral walls 
of the ventral part of the third ventricle. Rostrally, it is 
bounded by the lamina terminal is.
2Corpus Callosum
Posterior
Commissure
Thalamus
Anterior
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Pituitary Neural lobe
of the Pituitary
Fig. 1 Schematic, diagram of the rat hypothalamus.
AHA: anterior hypothalamic area; ARCN: arcuate nucleus;
DMN: dorsomedial nucleus; ME: median eminence;
MMN: medial mammillary nucleus; PMN: premammi1lary nucleus;
POA: preoptic area; PVN: paraventricular nucleus;
SCN: suprachiasmatic nucleus; SON: supraoptic nucleus;
VMN: ventromedial nucleus.
By anatomical structure, the hypothalamus is split into 
two major subdivisions: a medial area and a lateral area
(Raisman & Field, 1971) . The medial area is * predominantly 
nuclear in position. It is divided into three major groups:
a) a rostral or anterior group of nuclei which includes the 
medial preoptic nucleus (MPO), the anterior^ hypothalamic 
nucleus (AHA), the suprachiasmatic nucleus (SCH), the 
supraoptic nucleus (SON) and the paraventricular nucleus 
(PAN) ;
b) a tuberal group of nuclei, so named because of its 
association with the tuber cinereum (infundibulum), which 
consists of two very prominent nuclei: the ventromedial 
nucleus (VMH) and the dorsomedial nucleus (DMN). It also 
includes a much expanded component of the periventricular 
nucleus (PVN) and the arcuate nucleus (ARN). The ARN lies 
just above the median eminence (ME) and is adjacent to the 
third ventricle. There is also a large group of cells below 
and lateral to the VMH that has been termed the ventral 
tuberal area. This region contains clusters of large 
neurones, termed the lateral tuberal nuclei. The tuberal area 
is generally believed to be the region containing most of the 
neurones producing the various hypothalamic hormones. Caudal 
to the tuberal group of neurones lie;
c) the posterior hypothalamic group of nuclei containing 
the mammillary complex, the posterior hypothalamic nucleus, 
the supramammi1lary nucleus, and the tuberomammi1lary 
nucleus. In addition to these subdivisions, there is a narrow 
group of nerve cells lying just beneath the third ventricular 
ependyma, extending the entire length of the third ventricle.
4These neurones are termed the periventricular system of the 
hypothalamus.
The lateral hypothalamic area is that region which forms 
the lateral border of the entire medial hypothalamic nuclear 
complex. The neurones of this area are scattered amongst 
axons of a large fibre bundle, the medial forebrain bundle. 
This is the major pathway by which all medial hypothalamic 
nuclei are interconnected with the rest of the brain.
The anatomical loci in the hypothalamus that exert a 
direct control of the adenohypophyseal function are 
collectively known as the "hypophysiotrophic area". The 
neurones of this area, referred to as tuberohypophyseal 
neurones, are composed of a cluster of cell bodies in 
anatomically defined nuclei which have origins as remote as 
the preoptic area (POA). The neurones of the
hypophysiotrophic area produce a variety of peptide hormones. 
Some of these neurones terminate on capillary loops in the ME 
from where the neurosecretory products (neurohormones) are 
released into the portal circulation.
To date, five hypophysiotrophic hormones have been 
isolated: thyrotrophin releasing hormone (TRH), GnRH,
somatostatin, corticotrophin releasing hormone and growth 
hormone releasing hormone.
The Median Eminence - Hypophyseal Portal System
The ME is the final common pathway for neurohumoral 
control of the anterior pituitary. It receives peptidergic
5neurones of the tuberohypophyseal tract and their 
neuropeptides, the releasing and release-inhibiting hormones. 
From the substance of the ME, these hypophysiotrophic 
hormones are delivered to the portal capillaries (Jennes & 
Stumpf, 1986). The endothelium of these capillary loops is
fenestrated, thus permitting macromolecules to enter without 
a functional blood brain barrier.
The ME contains specialized cells, the tanycytes, which 
extend from the lumen of the third ventricle to the outermost 
zone of the ME. Tanycytes may thus serve an important role in 
active transport in either direction between the ventricular 
compartment and the portal system.
In the portal blood, all of the known hypothalamic 
peptides and some biogenic amines are present in high 
concentrations. Tuberoinfundibular DA is secreted into the 
portal circulation via the ME. ADR and 5-HIAA, a 5-HT 
metabolite, are also present in the portal blood. It is 
suggested that biogenic amines, in addition to serving as 
neurotransmitters, may have a regulatory role on anterior 
pituitary function (Johnston, Gibbs & Negro-Vilar, 1983).
The Ventricular System of the Brain
The primitive ectoderm, which evolves into neural plate 
folds and the dorsal edges' fuse to form the neural tube. The 
cerebral ventricles are developed from the lumen of this 
tube. At this stage, the nervous system is composed of a 
cylinder of cells surrounding a central cavity. The complex 
structure of the adult’central nervous system is only a
6series of permutations on this basic organization. These 
permutations occur largely as a consequence of differential 
rates of cellular proliferation along the neural tube and the 
growth of neuronal processes. With the growth of the brain, 
three primary and then five secondary brain vesicles are 
formed. The secondary vesicles are telencephalon, 
diencephalon, mesencephalon, pons and medulla which are the 
major subdivisions of the adult brain. The neural tube 
cavity persists in these as the lateral ventricles in the 
telencephalon, the third ventricle in the diencephalon, the 
cerebral aqueduct in the mesencephalon, and the fourth 
ventricle in the pons and the medulla (Figure 2). 
Cerebrospinal fluid (CSF) is formed by an active secretory 
process of the choroid plexus which is found in the lateral, 
third and fourth ventricles. Some interchange of water and 
solutes occurs between brain and CSF. The CSF formed in the 
ventricular system passes through it to emerge from the 
fourth ventricle. It circulates through the subarachnoid 
space and is removed over the convexity of the cerebral 
hemisphere from the arachnoid villi projecting into large 
dural venus sinuses.
The entire surface of the ventricular system is covered 
by a lining of modified neuroglial cells called ependyma. 
These cells are similar, in all areas of the ventricular 
system except at the bottom of the third ventricle, where the 
specialized ependymal cells, the tanycytes, are found.
The third ventricle extends from the region of the optic 
chiasma rostrally (optic recess) to the mammillary bodies and
7Lateral ventricle 
(anterior horn)
Inter ventricular 
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Choroid plexusCerebral aqueduct
Fourth ventricle
Central canal
Fig.2  Showing the ventricular system of the rat brain 
(adapted from Zeman & Innes, 1963).
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8the cerebral aqueduct caudally. In addition to the optic 
recess, there is an infundibular recess - a ventral extension 
of the ventricle above the cerebral aqueduct. The walls of 
the third ventricle are made up predominantly of the thalamic 
and hypothalamic nuclei.
In the rat brain, it has been found that the average 
volume of the lateral ventricles is 43 Ml, the third 
ventricle 38 pi and the fourth ventricle 10 Ml (Levanger, 
1971).
The Rat Oestrous Cycle
Rats are spontaneous ovulators and under controlled 
conditions ovulate every 4 to 5 days (see Feder, 1981) . The 
oestrous cycle is brought about by a neural timing mechanism 
operating through the ME (Everett, 1977). It consists of a 
day of pro-oestrus followed by oestrus and then 2 or 3 days 
of dioestrus. These stages can be characterized by the cell 
types present in the vaginal epithelium which may be assessed 
by the taking of vaginal smears. Hormonal changes occurring 
at different stages of the cycle are summarized in the 
Figure 3.
During the period of late dioestrus the follicles grow 
and secrete oestradiol. The increased levels of this hormone 
in plasma reaches a peak on the morning of pro-oestrus. The 
high concentrations of oestradiol exerts a positive feedback 
effect and initiate an increase in gonadotrophin release 
during the afternoon of pro-oestrus. This increase is called 
the 'preovulatory gonadotrophin surge'. The high levels of
ng
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Fig. 3 Showing changes in plasma hormone levels during 
the 4-day Oestrous cycle in the rat (adapted 
from Takeo#i 1984).
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LH then inhibit further production of oestradiol, and at the 
same time stimulate an increase in progesterone secretion. 
The high levels of oestradiol are followed by a rise in 
progesterone levels which exert a positive feedback action on 
gonadotrophin release inducing and maintaining the 
preovulatory gonadotrophin surge. This in turn induces the 
rupture of mature follicles and thus ovulation. This stage is 
identified as oestrus. The ruptured follicles develop into 
secretory tissue (corpora lutea) capable of producing high 
levels of progesterone. In the normal cycle, the life span of 
the corpus luteum is only one day and can be seen by the 
transient rise in progesterone of luteal origin occurring on 
dioestrus I. The progesterone from the corpus luteum, and 
the low levels of oestradiol from the maturing follicles on 
dioestrus II, exert a negative feedback effect on GnRH levels 
during this period.
Oestrous cyclicity is under the regulation of the brain 
and in particular the hypothalamus (see Ramirez, Feder & 
Sawyer, 1984). During the afternoon of pro-oestrus, the 
anterior pituitary is stimulated by GnRH, which is 
transported to it via the hypothalamo-hypophysea1 portal 
system, provoking discharge of the ovulatory quota of LH (see 
Ramirez, et al., 1984; Barr & Barraclough, 1978; Wise, Ranee 
& Selmanoff, 1981). As oestradiol attains maximum plasma 
concentrations in the morning of pro-oestrus, the release of 
GnRH increases in amplitude and frequency (1 pulse/50 minutes 
at the pro-oestrous afternoon maximum). More detailed study 
of the GnRH stimulus that precedes release of surge levels of 
LH in conscious, unrestrained rats by use of the push-pull
11
perfusion technique, reveals that the neural GnRH apparatus 
is activated from a low level of GnRH release (10 fg/min) to 
a maximal secretory activity (50-70 fg/min) on the afternoon 
of pro-oestrus. There are intermediate levels of activity 
during dioestrus-I and dioestrus-II (Levine & Ramirez, 1980). 
In the afternoon of pro-oestrus, an initial increase in GnRH 
activity is observed around 14.00 to 15.00 hours. A much 
larger and longer burst in GnRH release occurring 2 to 3 
hours later appears to coincide with the maximal secretion of 
LH from the pituitary. When the regimen of illumination is 
regulated, with lights on from 5.00 to 19.00 hours, the range 
of time during which the onset of the surge occurs is between 
14.00 and 15.00 hours. Initially there is a slow rise in 
circulating LH levels to reach a plateau between 16.30 and 
18.30 hours (Blake, 1976).
Two distinct modes of gonadotrophin release are 
observed during the oestrous cycle. Basal or episodic 
gonadotrophin release is reflected in the relatively low 
levels seen throughout most of the cycle and is essential for 
follicular development and oestradiol secretion. The 
frequency and amplitude of LH (Leipheimer, Bono-Gallo & 
Gallo, 1985) and follicle stimulating homone (FSH) (Culler & 
Negro-Vilar, 1987) pulses are dependent upon the time of day 
and the phase of oestrous cycle. The phasic pattern of the 
pre-ovulatory surge of LH leads to ovulation and the
formation of the corpora lutea (see Barraclough & Wise, 1982; 
Feder, 1981).
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Gonadotrophin - Releasing Hormone
The elucidation of the structure and the subsequent 
synthesis of hypothalamic GnRH, a decapeptide, by Schally and 
coworkers (1971) represented a milestone in the understanding 
of reproductive physiology. It is now established that the 
hypothalamus, particularly the ARN-ME region, produces and 
secretes GnRH, also known as luteinizing hormone-releasing 
hormone (LHRH). In the ME GnRH nerve terminals secrete the 
hormone directly into the portal capillaries, from which it 
is delivered by the portal circulation to the 
adenohypophyseal gonadotrophs.
The distribution of GnRH-producing neurones in the rat 
brain has been extensively investigated (Palkovits, 1973; 
Palkovits et al., 1974; see Figure 4). It seems that those 
GnRH neurones which project into the ME to exert a 
neurohumoral role are localized rostrocauda1ly from the 
diagonal band of Broca to the premammi11ary region in the 
pre-optic-tuberal pathway. Laterally they extend up to 2 mm 
from the midline in the preoptic region and the medial 
forebrain bundle (Kelly, Ronnekleiv & Eskay, 1982; King et 
al., 1982; Witkin, Paden & Silverman, 1982). A very high 
concentration of GnRH has been found in the ME; moderate 
levels have been detected in the ARN and small amounts in the 
SCH and preoptic regions (Palkovits, 1973; Palkovits et al., 
1974). In the POA, the bulk of GnRH seems to reside in the 
supraoptic crest, a vascular structure that forms part of the 
rostral tip of the third ventricle (Kizer et al., 1976). The 
supraoptic crest and the other circumventricular organs have
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Figure 4. Anatomical distribution of GnRH neurones. POA, 
Preoptic Area; AH, Anterior Hypothalamus; DMN, 
Dorsomedial Nucleus; VMN, Ventromedial Nucleus.
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LH
Figure 5. Humoral control of hormonal secretion. 
1. Long Loop; 2. Short Loop and 3. Ultra-Short Loop. AP, 
Anterior Pituitary; PP-Posterior Pituitary; G-Gonad.
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been found to be rich In GnRH which may be taken up from the 
CSF and disposed of, or secreted into the CSF to act on 
diverse areas of the brain. Shivers et al., (1983) reported 
that the major group of rat GnRH neurones occur in the POA and 
its vicinity (nucleus of the diagonal band, septum, AHA). The 
majority of GnRH fibres in the rat proceed from the POA to the 
ME. Most GnRH fibres originating in preoptic cells take a 
lateral course upon leaving that area, and travel along the 
medial forebrain bundle; then they turn medial to enter the 
MBH through the lateral retrochiasmatic area. Evidence
gathered from lesion and hypothalamic deafferentation studies 
suggest that GnRH perikarya in the region of the
retrochiasmatic area and elsewhere in the MBH are involved in 
the control of episodic LH release. Hence this region has been 
termed the "tonic pulse generating centre".. Whereas GnRH 
neurones within a distinct narrow medial zone from the medial 
PVN caudally to the SCH region are thought to regulate the 
preovulatory gonadotrophin surge, hence termed the "surge 
generator region" (see Barraclough & Wise, 1982; Kalra &
Kalra, 1983, 1985).
Hypothalamic GnRH binds to specific receptors on the 
adenohypophyseal gonadotroph and stimulates the synthesis and 
secretion of both LH and FSH (Conne et al., 1982). This 
secretory activity occurs intermittently in apparent synchrony 
with, and in response to, the pulsatile discharge of GnRH from 
the hypothalamus.Experimental data indicate that GnRH 
receptors on the gonadotroph change markedly under different 
physiological conditions. GnRH receptor numbers are highest 
when gonadotrophin responses to GnRH are maximal (Clayton & 
Catt, 1981) . In the absence of steroid hormone feedback, e.g..
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after castration,the rise in GnRH numbers is induced by 
increased GnRH secretion. At the level of the pituitary, 
gonadal steroids exert their negative feedback effect at a 
post-GnRH receptor site rather than by directly altering the 
number of GnRH receptors (Clayton & Catt, 1981).
Release of both FSH and LH is stimulated by the 
hypothalamic peptide, GnRH. Administration of antiserum to 
GnRH or sodium pentobarbitone will abolish LH release but 
have no effect upon FSH secretion (Culler & Negro-Vilar, 
1987; Berardo & De Paolo, 1986; see Everett, 1977). In 
addition, their release is reported to be dissociated in a 
number of physiological situations such as on the morning of 
oestrus (Smith, Freeman & Neill, 1975) and for the first few 
days post-ovariectomy (Berardo & De Paolo, 1986) when FSH is 
elevated but LH levels are basal. The release of LH seems to 
be completely dependent upon GnRH secretion, but GnRH is not 
the sole regulator of FSH secretion. McCann and his 
colleagues suggest that there is a separate FSH-releasing 
hormone that is produced in the PAN, AHA and surrounding ARN 
and ME to selectively regulate FSH release. Although the 
proposed FSH-RH has not yet been identified, there is some 
evidence for its existence (Lumpkins, De Paolo & Negro-Vilar, 
1986) .
Gonadal Steroid Hormones
Circulating gonadal steroid hormones exert a powerful 
influence on the regulation of reproduction by the brain. 
Gonadal steroids are apparently the primary hormonal signals
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that drive and sustain the intricate balance within the 
closed feedback loop of the hypothalamo-pituitary-gonadal 
axis.
Feedback control of GnRH secretion
The neurosecretory activity of the hypothalamus is 
controlled by long, short and ultra-short loop feedback
systems (Figure 5). In long-loop feedback, information is 
provided to the hypothalamic centres by hormone
concentrations in the peripheral blood. In this way the 
hypothalamus obtains information concerning the amount of 
hypophysial trophic hormone (LH) in the circulation and 
adjusts its own releasing hormone production to the actual
need. LH can influence.its own release by a short loop
feedback whereby the hormone-producing cells of the 
hypothalamus respond directly to pituitary LH. Ultra—short- 
loop feedback, by which GnRH regulates its own secretion, has 
been experimentally demonstrated within the hypothalamus.
Hypothalamic-pituitary-testicular axis
Testicular function is primarily under the control of 
the gonadotrophins, LH and FSH secreted by the anterior 
pituitary gland. Many of the neuromodulatory systems 
participate in the regulation of GnRH-secreting neurones by 
higher neural centres and by testicular steroids (Cicero et 
al., 1979; Miller et al., 1986; see Kalra, 1986). An
important component in the regulation of the hypothalamic- 
pituitary-testicular axis is the negative feedback control of 
gonadotrophin secretion exerted by the testis. Testosterone
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exerts a profound suppressive effect on both LH and FSH 
release (Cicero et al., 1979; see Cicero, 1980; Bhanot & 
Wilkinson, 1983; Herdon, Everard & Wilson, 1984). The site 
of the negative feedback effect of testosterone on 
gonadotrophin secretion is not entirely clear, but indirect 
evidence exists for an effect of this androgen at both the 
hypothalamic and pituitary level (Kalra & Kalra, 1983; Kalra, 
Sahu & Kalra, 1988).
Gonadectomy - Sexual Dimorphism
A striking sex difference exists between adult male and 
female rats in the initial increment in plasma LH levels 
after gonadectomy. LH levels begin to rise between 8-12 hours 
after orchidectomy, but do not increase until 3-4 days after 
ovariectomy when this surgery is performed on dioestrus 1 
(see De Paolo, 1982). In the female rat LH and FSH are
released in both a tonic and cyclic manner, while in the male
rat these gonadotrophins are secreted in only a tonic fashion 
(Neill, 1972). The different dynamics of LH release after 
gonadectomy may be attributed, at least in part, to distinct 
differences in the overall response of the hypothalamic
monoaminergic neurones to the removal of gonadal hormonal
feedback. The delay in LH response to gonadectomy seen in 
the female rat may be due to a more prolonged retention of 
oestrogen in specific brain areas (Negro-vilar et al., 1984). 
Oestrogen treatment of male rats before orchidectomy delays 
the onset of increases in plasma LH levels after cessation of 
treatment (Justo & Negro-Vilar, 1979). It has also been 
suggested that the action of oestrogen is exerted within the
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preoptico-hypothalamic region to ultimately inhibit the 
release of GnRH from the peptidergic neurones (Nigro-Vilar et 
al. , 1984) .
Neuroendocrine responses to Orchidectomy
Castration of adult male rats results in a rapid rise in 
plasma LH to a plateau within 16—24 hours (Ojeda & McCann, 
1973, see Kalra, 1986). There is a further increase between 
days 5 and 15 after castration (Badger et al., 1978; Caraty 
et al., 1981) and a still further elevation after day 30 
(Howland & Skinner, 1975; Sodersten et al., 1980; Linkie, 
Furth & Kourelakos, 1981). Plasma FSH levels also rise 
within 24 hours, continue to increase at a steady rate until 
day 8, and then at a slower rate until day 30 (Ojeda & 
McCann, 1973; Badger et al., 1978; Caraty et al., 1981) with 
a continuing gradual rise thereafter (Howland & Skinner, 
1975; Linkie et al., 1981).
Plasma
LH
2
S
Figure 6. Orchidectomy (ORDX) and plasma LH.
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Blockade of pituitary GnRH receptors with a GnRH- 
antagonist prevents the postcastration rise of both plasma LH 
and FSH (Condon et al., 1985). A postcastration rise in GnRH 
receptor numbers is induced by increased GnRH secretion 
(Clayton & Catt, 1981). The continuing rise of gonadotrophins 
after castration probably involves increased pituitary 
responsiveness to GnRH (Badger et al., 1978).
Castration has been reported to alter the dynamics of 
catecholamines in the brain in a variety of ways. (Simpkins, 
Kalra & Kalra, 1980; De Paolo, McCann & Negro-Vilar, 1982; 
Herdon, Evarard & Wilson, 1984; Al-Hamood et al, 1987; 
Gabriel et al., 1986a, b).
Administration of testosterone to castrated rats, either 
at the time of castration or at any time interval thereafter, 
reduces gonadotrophin levels to normal (Clayton & Catt, 1981; 
Conne et al., 1982; Kalra, Sahu & Kalra, 1988). At the
hypothalamus, testosterone has been shown to prevent the
reduction in GnRH concentration in the MBH which normally
occurs after castration (Kalra & Kalra, 1978, 1980); the
testosterone probably acts by preventing GnRH release into 
the hypophysial portal system (Gross, 1980). Acute castration 
(4-24hours) is reported to increase the concentration of NA 
but not of DA in the ME. Testosterone has also been shown to 
reduce noradrenergic activity in the medial basal
hypothalamus (Simpkins et al., 1980) and to augment
dopaminergic activity in the ME (Simpkins, Kalra & Kalra, 
1983). Pharmacological evidence indicates that the
hypersecretion of LH after castration may be mediated by the
2 0
alpha- and beta-adrenergic system (Ojeda & McCann, 1973; 
Herdon et al, 1984; Al-Hamood et al., 1987).
The Aminergic System
The MBH is richly innervated by catecholaminergicI
terminals. Neuropharmacological studies of the effect of 
blockade and stimulation of biogenic amine receptors have led 
to an understanding that hypophysiotrophic hormone secretion 
is controlled by aminergic neurones. Many neurotransmitters 
have been identified in the brain. The catecholamines such as 
NA, ADR and DA, the indolemine, 5-HT, acetylcholine (ACh), 
histamine and gamma-aminobutyric acid (GABA) are all said to 
have neurotransmitter functions, but their physiological role 
remains to be fully understood. NA and 5-HT neurones from 
the midbrain come in contact with peptidergic neurones in the 
hypothalamus. DA cell bodies with their origin in the ARN 
send short axons to the ME. The role of these three 
monoamines influencing hypothalamic-pituitary function has 
been extensively studied. They produce biochemical inputs at 
the synaptic junction that triggers the action of 
hypothalamic peptidergic neurones following binding to the 
appropriate receptors.
The release of transmitters and their resulting actions
are dependent on three important factors:
1. The degree of reuptake by presynaptic terminals and
intraneuronal activation by monoamine oxidase;
2. The metabolism by catechol—0-methyl transferase (COMT),
which rapidly inactivates some neurotransmitters at the 
synaptic junction; and
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3. The comparative availability of receptors at pre- and 
postsynaptic sites.
The role of central catecholamines in the regulation of 
gonadotrophin release
The involvement of catecholamines in the regulation of 
LH release has been extensively studied (see Barraclough. 
Wise & Selmanoff, 1984; Barraclough & Wise, 1982; Kalra, 
1986). Before considering their role individually in the 
regulation of LH release, the neuropharmacological properties 
will be briefly discussed.
Neurochemistry of Catecholamines
The biosynthesis and degradation of catecholamines has 
been reviewed by Moore & Johnston (1982). A diagrammatic 
representation of the neurochemical events occurring at the 
DA nerve terminals is shown in Figure 7.
The catecholamines are synthesized from the precursor 
amino acid L-tyrosine. This compound is actively taken up by 
DA neurones where it is converted to L-dihydroxyphenylalanine 
(DOPA) by the rate-limiting synthesizing enzyme, tyrosine 
hydroxylase. This enzyme is regulated, in part, by an end- 
product inhibitory process so that decreases in intraneuronal 
DA concentrations result ,in increased DA synthesis, and vice 
versa. By this mechanism, concentrations of DA within the 
nerve terminal remain fairly constant despite alterations in 
the amount of transmitter released. DOPA is rapidly 
decarboxylated to DA by L-aromatic amino acid decarboxylase
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Figure 7. Schematic diagram of A. dopaminergic and
B. noradrenergic nerve terminals and receptors depicting 
sites of drug action. Numbers represent the sites of drug 
action: 1. tyrosine hydroxylase inhibitors, 2. aromatic L-
aminoacid decarboxylase inhibitors, 3. -monoamine oxidase 
inhibitors, 4. DA agonists and antagonists, 5. DA uptake 
inhibitors, 6. amine deplators, 7. NA agonists and 
antagonists, 8. NA uptake inhibitors and 9. DA-JiJ-hydroxy 1 ase 
inhibitors, (adapted from Moore & Johnston, 1982).
23
Monoamine Biosynthesis In Mammal*
C H .- CH
COOH
TYROS IKE
Tvrosine hvdroxvlase
2 * Fe2* ♦ DMPH .
HO
0 " ,NH.
CH.-CH
2 "COOH
L-DQPA
1 aromatic amino acid decarboxylane (AAD) * pyrldoxalphosphale B$ HO coenzyme
-OH
Catechol forming enzyme
TYRAMINE
0-oxidase
C H.-CH.-NH,‘2 2 “ 2 
DOPAMINE
0-oxidase ♦ Cu protein 
Ascorbic acid ♦ Oj
CHOH-CH2-K H j 
OCTOPAMIKE 
TNMT
.C H j
c h o h - c h . - n .
CHOH-CHj-N H j
NORADRENALINE
1 Phenyl ethanol N-methyl translerase (PNMT)HO
HO.
C^Hj
C H O H -C H -- N .
SYNEPHRINE ADRENALINE
Figure 8. Metabolic Pathways of Catecholamines.
24
released from the nerve terminal in response to action 
potentials. In the ME the released DA may activate receptors 
on axon terminals of other neurones (e.g. those containing 
GnRH), but most DA terminals are believed to release DA into 
the primary plexus of the hypophysial portal blood.
DA neurones have a high affinity uptake mechanism which 
transports released DA back into the nerve terminal. In this 
way the actions of DA at pre- and postsynaptic receptors are 
terminated. Such a high affinity DA uptake system appears to 
be absent from tuberoinfundibular neurones (Demarest & Moore, 
1979a; Annunziato et al., 1980). An uptake mechanism is 
probably not needed by these neurones since DA is rapidly 
removed from the region of the terminals by the blood. 
Tuberoinfundibular DA neurones also differ from nigrostriatal 
and other major ascending DA neurones in that they lack 
presynaptic autoreceptors which regulate the synthesis (and 
possibly release) of DA in the latter neurones (Demarest and 
Moore, 1979b).
In the NA nerve terminals, the synthesized DA is taken 
up by storage vesicles containing dopamine-B-hydroxylase 
(DBH), and converted to NA. It is then released in response 
to the arrival of nerve action potentials or to the actions 
of drugs. Within the synaptic cleft NA is free to interact 
with pre- or postsynaptic receptors. The action of this 
neurotransmitter at these receptors is terminated when the 
amine is actively transported back into the NA nerve terminal 
and oxidatively deaminated by intraneuronal monoamine oxidase 
(MAO). The deaminated products (3,4—dihydroxypheny1glycol is
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the main metabolite in the brain) can then be further 
metabolized by catechol-O-methyltransferase which is 
localized in glial cells to 3-methoxy,4-hydroxypheny1glycol 
(MHPG) which is the metabolite that has generally been 
regarded to reflect NA neuronal activity, i.e., increased 
concentrations of MHPG reflect increased activity of NA 
neurones, and vice versa.
Estimation of catecholaminergic activity
The concentrations of catecholamines in nerve terminals 
do not change during periods of increased or decreased 
neuronal activity. It is believed, therefore, that synthesis 
of these amines keeps pace with release, and that degradation 
of amine transmitters occurs primarily after they have been 
released. Thus, synthesis, release and degradation are 
related in such a way that a change in one process is 
associated with reciprocal changes in the other processes. 
Hence, changes in any of these processes can be used to 
estimate the activities of aminergic neuronal systems.
There are several biochemical techniques that can be 
employed to estimate the activity of catecholaminergic 
neurones. These are primarily based upon the measurement of 
turnover which enables the simultaneous measurement of NA, 
ADR and DA neuronal activity.
Since the rates of synthesis of catecholamines are 
regulated at the step catalyzed by tyrosine hydroxylase, many 
estimations of catecholamine turnover are based upon in vitro 
and in vivo measurements of the activity of this enzyme.
26
Administration of an inhibitor of tyrosine hydroxylase, 
alpha-methy1-para-tyrosine, OC-MPT, decreases the
concentrations of these amines in the brain in an exponential 
manner, the rate being proportional to impulse activity in 
the neurones (Brodie et al., 1966). The exogenous 
administration of o£-MPT permits the simultaneous estimation 
of NA, ADR and DA turnover(Spector et al., 1965). The method 
of Brodie et al^(1966) has subsequently been applied by many 
workers (Hohn & Wuttke, 1979; Ranee et al., 1981; De Paolo et 
al., 1982, Herdon et al., 1984; Coen & Coombs, 1983) to 
simultaneously derive turnover rates for both DA and NA.
The role of central noradrenaline in the control of 
gonadotrophin release
Noradrenergic neuronal system originate from two main 
brain regions; the locus coeruleus and the lateral tegmental 
region. A« and A*, cell bodies originate from the locus 
coeruleus; Ai , As , Ass and Av from the lateral tegmental 
region, which ranges from the caudal medulla to the caudal 
mesencephalon. Most hypothalamic nuclei including the 
supraoptic, MPO and ARN, and also the ME appear to be 
innervated by the lateral tegmental system (Jones and Moore, 
1977). However, the PVN may also receive as much as 40% of 
its NA innervation from cells in the locus coeruleus. Axons 
from NA cell bodies in the lateral tegmental region ascend in 
the medial forebrain bundle to the level of the hypothalamus 
and then turn medially along the ventral surface of the brain 
to terminate in the ME; these neurones have been referred to 
as the reticuloinfundibular NA system (see Figure 9).
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NA has been shown to act as an excitatory 
neurotransmitter (Renaud, 1988, Ching & Krieg. 1986; Miyake 
et al., 1983; see Kalra & Kalra, 1985; Ramirez et al.,
1984; Barraclough & Wise, 1982). It has been demonstrated 
that NA consistently stimulates LH release in a dose- 
related fashion in oestrogen and progesterone-treated 
ovariectomized rats (Kalra & Gallo, 1983). Surprisingly, only 
a high dose of NA (lO-^M) has been shown to stimulate GnRH 
release in vitro from the ME of steroid-primed 
ovariectomized rats (Nigro-Vilar & Ojeda, 1978). In addition, 
NA induced ovulation has been demonstrated in a variety of 
experimental models (Sawyer 1975; Sawyer & Clifton, 1980) 
where the LH mechanisms were suppressed such as disruption of 
NA pathways, exposure to constant illumination, 
pentobarbitone blockade (Al-Hamood, Gilmore & Wilson, 1985; 
Gopalan, Meek & Gilmore, 1987; see Kalra & Kalra, 1983). 
Crowley et al., (1978 & 1982) have suggested an association 
between the increased NA activity in discrete sites within 
the hypothalamus and the spontaneous or steroid-induced LH 
surge. They observed that NA turnover in the ARN and ME was 
significantly elevated in association with stimulation of LH 
release by progestrone in oestrogen-primed rats (Crowley et 
al., 1978; Crowley, 1982). Likewise, Wise and co-workers 
(1981) noted that, in association with the peak LH levels at 
15.00 hours induced by oestrogen in ovariectomized rats, 
there was increased NA turnover between 15.00 and 17.00 hours 
in the ME, ARN, POA and in the SCH. With additional 
progesterone administration to oestrogen—primed rats at 09.00 
hours, elevated LH levels were seen at 12.00 hours and peak
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levels at 15.00 hours. In these rats, NA turnover In the ME 
was Increased at times when LH levels were either rising 
(12.00 hours) or had peaked (15.00 hours). A similar NA 
response in the ME was seen after the preovulatory LH surge 
had either progressed or peaked on pro—oestrus (Ranee et al., 
1981). It has been demonstrated that electrical stimulation 
of the locus coeruleus or ascending noradrenergic pathway 
stimulated LH release and induced ovulation (Gitler &.
Barraclough, 1987). Phentolamine, an alpha—adrenergic
receptor blocker, has been shown to inhibit the action of NA 
in the ME of ovariectomized, steroid-primed rats (Negro-Vilar 
et al., 1979). Non-selective antagonists, phenoxybenzamine 
and phentolamine also blocked ovulation when infused on the 
morning of pro-oestrus (Al-Hamood et al., 1985). Further
evidence suggests that this stimulatory effect of NA is 
mediated via alpha*-adrenergic receptors (Drouva, Laplante & 
Kordon, 1982; Heaulme & Dray; 1984; see Kalra, 1986). Beta- 
agonists, isoprenaline and fenoterol are stimulatory to
ovulation in pentobarbitone-treated rats when administered on 
the morning of pro-oestrus. Fenoterol could overcome the 
effect of pentobarbitone, stimulating ovulation even when 
administered on the afternoon of pro—oestrus. Beta— 
antagonists, propranolol and metoprolol stimulate ovulation 
only when administered on the afternoon of pro—oestrus (Al- 
Hamood et al., 1985).
Intracerebroventricular (icv) administration of NA is
inhibitory to LH release in unprimed ovariectomized rats 
(Gallo & Drouva, 1979). Microinfusions of NA, and of 
phenylephrine and clonidine (alpha—ag,on is ts) or of
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isoprenal ine (a beta-agonist) into the third, ventricle, 
significantly and acutely suppress the frequency of ultradian 
LH pulses in unanaesthetized, ovariectomized, unprimed rats 
(Leung et al., 1982). Chemical lesion of the ventral 
noradrenergic bundle depletes hypothalamic NA levels and
c
disrupts the normal four day oestrous cycle with 
preovulatory LH release being much reduced (Hanke & Wuttke, 
1979). In contrast, electrical stimulation of the dorsal 
noradrenergic bundle has been shown to abolish the 
preovulatory LH surge (Dotti & Taleisnik, 1982) indicating an 
inhibitory effect of NA in addition to its more widely 
recognized stimulatory one. Moreover, the blockade of 
ovulation, by electrical stimulation of NA cell groups in the 
brainstem on pro-oestrus, can be abolished by beta- 
adrenoceptor antagonists propranolol, but not by alpha 
receptor antagonists such as phenoxybenzamine (Dotti & 
Taleisnik, 1984). Beltramino & Taleisnik (1984) have reported 
that inputs from the nuclei of the posterior hypothalamus are 
inhibitory to LH release and can participate in determining 
the timing and magnitude of the preovulatory surge. They have 
demonstrated that the transverse cuts of the rat brain placed 
just in front of the mammillary bodies and caudal to the 
VMH result in an advance of the onset of the pre-ovulatory LH 
surge. Thus, it has been concluded that NA, acting via beta- 
adrenergic receptors, mediates the transmission of inhibitory 
impulses originating in the locus coeruleus nucleus. Ramirez 
et al., (1984) have speculated that during a normal oestrous 
cycle, the beta-adrenergic inhibitory component is quiescent 
in pro-oestrus thus helping to ensure a maximal LH surge, but
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It becomes activated subsequently to restrict LH output at 
other stages of the cycle.
Kalra & Kalra (1983) have suggested a dual mode of NA 
involvement in controlling episodic LH secretion. According 
to this hypothesis, each LH pulse is evoked by the 
synchronous discharge of a "packet" of GnRH into the 
hypophysial portal vessels. The pulsatile GnRH release in 
turn, is tightly coupled with, and driven by, alpha-j- 
adrenergic receptor stimulation following an episodic 
discharge of NA in the proximity of GnRH neurones in the 
hypothalamus. As the NA discharge proceeds, at certain 
thresholds alphas-adrenergic receptors are activated to 
turn off further GnRH secretion. The abrupt shutting off of 
GnRH secretion may be due to a selective desensitization of 
adrenergic receptors as NA release proceeds uninterrupted. 
Thus it is possible to explain the episodic release of LH 
solely on the basis of the precisely tuned and temporally co­
ordinated function of two different types of adrenergic 
receptors in the hypothalamus.
The role of central adrenaline in the regulation of 
gonadotrophin release
The role of ADR in controlling gonadotrophin release is 
less well understood (see Ramirez et al., 1984). ADR seems 
to play an important role in regulating the preovulatory LH 
surge (see Kalra, 1985, 1986; Fuller, 1983).
ADR—containing perikarya have been demonstrated to 
exist in only two brainstem areas. In the rat, the Cl cell 
group lies within the lateral reticular nucleus, about 500 jum
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rostral to the Al cell group. Other cells (C2 cell group) are 
scattered in the dorsomedial medulla oblongata mainly in and 
around the nucleus of the solitary tract, about 1500 jjm 
rostral to the A2 cell group (see Moore & Johnston , 1982).
Pheny1ethanolamine-N-methyltransferase, PNMT (the enzyme 
responsible for the conversion of NA to ADR)—positive 
terminals have been identified in various hypothalamic nuclei 
including the ventrolateral region of the ARN and in the ME. 
Biochemical measurements have also ,revealed PNMT activity in 
the ME. Thus current evidence suggests that adrenaline- 
containing neurones project directly to the ME and also onto 
other neurones (eg.in the ARN) that, in turn, project to the 
ME. These fibres originate mainly from the Cl cell group.
The precise mode of participation of adrenergic neurones 
in transmission of the excitatory impulses which evoke the 
basal and cyclic release of LH release is poorly understood. 
Many studies have alluded to a predominant role for ADR in 
evoking the preovulatory LH surge (Adler et al., 1983; Coen & 
Coombs, 1983; Coombs & Coen, 1983; Crowley & Terry, 1981; 
Crowley, Terry & Johnson, 1982; Kalra, 1985).
PNMT-inhibitors block the^preovulatory LH surge and also 
that induced by ovarian steroids in ovariectomized rats 
(Adler et al, 1983; Coen &. Coombs. 1983; Crowley & Terry, 
1981; Crowley, Terry & Johnson, 1982; Kalra, 1985). PNMT 
inhibitors may block LH release by decreasing ADR 
transmission and, in part, by antagonizing the activation of 
alphai—adrenoceptors (Kalra, 1985) . ADR turnover, as
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determined by the rate of decrease in ADR levels after 
administration of PNMT inhibitors, is reported to increase 
before and during the period of LH hypersecretion. 
Furthermore, Coen & Coombs (1983) noted an increase in the 
rate of ADR depletion in the POA when the preovulatory LH 
surge had peaked. A small increase in ADR turnover in the 
MBH and MPO has also been reported to occur during the 
preovulatory LH surge (Sheaves, Laynes & MacKinnon, 1985; 
Sheaves et al., 1984). However, because a parallel study on 
the time course of LH release was not performed, it is 
difficult to assess the significance of this rise in ADR 
turnover in evoking LH release.
The contribution of adrenergic neurones to the 
preovulatory LH discharge is also evident from another line 
of study. Surgical transection of brainstem projections into 
the hypothalamus drastically lower NA levels, whereas 
hypothalamic levels of ADR are only moderately reduced 
(Fuller, 1983; Fuller, Perry & Hemrick, 1980; Saavedra et al, 
1983). Moreover, there is no apparent effect of these 
procedures on the occurrence of oestrous cycles and 
gonadotrophin secretion (Clifton & Sawyer, 1980).
The role of central dopamine in the regulation of 
gonadotrophin release
The role of DA in the regulation of gonadotrophin 
release is controversial since both stimulatory (see Vijayan, 
1985; James et al., 1987; MacKenzie, James & Wilson, 1986) 
and inhibitory (Gallo, 1980) effects have been suggested in 
the control of LH. The variation in effect seems to depend
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on the endocrine state of the experimental model (Beck, Hank
6T Wuttke, 1978). In general, stimulatory effects seem to
£
occur only in the adult animal and in the presence of
steroids whereas in the absence of steroids increasing DA 
activity in the whole brain or in the hypothalamus produces 
an inhibition of gonadotrophin release (see Weiner & Ganong, 
1978; Sarkar & Fink, 1981).
There are two anatomically distinct dopaminergic 
neuronal systems that innervate the hypothalamus; the
tuberoinfundibular and the incertohypothalamic tracts (see 
Moore, 1987; Moore & Bloom, 1978). Cell bodies of the
tuberoinfundibular neurones are located in the ARN and in the 
regions of the anterior PVN nucleus lying just dorsal to the
former nucleus (Ai^). DA terminals in the ME appear to 
originate from perikarya that are within the MBH (i.e., ARN 
and PVN).
The tuberoinfundibular DA neurones have short axons
which project ventrally to terminate in the ME. Some DA
neurones appear to terminate in close proximity to GnRH-
containing nerve terminals (Sladek et al., 1978). Thus DA
released from terminals of tuberoinfundibular neurones may 
alter the release of GnRH.
The incertohypothalamic tract, arising from the zona
incerta projects into the MPO (Bjorklund et al., 1975). 
These neurones are thought to mediate endogenous inhibition 
of LH secretion, mimicked by the central action of the DA 
receptor agonists apomorphine (Drouva & Gallo, 1977) and
DA (Gallo & Drouva, 1979). Despite this evidence, a
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stimulatory role for DA in LH release has been favoured by
s'
other workers after demonstrating a positive relationship 
between DA and LH release (Negro-Vilar et al., 1982). 
Conflict existing in the literature concerning the action of 
DA could be due to the involvement of multiple dopaminergic 
pathways (the tuberoinfundibular, mesolimbic and
incertohypothalamic neuronal systems) in the control of both 
the tonic and/or phasic release of LH.
DA does not act directly on the pituitary to affect LH 
release (Schneider & McCann, 1969), so any observed effects 
must be indirect. lev administration of DA was observed to 
have no effect on LH secretion in ovariectomized rats 
(Schneider & McCann, 1970; Vijayan & McCann, 1978), whereas 
the systemic injection of the DA agonists apomorphine and 
piribedil inhibited LH secretion (Beck & Wuttke, 1977). In 
another study, icv infusion of DA has been reported to 
elevate LH levels on the morning of pro-oestrus (Schneider & 
McCann, 1970). Kamberi, Mical & Porter (1970) have provided 
evidence suggesting a stimulatory effect of DA on GnRH 
release both in vitro and in vivo. Incubation of 
hypothalamic synaptosomes or ME tissue with DA resulted in a 
dose-related increase in GnRH release which could be 
prevented by the DA receptor blocker, pimozide (Negro—Vilar 
et al., 1979). The stimulatory action of DA on LH release did 
not appear to be via uptake and conversion to NA since 
pretreatment with a NA-synthesis inhibitor,
diethyldithiocarbamate, did not block the observed effect 
(Vijayan & McCann, 1978). Furthermore, apomorphine is not
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taken up by aminergic terminals and has little inherent
noradrenergic activity. Implantation of DA into the POA,
*
containing incertohypothalamic dopaminergic neurones, 
stimulates LH release in ovariectomized oestrogen-primed rats 
(Kawakami et al, 1975). In vitro incubation of the MBH from 
oestrogen-primed ovariectomized rats with DA also results in 
GnRH release (Rotsztejn et al., 1976).
The turnover rates of DA in neurones of the MBH at 
different phases of the oestrous cycle, measured by Fuxe et 
al., (1978) showed that increased activity in DA neurones 
inhibits the release and/or synthesis of GnRH. Changes in
DA turnover in specific hypothalamic nuclei during pro­
oestrus in rats have been evaluated (Ranee et al., 1981). 
Concurrent changes in GnRH and LH levels were also recorded. 
Between 9.00 and 12.00 hours on the morning of pro-oestrus, 
when GnRH levels are increasing in the ME, DA turnover rates 
in the MPO, SCH, ARN and ME are low, and peripheral 
gonadotrophin concentrations remain basal. Before and during 
the pro-oestrous gonadotrophin surge, ME GnRH declines and ME 
DA turnover rate is greatly increased (12.00 to 14.00 hours). 
During the interval (15.00 to 17.00 hours) in which LH and 
FSH are still rising to peak serum concentrations, DA 
turnover rates dramatically decline in the ME and ARN but not 
in the MPO.
Interruption of the preovulatory surge of LH by 
pentobarbital (Rubinstein & Sawyer, 1970) or AHA lesions 
(Tima & Flerko, 1974) was not reversed by icv administration 
of DA. Histochemical techniques used to monitor changes in
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fluorescence intensity of the tuberoinfundibular DA system 
over the oestrous cycle (Ahren et al., 1971) suggest a 
decrease in the activity of this system occurs during pro­
oestrus .
It appears that treatment of ovariectomized rats with 
gonadal steroids converts the inhibitory action of DA on LH 
to stimulation (Rotsztejn et al., 1976). Oestrogen treatment
results in a reversal of the effects of electrical 
stimulation of the ARN (Gallo & Osland, 1 9 7 6 ) . In untreated 
ovariectomized rats stimulation of this region inhibits LH 
release, whereas in treated animals an increase in plasma LH 
levels is observed. In ovariectomized rats treated with 
oestrogen and progesterone, Vijayan & McCann (1978) observed 
that DA injected icv stimulate LH release. On the other 
hand, in a similar experimental model, Kreig & Sawyer (1976) 
did not find any effect. There are at least two sets of data 
which may explain the conflicting results obtained by the 
different techniques used to investigate the role of the 
central DA neurones in the control of gonadotrophin release; 
first, by supposing that the tuberoinfundibular tract is 
inhibitory and the incertohypothalamic tract is stimulatory; 
second by assuming that GnRH release may be affected by the 
actions of DA on two pharmacologically distinct receptor 
systems, the activation of which might have opposite 
effects.
The role of central 5-hydroxytryptannine in the control of 
GnRH release
The involvement of 5-HT in the regulation of LH release
has been extensively reviewed by Wilson (1979), Kalra &. Kalra 
(1983; 1985). Evidence suggests that both inhibitory and
stimulatory components may operate in the overall modulatory 
influence of 5-HT neurones on LH release.
Neurochemistry of 5-HT
Figure 11 diagrammatically represents the neurochemical 
events occurring at the serotoninergic nerve terminal.
5-HT is synthesized from the precursor amino acid 
tryptophan. This compound is actively transported into 5-HT 
neurones where it is hydroxylated to form 5-hydroxytryptophan 
(5-HTP) by tryptophan hydroxylase. This enzyme controls the 
rate-limiting step in the synthesis of 5—HT but the precise 
manner by which it is regulated is not completely understood. 
Tryptophan hydroxylase, unlike tyrosine hydroxylase in 
catecho1aminergic neurones, is not tightly regulated by an 
end-product inhibitory mechanism. Furthermore, tryptophan 
hydroxylase is not saturated by concentrations of tryptophan 
that are normally found in the brain, so that raising or 
lowering brain concentrations of tryptophan can alter the 
saturation of the enzyme, and thus the rate of 5-HT synthesis 
(Fernstrom & Wurtman, 1971). Hence, alterations in the 
availability of 'free' tryptophan in the brain induced by 
dietary, hormonal, environmental, and/or pharmacological 
manipulations can influence brain 5-HT synthesis (see Ramirez 
et al., 1984). 5-HTP synthesized in 5-HT neurones is rapidly
decarboxylated by AAD (thought to be the same enzyme that 
converts DOPA to DA) to 5-HT. Newly synthesized 5-HT, in
I4 0
5HIAA
MAO
AADTPH 5HT5HT5HTPTryptophan
5HT
Serotonlnerglc neurone
Hypothalamic 
Peptidergic 
Neurone
receptors
Figure 11(a). Schematic diagram of serotoninergic nerve 
terminals and receptors depicting sites of drug action. 
Numbers represent the sites of drug action. 1. aromatic L- 
amino acid decarboxylase inhibitors, 2. amine deplators,
3. tryptophan hydroxylase inhibitors, 4. serotonin agonists 
and antagonists and 5. serotonin uptake inhibitors (adapted 
from Moore & Johnston, 1982).
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Figure 11 (b). Metabolic Pathways of Serotonin.
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turn, may be stored In vesicles or released from the nerve
terminals in response to the arrival of nerve impulses,
*
electrical stimulation or drugs (Muller, Nistico & 
Scapagnini, 1977). Following its release, 5-HT is free to 
interact with postsynaptic 5-HT receptors. Activation of 
these receptors is terminated when 5—HT is either
metabolized by extraneuronal MAO or is transported back into 
the nerve terminal by a stereospecific active uptake 
mechanism. Within the neurone 5-HT is oxidatively deaminated 
to form the end-product of 5-HT degradation, 5-HIAA (Figure 
11). This acid metabolite is then removed from the brain by 
a probenecid-sensitive acid transport mechanism.
Estimation of Serotoninergic Activity
Although a relation between nerve impulse flow and 
turnover of 5-HT has been demonstrated (Carlsson et al., 
1972), synthesis and degradation of 5-HT in the CNS may not 
be exclusively linked to 5-HT neuronal activity. 
Nevertheless, changes in the rate of synthesis and metabolism 
of this amine have been used to estimate the activity of 5-HT 
neurones. Of the methods available to measure the turnover 
of 5-HT, either the relative concentrations of 5-HT and 
5-HIAA (Shannon et al., 1986) or the use of pargyline (a MAO- 
inhibitor) (Johnson & Crowley, 1984) are commonly employed.
Neuroanatomy
Dahlstrom and Fuxe (1964) originally described nine 
major groups of 5HT-containing cells in the rat brainstem, 
designated Bi — B=? (see Figure 12) . Perikarya in at least four 
of these nuclear groups project to the forebrain. Most
S
IV
d
lfJV
O
O
d
dIM
42
u
o
o * >1
*H cr> c H
b> 1 o O
H 1 < P
0 pq d u • »
c 43 d tn
rH Cl, v m c
c 0 rH 0
o tn U O £
p 0 C d
o •i—i 0 * p
tn H d
0 o 0  o  a,
tn 43 £
(1) ■pH 0
X rH ■d 0 p
p r -H c r—H d
0 d U  xj
tn U d d
G c d
•r-1 tn U
p £ c 0
C o o  4:
a> a a -
tn M—• d p
0 d
in * a
a d d •
<D g p 0  0
d d rH
£ <0d jc 
U  p  
tn o 
d a
• h  >, 
■d X
u
•M 0)
4-> 43 
d  p  
6 
0
43 <4-1
o o 
CO
c 
• o
CNj h  
«H P
JQ O
o tn
d  <d  
-• 43
r-« 4J
d
■d c 
<d  h  
£ 43
-p
0 "rH
43 S 
P
c §
rC
-P
XJ <P 
0 O 
-P
d  p  
o (0 
o o
£d
p
a
<D
in •
d
- d 
P  G  
a  <d  
0 43 
tn d  
X
CL| -1-4 r— I g
-* tn 
d d
o £
k  d
Q) r— I
43 d
SfS
43
evidence suggests that projections to the medial 
hypothalamus, including the ARN, PVN and ME, originate from 
perikarya in the dorsal raphe nucleus(B^). More recently, 
5-HT receptors have been visualized in the rat hypothalamus, 
being more concentrated in the POA and VMH (Beigon, Rainbow &
t
McEwen, 1982). Cell bodies staining for both retrograde and 
fluorescent labels have been demonstrated in the dorsal and 
medial raphe nuclei and the medial lemniscus of the brain 
stem (Simerly, Swanson & Gorski, 1984). Vi liar, Chiocchio & 
Tramezzani (1984), using a similar technique, have shown that 
the 5-HT innervation of the ME originates from the rostral 
third of the dorsal raphe nucleus.
Neuropharmacological Evidence
Administration of 5-HT into the cerebral ventricles, 
inhibition of 5-HT synthesis with PCPA, or destruction of 5- 
HT neurones with 5,6- or 5,7-DHT have been reported to 
increase, decrease and produce no change in the basal 
secretion of LH (Gallo & Moberg, 1977; Wilson et al., 1977; 
see Wilson, 1979). In rabbits, icv infusion of 5-HT was shown 
to inhibit ovulation when given just before the expected pre­
ovulatory. LH surge (see Wilson, 1979). Nevertheless, the
marked increases in serum LH concentrations that occur on the 
afternoon of pro-oestrus or in oestradiol-pretreated 
ovariectomized rats can be prevented by drugs which disrupt 
5-HT neurotransmission (Weiner and Ganong, 1978; Baumgarten 
et al., 1978). Electrical stimulation of 5-HT neurones in the 
dorsal raphe nucleus inhibits LH secretion in ovariectomized 
rats (Arendash and Gallo, 1978; Gallo, 1980) and the
inhibition of LH and GnRH release caused by stimulating the
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ARN can be reversed by pre-treating animals with PCPA-an
s'
inhibitor of 5-HT synthesis (Gallo and Moberg, 1977).
lev administration of 5-HT has been shown to elevate 
plasma LH levels (Porter, Mical and Cramer, 1971). Further in 
support of the stimulatory effect of 5-HT, blockade of 5-HT 
transmission by the administration of PCPA inhibited the GnRH 
surge in intact and steroid-primed ovariectomised rats, the 
effect of which could be reversed by the administration of 5— 
HTP or an agonist (see Wilson, 1979; Coen &. McKinnon,1980; 
Iyengar & Rabii, 1983). 5-HT antagonists have also been shown 
to inhibit ovulation in intact and ovariectomized rats 
(Walker, 1980).
The turnover of 5-HT in the hypothalamus of female rats 
is reported to be greater at the time of the pro-oestrous 
preovulatory surge of LH than it is at the end of the surge 
(Walker, 1980). Furthermore, when the LH surge was prolonged 
by exposing the rats to light on the evening of pro-oestrus 
the hypothalamic 5—HT turnover remained high. These reports 
suggest that the pro-oestrous surge of LH is accompanied by 
and may be partially dependent upon 5-HT neuronal activity.
5-HT neurones may play a role in the feedback regulation 
of LH secretion by gonadal steroids. The castration-induced 
increases of serum LH concentrations and 5-HT concentrations 
in the VMH can be reversed by the administration of 
testosterone (Van de Kar et al., 1978). In ovariectomized
rats a single ip or sc injection of oestradiol has been 
observed to reduce the serum concentration of LH without 
altering the 5-HT content in the ME; the administration of
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progesterone caused a surge of LH and a marked increase in 
tfie concentration of 5-HT (Crowley et al., 1979) . Fuxe et 
al., (1975) reported that the inhibitory feedback exerted by 
oestrogen on LH secretion was associated with an increase of 
5-HT after the administration of a tryptophan hydroxylase 
inhibitor. Kizer et al., (1978) reported that tryptophan 
hydroxylase activity in the ME did not change following 
castration or the administration of testosterone.
A number of actions attributed to 5-HT appear to be 
mediated via 5-HT receptors which are divided into 5—HTi,
5-HTs; and 5-HT3 . The definite characterization of these 
receptors await the identification of specific antagonists.
The Opioid System
The discovery of opioid receptors in the brain
(Goldstein, Lowney & Pal, 1971; Pert & Snyder, 1973) led to 
the search for endogenous opioids. In 1975, Hughes et al.,
identified two pentapeptides, met-enkephalin and leu- 
enkephalin. This was followed by the discovery of numerous 
larger opioid peptides such as beta-endorphin, dynorphin and 
many others (Li, Chung & Doneen, 1976). All these opioid 
peptides have analgesic activity and bind to opioid receptors 
within the brain and elsewhere. Chemical and structural 
relationships between these neuropeptides and their
distribution in the rat brain have been extensively reviewed 
by Cox, 1982; Kalra, 1983; Morley, 1981; Bicknell, 1985; 
Atweh & Kuhar, 1983; Pfeiffer & Herz, 1984).
The multiplicity of opioid receptors was suggested by 
the physiological studies of Martin et al., (1976) who
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concluded that there are at least three different opioid 
receptors termed mu, kappa and sigma. One class of receptors 
called morphine or mu-receptors, preferentially bind opiates. 
Enkephalin or delta receptors preferentially bind enkephalin. 
Ketocyclazocine, a kappa receptor agonist, binds to a class 
of receptors that are insensitive to naloxone. Dynorphin 
represents the natural ligand, but both enkephalin and 
morphine possess high binding affinity to the putative kappa 
receptor. An endogenous ligand for the sigma receptor has 
not been described. The specificity of endogenous ligand 
for the receptor type is summarized in Table 1.
Table 1. Endogenous opioid ligands and their receptors.
Endogenous Ligand Receptor Type
/3-endorphin Mu, Delta
Enkephalin Delta
Dynorphin Kappa
? Si gma
Mu, delta, kappa and sigma receptors have been 'mapped' 
within the CNS.
These receptors are widely distributed throughout the 
brain, but are not uniform in number in the different areas. 
This would indicate multiple hormonal and/or transmitter 
roles with differences in contribution to neuronal activity 
in different areas subserving different functions. Indeed, 
the distribution of the opioid peptides in general is closely 
correlated to the distribution of opioid receptors (Bloom et
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al., 1978; Sar et al., 1978). Of particular Interest are the 
relatively high levels of both receptors and opioid peptides 
in the hypothalamus (see Kalra, 1986).
There are three families of opioid peptides in the CNS:
1 . 0-endorphin,
2. Enkephalins and
3. Dynorphin/neo-endorphins.
All three are derivatives of a large, common precursor 
molecule, the pro-opiomelanocortin.
0-endorphin is present both in hypothalamic and 
extrahypothalamic brain areas in various concentrations. 
Immunohistochemical studies (De Kloet, Palkovits & Mezey, 
1981) have visualized 0-endorphin in cell bodies in the ARN 
and in nerve fibres and terminals throughout the entire CNS. 
p-endorphin co-exists with 0-LPH, ACTH and cr-MSH in the same 
neurones in the ARN and the ventral premammi1lary region. 
Several p-endorphin-containing fibre bundles arising in the 
ARN have been reported (De Kloet et al., 1981). Fibres 
proceed from the MBH in rostral (to the ventral forebrain), 
dorsal (to the thalamus and the dorsal midbrain)-, lateral (to 
the amygdala) and caudal (to the lower brainstem) directions.
Enkephalins are derived from pro-enkephalin A and pro­
enkephalin B. Pro-enkephalin A is the common precursor for 
methionine-enkephalin (met-enk) and leucine-enkephalin (leu- 
enk). Pro-enkephalin B is another precursor for leu-enk and 
a variety of opioids such as dynorphin 1-17 and alpha-neo-
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endorphin. Met-enk and leu-enk are widely distributed in the 
CNS. Enkephalins are present in measurable amounts in all 
major brain areas, the ratio of met-enkephalin versus leu- 
enkephalin varies from 1:1 to 6:1, being an average of 4:1 in 
the rat. The extremely high concentrations of both 
enkephalins in the globus pallidus is the most characteristic 
feature. Rich enkephalin innervation is found in the rostral 
forebrain, hypothalamus, amygdala, midline and
periventricular thalamic nuclei and the lateral septal 
nucleus. The enkephalins are found exclusively in the 
neurohypophysis where they are associated with nerve fibres 
that also contain vasopressin and oxytocin.
Immunohistochemical studies have revealed that many 
hypothalamic nuclei contain groups of enkephalin cell bodies 
(Hokfelt et al., 1979). These include the PVN, MPO, PAN, VMH, 
the dorsal and ventral premammi11ary nuclei, the perifornical 
area, and the ARN. All hyothalamic nuclei appear to contain 
moderate to high concentrations of enkephalin fibres and 
terminals. In particular, immunofluorescence localizations 
have revealed enkephalin-positive nerve terminals within the 
external layer of the ME suggesting that this opioid peptide 
has a role in neuroendocrine regulation (see Figure 13).
The most dense network of dynorphins is found in the 
substantia nigra followed by the lateral POA and the nucleus 
accumbens, the substantia innominata and the entopeduncular 
nucleus.
Prior to the discovery of the endogenous opioid 
peptides, the actions of morphine on pituitary hormone
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secretion had been described. Early research indicated that 
morphine would block ovulation in the rat (Barraclough & 
Sawyer, 1955). Although it was originally thought that this 
was a pharmacological action of morphine, it now appears 
likely that morphine interacts with opioid receptors in the 
brain to evoke these hormonal changes. Following the 
synthesis of the enkephalins and endorphins, a number of 
workers administered these systemically, or microinjected 
them into the brain ventricles to evoke a similar pattern of 
hormonal responses (Dupont et al., 1977; Cusan et al., 1977). 
The potency of enkephalin analogues parallels their potency 
in other indices of enkephalin action (Meltzer et al, 1978). 
That the action of morphine, enkephalins and endorphins are 
specific is suggested by the fact that their effects are all 
blocked by the opiate antagonist, naloxone.
Since the enkephalins have a hypothalamic distribution 
different from that of the endorphins (Elde and Hokfelt, 
1979), the site of action of the various opioid peptides 
following their injection into the brain ventricle has not 
been established. It appears that one site of action is 
probably in the region of the ARN. This is the site of 
neuronal perykaria which synthesize proopiocortin and whose 
projections extend into various other regions of the brain. 
On the other hand, the■enkephalinergic neurones seem to be 
located more in the periventricular region and in the rostral 
hypothalamus. Some of these neurones have cell bodies in the 
PAN and axons which extend to the neurohypophysis (Elde and 
Hokfelt, 1979).
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After an acute injedtion of morphine in the normal male 
animal, LH levels begin to decline within 30-45 minutes 
reaching a peak level of depression approximately one hour 
later (Cicero et al., 1977). In the castrated male rat, 
however, a single injection of morphine produces a fall in 
serum LH levels within 10-15 minutes and the peak level of 
depression is attained 30 minutes afterwards (Cicero et al., 
1979). The reason that LH levels fall somewhat more promptly 
after morphine administration in the castrated male than in 
the normal animal is probably related to the fact that LH 
levels are already markedly suppressed in the normal animal, 
as a result of the negative feedback effect of testosterone, 
and any further statistically significant decrease takes 
longer to be produced. In addition, this morphine-induced 
blockade of the postcastration-induced increase in serum LH 
can be readily overcome by the administration of GnRH.
Opiates have no direct effect on the secretion of 
gonadotrophin from the anterior pituitary (Cicero et al., 
1977) and the gland contains very few opioid receptors 
(Simantov & Snyder, 1977; Atweh & Kuhar, 1983, see Bicknell, 
1985). Thus opioids appear to inhibit gonadotrophin release 
by preventing the secretion of GnRH from the ME. Injection of 
the opioid antagonist naloxone will bring about a prompt rise 
in plasma gonadotrophins in many circumstances, suggesting 
that endogenous opioids are exerting a similar inhibitory 
influence (see Kalra & Kalra, 1984). It has been reported 
that intracranial implantation of naloxone in regions outside 
the hypothalamus fails to stimulate LH release (Kalra, 1981). 
On the other hand, implants containing minute amounts of
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naloxone or intracerebral injection of naloxone anywhere in 
the MPO and extending to the ME-ARN stimulates LH release 
(Kalra, 1981). Furthermore, morphine pretreatment blocks the 
local effects of naloxone implants in eliciting GnRH release. 
The strict regional specificity of naloxone action, together 
with the fact that morphine blocks the local excitatory 
action of naloxone, point out that opiate receptors which 
influence LH release may be confined to a narrow neural zone 
in the preoptic-tuberal pathway (Everett, 1977; Kalra et al., 
1981). A hypothalamic locus of action for the opiates has 
been suggested by the results from several other in vivo and 
in vitro studies in both rodents and humans (Cicero et al., 
1977, 1979; Arita & Kimura, 1988, Allen et al., 1988;
Elingboe et al., 1978).
The effects of opiates on the hypothalamic-pituitary-LH 
axis appear to be mediated by specific opioid receptors in 
the brain (Cicero, 1980; Cox, 1982; Wood, 1982; McDowell & 
Kitchen, 1987; Ranee, 1983; Stojilkovic, Dufau & Catt, 1987). 
Administration of naloxone to the rat results in a sharp 
increase in plasma LH (Bruni et al., 1977; Cicero et al., 
1979; Piva et al., 1986) suggesting the presence of an 
endogenous opioid-like substance that normally plays an 
inhibitory role in the secretion of LH. Furthermore, it has 
also been demonstrated tbat naloxone prevents the suppression 
of testosterone's feedback control of LH in castrated male 
rat (Kalra, Leadem, Kalra, 1984). These effects are not due 
to a direct receptor interaction between testosterone and 
naloxone, since it has been demonstrated that testosterone
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and naloxone do not compete with one another for their 
respective binding sites in the hypothalamus (Cicero et al., 
1979). Hence, it appears that testosterone is acting in some 
way through an opioid-containing system to suppress the 
secretion of LH.
The mechanism of action of opiates at the hypothalamic 
level may involve monoaminergic systems (Dyer et al., 1988; 
see Bicknell, 1985, Kalra, 1986). It has been suggested that 
opiates decrease NA and ADR activity (see Kalra, 1983). Prior 
NA and ADR depletion by diethyldithiocarbamate or bis-(4- 
methy1-1-homopiperanzinthylthiocarbony1) disulfide (FLA 63) 
prevents the LH release elicited by naloxone administered 
either systemically or intracranially in the MPO or ME—ARN. 
These suggests the fact that sites of opiate-NA action may 
occur within the preoptic—tuberal pathway. It has been 
postulated that naloxone may promote NA discharge from the 
terminals in the preoptic-tuberal pathway. The increase in 
endogenous NA release, in turn, may excite GnRH discharge 
leading to enhanced LH release from the pituitary gland (see 
Kalra, 1983). It is further supported by the findings that 
naloxone could enhance the release of GnRH from hypothalamic 
fragments in vitro (Wilkes & Yen, 1981). Also, clonidine, a 
post-synaptic NA agonist, injected to overcome the inhibitory 
action of morphine in steroid-primed rats readily stimulates 
LH release (Kalra & Simpkins, 1981). Following morphine 
treatment, NA, and not DA, could induce LH release in 
steroid-primed ovariectomized rats (Kalra & Simpkins, 1981) 
supporting the inhibitory action of opiates on NA 
neurosecretion.
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It appears that morphine or opioid peptides inhibit 
dopaminergic activity (Arita & Kimura, 1988, Meites et al., 
1979; VanLoon et al.; 1980, Haskins et al., 1981) and augment 
serotoninergic turnover (Yarbrough et al, 1973; Van Loon et 
al., 1978; Garcia-Sepi 1 la et al., 1978; AlgerL- et al., 1978; 
Johnson & Crowley, 1984).
The involvement of opiate-mediated monoaminergic 
regulation of LH release will be further considered in detail 
with the present results in the discussion part of this 
thesis.
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Aims of the study:
This study was designed to further investigate
1. The involvement of opioidergic and monoaminergic 
systems in regulating the preovulatory luteinizing
hormone (LH) surge in rats.
Three major experiments undertaken included:
a. The effects of specific adrenergic agonists and
antagonists on hypothalamic noradrenaline (NA) and 
adrenaline (ADR) concentrations,
b. The actions of specific opiate receptor agonists 
and their antagonist, naloxone, on the hypothalamic 
content and the turnover of NA, ADR, dopamine (DA), 
serotonin (5-HT) and its metabolite, 5-hydroxy- 
indoleacetic acid (5-HIAA) and on plasma LH
concentrations.
c. The effects of opiates on amine concentrations 
and turnover in specific hypothalamic nuclei.
2. The effects of specific opiate receptor agonists and
their antagonist, naloxone, on the content and turnover of 
hypothalamic neurotransmitter concentrations and on plasma LH 
levels in short-term orchidectomized rats.
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animals
The Sprague-Dawley rats were either purchased from Tuck 
& Sons, Battlesbridge, Essex or bred in the Animal Unit 
facilities at the Institute of Physiology, Glasgow 
University. Rats were housed in groups of 3 per cage under 
standardized conditions of temperature (21°C + 1°C) and
1ight/darkness rhythm (12h light : 12h darkness; lights on
06.00-18.00 hours), with free access to food and water.
Cages used were of transparent polycarbonate (macroIon) 
with a removable galvanised grill lid. The dimensions were 
approximately 42 x 25 x 20 cms. They were cleaned once a 
week when fresh sawdust was supplied.
Two different types of animal models were used during 
the course of this study.
1. Adult male rats
Animals weighing between 350-600g were used during this 
study. 5-12 rats were included in each experimental group.
i) Castration:
Rats were removed from the colony between 16.00 and 
17.00 hours preceding the day of the experiment. They were 
weighed and colour-coded. Subsequently the animals were 
anaesthetized. While under deep ether anaesthesia the rat 
was secured to the dissecting board in a supine position and 
a midline incision made in the lower abdominal skin. The 
exposed subcutaneous fat was dissected out to reveal the 
abdominal muscle coat. The abdominal muscle was then cut on
one side of the midline incision to expose the viscera. 
Lateral to this position and superior to the viscera lie the 
epididymal fat pads. These were gently withdrawn to 
exteriorise the testes. Blunt dissection allowed 
identification of the spermatic artery, vein and the vas 
deferens. A haemostatic ligature was made around the 
spermatic cords and their associated blood vessels and 
divided just distal to the ligature. The tied ends were 
returned to the abdominal cavity and the muscle layer was 
sutured with surgical silk. The skin was closed using Michel 
suture clips (size 3).
Once removed, the testes were dissected free of 
connective tissue and fat and weighed. The normal combined 
weight of the two testes was about 3gms. Rats which had 
testes weighing less than 2.5gms were not used in the 
experiments, as testicular weight was used as an index of 
normal functioning of the brain. The castrated rats were 
returned to the Animal Unit until the next morning.
ii) Intracerebroventricular Infusion:
Stereotaxic Apparatus:
All infusions were performed using a 10 jil graduated 
Hamilton Syringe mounted upon a David Kopf stereotaxic 
equipment (Tujunga - California). Three dimensional 
construction of the frames of this instrument allows the 
fixation of the rat's head at three different points. An ear 
plug was fixed at the external auditory meatus on either side 
and the nose was adjusted to a position in which the upper
Figure 14a. Fixation of Rat in the Stereotaxic Apparatus for 
intraventicular infusion of pharmacological agents used in 
this study.
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Figure 14b. Stereotaxic apparatus showing the intraventicular 
infusion technique.
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incisor bar firmly supports the upper jaw at the gingival 
margin behind the incisor teeth and a clamp was lowered onto 
the nasal region. The interaural rostro-caudal fixation 
maintained a recognised position of the head during infusion 
(Figure 14 a,b). Thus the infusion apparatus could be moved 
anteriorly and posteriorly along the long axis of the skull 
and the underlying brain.
The placement of the syringe needle into the lateral 
ventricle was assessed with the aid of the De Groot Rat Atlas 
(1959) using bregma as the reference point. Bregma is where 
the frontal and parietal bones meet in the midline. The 
position of bregma according to the De Groot atlas was found 
to be approximately 5.9mm anterior to the vertical zero plane 
(A5.7 to A6.1) and 6.3mm above the horizontal zero plane (H +
6.1 to H 6 .6)(Figure 15).
On the day following castration, the animals were
anaesthetized with saffan (Althesin) (Glaxo, Ware, Herts)
anaesthesia (2-3ml/rat i.p.) . This steroid does not block 
preovulatory LH surge or GnRH surge in female rats (Sarkar, 
1987). The anaesthetized rat was mounted on the stereotaxic 
apparatus. A midline incision was made in the scalp, the 
skin deflected and the membranous connective tissue scraped 
from the superior aspect of the skull. This revealed the
bregma. The position of bregma was marked and the co­
ordinates were noted. A hole was drilled at bregma using a 
5mm dental burr to expose the superior saggital sinus from 
which a blood sample was collected (approximately 1 ml). The 
Hamilton syringe was filled with a freshly-made solution 
containing the drug under investigation, or with the vehicle
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alone. The Infusion apparatus was placed on the stereotaxic 
frame and the needle tip lowered on to the brain surface and 
then advanced deeply to a pre-determined position (determined 
by reference to the De Groot Atlas). The solution was 
infused gently over a period of 60 seconds after which the 
syringe was raised and the infusion apparatus removed. Once 
the infusion had been completed, the animal was kept warm by 
wrapping in cotton wool. Blood samples were collected from 
the femoral vein at 15, 30, 60 and 90 minutes after the
infusion. Immediately after each collection heparinized 
physiological saline (approximately 1ml) was infused via the 
femoral vein to compensate for the volume depletion. After 
the final blood collection, the heart was perfused with 10% 
formol saline and the brain removed from the skull and fixed 
in formol saline for subsequent histological verification of 
the needle positioning. Each blood sample collected was 
centrifuged at 4°C for 10 minutes at 3000 rpm. The plasma was 
snap frozen in liquid nitrogen and stored at -20^0 until 
assayed for its LH levels at St.George's Hospital Medical 
School, London.
LH Radioimmunoassay:
Blood samples were placed in the relevant heparinized 
tubes and spun at 2000 rpm for 10 minutes at 4°C. The 
plasma was collected by aspiration and stored at -20°C. LH 
was measured in duplicate by a double antibody 
radioimmunoassay (RIA).
LH concentrations were determined by a heterologous 
double antibody RIA according to the modified method of
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Naftolin and Corker (1971) as described by Kendle, Paterson & 
Wilson (1978). Ovine LH fraction LER-1056-C2* (provided by 
Professor L.E.Reichert Jr., Albany University, NY) was used 
for iodination by the chloramine T method and as the standard 
diluted to provide a range of 10 pg .to 2560 pg per assay tube 
(covering 10 to 90% displacement of the label). The 
rabbit/rat LH antibody No. 15 (provided by Prof.
G.D.Niswender, Colorado University) was used as the rat 
antiserum. The samples were counted on a LKB 1272 Glinigama 
Scintillation Counter with a 70% counting efficiency. LH 
concentrations were expressed as ng/ml in terms of the LER— 
1056-C2 standard (potency 1.73 times NIH-LH-S1). The intra- 
and interassay coefficients of variation were 9.8 and 9% 
respectively and the sensitivity of the assay was 2 ng/ml.
Histological Verification:
The brains fixed and stored in formol saline were rinsed 
with water. The frontal lobes and the hind brain were
separated by coronal cuts. The dorsal portion of the brain 
was mounted on the specimen holder of a freezing microtome 
(Leitz-Wetzler) and then set at -80°C. The tissue was held 
firmly in place by encasement of the base in Cryo-Gel. 100 
pm sections were cut and arranged on a slide in series. They 
were stained with thionin blue and examined under a 
dissecting microscope (x40 objective). The infusions were 
considered to be intraventricular if the tract of the needle
was seen in the ventricle or if drops of blood were seen
within its swollen cavity. 99-100% of the rats fulfilled one 
of these criteria.
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Drugs
The pharmacological agents that were used in this 
experiment are listed in A1 Hamood et al., (1987).
The above described methodology was employed in my 
thesis work mainly to enable me to become familiar with the 
various techniques involved, and also to finish some work 
that had already been commenced. However, a slightly modified 
method to that previously mentioned was applied in the 
reminder of the study.
Animals were castrated and the infusions were made as 
described above. The rats were kept under anaesthesia 
throughout the duration of the experiment. After infusion, 
the rats were divided into two groups. In the first group of 
animals, blood samples were collected at 0, 10 and 20 minutes 
after the drug administration, at which time the animals 
were decapitated by guillotine.
In the second group, the blood samples were collected at 
0, 1 and 2 hours after the drug administration, at which time 
the animals were decapitated. The third and the final blood 
sample (at 20 minutes in the first group and two hours in the 
second group) was collected from the trunk at the time of 
decapitation. All the samples were centrifuged and the plasma 
stored at -20°C for LH radioimmunoassay.
Removal of the Brain and Isolation of the Hypothalamus:
The decapitated head was immediately placed on crushed 
ice. The skin lying over the skull was removed and the
6 5
occipital muscles from the occipital bone cut to reveal the 
foramen magnum. One blade of the scissors was cautiously 
introduced into the foramen. Keeping the blade parallel to 
the inner wall of the calvarium and as close to it as 
possible to avoid damaging the brain, cuts were made through 
the bone. These cuts were extended rostrally as far as 
bregma. After two parallel cuts had been made through the 
bone on each side of the skull, the bone was lifted forward 
and its rostral point of attachment separated. The closed 
scissors were then slipped under the frontal lobe and the 
brain lifted upwards. The optic and trigeminal nerves were 
cut, and the whole brain was coaxed gently out of the skull 
(Palkovits and Brownstein, 1983). The entire procedure was 
carried out.within about 60 seconds to prevent post mortem 
degradation of the amines prior to the assay.
The hypothalamus was removed en bloc by a saggital cut 
medial to the temporal lobes and by a coronal cut rostral to 
both the optic chiasma and mammillary bodies. Once removed, 
the hypothalamic sample was immediately frozen in liquid 
nitrogen. It was then weighed and placed in a glass 
homogenizer, kept in ice. 600 jul of 0 .1M hydrochloric acid 
containing 100 ng of an internal standard - IS (Dihydroxy 
benzyl amine - DHBA ) was added and the tissue homogenized 
for a period of 60 seconds. HC1 precipitates proteins and 
hence inactivates oxidising enzymes (monoamine oxidase), in 
addition to chemically stabilizing the amines. The 
homogenate was centrifuged at and the supernatant thus
obtained either injected immediately on to the reversed-phase 
High-Performance Liquid Chromatography (HPLC) column coupled
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to an electrochemical detector (ECD) or snap frozen in liquid 
nitrogen and stored at -80°C until assayed. However, all 
samples were analysed within a month of their preparation. 
20 jil of the supernatant was injected on to the HPLC column 
in duplicates and the concentrations of NA, ADR, DA, 5-HT and 
its metabolite 5-HIAA were simultaneously measured.
The total content of the individual amine in each sample 
was divided by the wet weight of the hypothalamus and the 
concentration expressed as ng/gram wet weight of the tissue.
Histology:
As the brains were removed without fixation for 
hypothalamic sampling, a slightly different method had to be 
adopted to check for the position of infusion needle. After 
the separation of the hypothalamus, rest of the brain was 
frozen on ice. The hind brain was separated from the 
remaining tissue and the dorsal portion mounted on the 
specimen holder of a freezing microtome. 100 /am sections 
were cut and immediately checked for the needle placement 
under the dissecting microscope.
Opiate Drugs used in the Experiment:
Various opiate receptor agonists and the opiate 
antagonist, naloxone, were dissolved in physiological 
saline and administered in a 10 ;ul volume 18-20 hours 
postcastration.
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Drug Dose (jug/kg) Receptor Subtype
Naloxone 
Morphine 
Levorphano1 
Cyclazoclne 
SKF 10,047 
FK 33 824
30, 60 
400, 800 
400 
50 
100 
2
Opiate antagonist
Mu agonist
Mu agonist
Kappa agonist
Sigma agonist
Met-enkephalin 
analogue
Table 2. Names, dosages and the specific opiate receptor 
agonists and the antagonist used in the study.
Estimation of Turnover:
It has long been recognized that measurements of brain 
content or concentrations of amines do not provide a true 
index of their functional activity (Brodie et al., 1966). 
For this reason, turnover studies have been used to acquire 
more meaningful information on the dynamics of change in the 
aminergic system.
The turnover of the catecholamines, NA and DA, were 
measured using oc— methy 1-DL-par a-tyrosine methyl ester 
HCl(oC-MPT) (Sigma Chemicals, Poole, Dorset), a competitive 
inhibitor of tyrosine hydroxylase, to block the rate- 
limiting step in catecholamine biosynthesis (see Brodie et 
al., 1966). The rate of serotonin synthesis was measured by 
using the steady state kinetics in which rates of synthesis 
and loss are equal (Tozer, Neff & Brodie, 1966) .
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Experimental Design
The second group of animals, from which the blood 
samples were collected at 0, 1 and 2 hours used for the study 
of amine turnover. The rate of fall of biogenic amines was 
observed at two different intervals by blocking the synthesis 
of catecholamines by a-MPT.
a) Control Group (Group 0):
Rats were infused with one of the specific opiate 
receptor agonists or the opiate antagonist, naloxone, and 
decapitated after two hours of treatment. No <*-MPT was given 
at any stage, and those thus served as controls.
b) Group I:
Rats were infused with one of the above mentioned 
drugs, and after an interval of one hour, the animals were 
injected with 1 ml of a-MPT (250 mg/kg, i.p.) dissolved in 
physiological saline. Thus the synthesis of catecholamines 
was blocked for an hour before the animals were decapitated.
c) Group 11:
Immediately after infusion, in this group, the animals 
were given «-MPT thus blocking the catecholamine synthesis 
for two hours before decapitation.
Blood samples were collected at 0, 1 and 2 hours after
drug administration and the plasma stored for LH assay. The 
brains were removed and the hypothalami separated. After 
homogenization and centrifugation, the supernatants analysed
6 9
for amine content using HPLC.
Calculation of turnover and rate constants 
Catecholamines
Turnover rates and rate constants were calculated by the 
method of Brodie et al . , 1966.
The values for the tissue levels of NA and DA were 
logarithmically transformed for calculation of linearity of 
regression, standard error of the regression coefficients 
and significance of differences between regression 
coefficients. A regression curve was obtained for the 
amine concentrations against time by computer
(Glasgow V.M.E.).
The regression equation was of the form y = mx + C with 
gradient m and intercept C on the Y axis.
Equation of the line: ln[CA3 = kt + ln[CA]o
where [CA] is the concentration of catecholamine, (ng/gm), 
[CA]o is the concentration of catecholamine at time = 0
(ng/gm), k is the rate constant of amine depletion (hr ;L) , t 
is the time (hours).
The linear value of the intercept + its standard 
deviation was calculated by taking the antilogarithms. The 
mean intercept was multiplied by k to obtain a turnover rate 
(TR), the unit of which was ng amine/gram tissue/hour. The 
standard deviation (SD) of the turnover was calculated by the
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following formula (Hohn & Wuttke, 1979):
SDtr = y [(k)2 (SDcc«3 ) = +2(k) [CA]o (Covariance) + (SD*)S [CAlo^]
where SDl:o «^ is the standard deviation of the intercept and 
SDk is the standard deviation of the rate constant k; both 
values were obtained by the computer. The covariance was 
calculated from this expression,
-X<T
Covariance =
Z( X—X)22
where X is the mean of all observations of X (hours) . o'2 is 
the residual sum of squares divided by the degrees of freedom 
ft (where fi = n-2) of which both relate to the regression 
equation, and 2 (X-X):2 is the sum of the squares about the 
mean, X.
In[NA]
1 nCNAH«g«i nmt til
V .
1O
Time (hrs)
Regression Analysis of Amine Depletion
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Serotonin
v*'
The turnover rate of 5-HT was calculated by taking the 
ratio between the content of 5-HT and its metabolite 5-HIAA.
Catecholamine Turnover: Statistical Analysis
Catecholamine turnover constants, initial tissue levels 
and turnover rates in the drug-treated groups were compared 
with the saline-treated groups. The degree of significance
between the control and the drug-treated groups were
determined by the Student's t-test with Fisher's adaption for 
multiple comparisons using the following formula:
Xo - X* 
t = ______________________
^  (se02 + set12)
where Xo is the mean value in the control group and se0 , the
standard error of this value and Xt , the mean value in the
treated group and set, the standard error.
Serotonin Turnover: Statistical Analysis
The ratio between 5-HIAA and 5-HT was calculated for 
individual values obtained. The figures were converted to 
their percentage values. An unpaired Student's t-test was 
applied to calculate the level of significance between the 
control- and the treated-groups.
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2. Adult female rats
3-4 month old rats weighing between 200-300g were 
purchased from Tuck and Sons, Battlesbridge, Essex. Upon
their arrival in the Animal Unit, they were numbered and
vaginal smears taken. The technique of smearing for the 
assessment of changes in the vaginal cytology is simple and 
rapid (Stockard & Papanicolaou, 1917). The smearing
procedure involved swabbing of the vaginal lumen and 
examining the smear obtained under the xlOO objective of a 
light microscope. Four different stages of the oestrous
cycle were determined by the cell type present in the vaginal 
smear.
Stage of Cycle Vaginal Smear
Dioestrus I Nucleated epithelial cells and poly­
morphonuclear leucocytes with some 
keratinised squamous epithelial 
ce1 Is.
Dioestrus II Nucleated epithelial cells and
leucocytes.
Pro-oestrus Nucleated epithelial cells.
Oestrus Keratinised squamous cells only.
Table 3. Assessment of oestrous cyclicity by vaginal 
cytology.
The vaginal smears were monitored every day and only 
those rats showing three or more consecutive 4-day oestrous 
cycles were selected on the day of pro-oestrus for use in the 
experiment. The onset of pre-ovulatory LH surge occurs 
between 14.00 - 15.00 hours which reaches a peak at 16.30
hours on the day of pro-bestrus (Blake, 1976), and the GnRH 
surge slightly precedes'the LH surge which it evokes (Sarkar 
et al., 1976). The central neurotransmitters have been shown 
to be involved in regulating this process (Cramer &
Barraclough, 1978). Therefore, the specific adrenergic and 
the opiate agonists and antagonists were administered between
12.30 - 13.30 hours so that they would interfere with these
surges and the animals were decapitated at 14.30 hours as it 
was anticipated that by this interval changes would have
occurred in the amine concentrations and LH levels. Between 
5-10 animals were used in each experimental group studied.
Three different types of experiments were used.
i) Effects of specific adrenergic agents on hypothalamic 
catecholamine levels
Rats were given pentobarbitone sodium (PB), 35mg/kg, 
i.p., at 13.30 hours on the afternoon of pro-oestrus to block 
the pre-ovulatory LH surge (see introduction). To determine 
the effects of stimulatory adrenergic agents, these were
injected (i.p., 20mg/kg) in a 1ml volume of either
physiological saline or 5% glucose between 14.00 and 14.30 
hours. The animals were decapitated between 15.30 and 16.00 
hours.
Adrenergic blocking agents were dissolved in 5% glucose 
and administered (i.p., 20mg/kg) to pro-oestrous rats at
13.30 hours. These animals had not previously been treated 
with PB. The rats were decapitated between 14.30 and 15.00 
hours.
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The trunk blood ,was collected at the time of 
decapitation, centrifuged and the plasma stored at -20c*C for 
LH assay. *
t
The brains were removed, hypothalami isolated and the 
samples prepared as already described. 20 i^l aliquots of the 
supernatant was injected on to an HPLC column and the 
concentrations of NA and ADR were simultaneously analysed.
Drug
Clonidine 
Yohimbine 
Salbutamo1 
Fenotero1 
ICI 118,551
Receptor Subtype
«3>-agonist 
®22 antagonist 
^-agonist 
#2—agonist 
^-antagonist
Table 4. Names and the specific adrenergic receptor agonists 
and antagonists used.
ii) Effects of opiates on the hypothalamic aminergic content:
Various opiate receptor agonists and the opiate
antagonist, naloxone, were dissolved in physiological saline 
and administered in the dosages shown in Table 5, in a 1ml 
volume, at 12.30 hours on the afternoon of pro-oestrus.
Three different modes of injection were used:
intraperitoneal, subcutaneous and intraventricular.
Tifluadom, a kappa receptor agonist, was more potent when 
administered subcutaneously than when given intraperitoneally 
(Morley et al., 1983; Cooper et al., 1985). A similar mode of
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injection was also used for SKF 10,047. Subcutaneous 
injections are known to cause discomfort and so were 
performed under light ether anaesthesia. However, a group 
of control animals treated in the same manner were used for 
comparison. The synthetic met-enkephalin analogue, FK 33,824 
does not cross the blood-brain barrier (Wilkinson & Bhanot, 
1982). Therefore, this drug was administered directly into 
the brain ventricles using the stereotaxic apparatus by the 
procedure already described. However, a control group treated 
in the same manner was also used. There were, thus, three 
different control groups, one treated intraperitoneally, the 
second treated subcutaneously and last group treated 
intracerebroventricularly.
Drug Dose (mg/kg) Mode Receptor Subtype
Naloxone 10
Morphine 10,40
Levorphanol 10
cyclazocine 5
Ketocyc1azocine 5
Tifluadom 10
SKF 10,047 10
FK 33,824 2,4
ip
ip
iP
ip
ip
sc
sc
icv
Opiate antagonist
Mu agonist
Mu agonist
Kappa agonist
Kappa agonist
Kappa agonist
Sigma agonist
Met-enkepha1 in 
analogue
Table 5. Names, doses and modes of injection and main 
receptor specificity of the opiate drugs used.
After an interval of two hours, the rats were
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decapitated, brains removed and the hypothalami separated. 
The hypothalamic samples were homogenized and centrifuged at 
4^0. The supernatant was analysed for NA, ADR, DA, 5-HT AND 
5-HIAA using the HPLC.
FK 33,824, a superactive enkephalin analogue, had no 
significant effects at the two different doses studied and 
hence was omitted from further experimental studies.
Turnover studies:
The rats treated with specific opiate receptor agonists 
or the antagonist, naloxone, at 12.30 hours on the day of 
proestrus were given o<r-MPT (250 mg/kg, i.p.) at two 
different intervals.
Control (Group 0):
Pro-oestrous rats were treated with the drug at 12.30 
hours and decapitated at 14.30 hours at which time trunk 
blood was collected for LH analysis. These animals served as 
controls as they were not injected with oc-MPT at any stage 
before decapitation.
Group I :
Various opiate agonists or the antagonist, naloxone, 
were injected into pro-oestrous rats at 12.30 hours and 
oC-MPT, a tyrosine hydroxylase blocker, was given at 13.30 
hours to block the rate-limiting step of catecholamine 
biosynthesis. The animals were decapitated at 14.30 hours and 
the blood sample collected. Thus the synthesis of 
catecholamines was blocked for 60 minutes before
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decapitation.
Group 11:
oC-MPT, dissolved in physiological saline was injected in 
a volume of one ml at 14.00 hours followed by the 
administration of specific opiate drugs. The animals were 
decapitated at 14.30 hours and the blood sample collected for 
LH determination. In this group, the catecholamine synthesis 
was blocked for 30 minutes.
The calculation of turnover of catecholamines, NA and DA 
using a blocker, and the indoleamine, serotonin using the 
steady state kinetics has been described in the earlier part 
of this section.
iii) The effects of opiates on biogenic amine levels in
specific hypothalamic regions
Studying the effects of drugs on central 
neurotransmitter levels in the whole hypothalamus lacks 
specificity as there are several nuclei included within the 
hypothalamus. To study the action of the drugs under 
investigation on these nuclei, Palkovit's technique of 
punching the specific areas within the brain was developed, 
and the earlier work described in experiment 2 was repeated.
Brains were removed as previously described and were 
frozen immediately on dry ice in an upright position to 
ensure the brain remains symmetrical. Under these conditions 
there are no detectable changes in amine concentrations 
(Gaitonde, 1971). The frozen brains were wrapped tightly in
78
seacon film to prevent dehydration of the brain and stored at 
-80° C for a maximum of one month before analysis. Samples 
stored at -80° C displayed almost negligible degradation of 
any components (Kilpatrick et al., 1986).
Microdissection (Palkovits's) Technique:
The frozen brains were allowed to partially thaw to 
promote adherence. The hind brain and the anterior most 
portion of the forebrain were removed by coronal cuts. The 
remaining portion of the brain was mounted on the specimen 
holder of a freezing microtome which was then set at -70°C. 
The base of the tissue was held in place using Cryo-Gel. 
There are several landmarks in various parts of the brain 
which are of assistance in cutting the sections (see 
Palkovits & Brownstein, 1983). The first one of importance in 
punching the hypothalamic nuclei was the fusion of the 
corpus callosum. 100 jum sections were cut until this fusion 
was confirmed. Subsequently, serial 500 Aim coronal brain 
slices were taken in the frontal plane and arranged on 
labelled slides (0-11) kept on dry ice. The last section (No.
12) was at the mamillary peduncles. Cut in this manner the 
whole of the hypothalamus which measured 4.2 mm in the 
rostral caudal diameter in a 200g rat, is contained within 
the last 8 (4-11) sections. The remainder of the brain was 
discarded. There were no punches made from the first four 
sections (0-3); they were merely cut to ensure the correct 
plane of sectioning. It was necessary to have ample space for 
correction of the sectioning plane. The sections numbered 4— 
11, which contained the areas of interest, were, in turn.
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transferred on to a cold plate (set between -5°C to -20°C)
*
under a dissecting microscope (x40 objective). Bilateral 
homologous tissue samples of suprachiasmatic n'ucleus (SCH), 
medial preoptic area (MPO), anterior hypothalamic area (AHA), 
median eminence (ME), ventromedial hypothalamus (VMH) and
arcuate nucleus (ARN) were dissected from the sections using 
a stainless steel hypodermic needle with 0.7 mm or 0.9 mm 
internal diameter by cutting and sharpening the tip
perpendicular to the long axis. A separate needle was used
for each area and washed thoroughly with absolute alcohol 
between each brain dissection. The needle was always kept 
cold on dry ice before its use. The location of discrete 
brain regions were identified by reference to the Paxinos and 
Watson atlas (1982) in conjunction with section number and 
standard neuroanatomical landmarks such as the ventricle and 
midbrain (Palkovits, 1973) in a standardized manner. For a 
complete review of the methods and equipment required for 
microdissection the reader is referred to Palkovits & 
Brownstein (1983). To position the tip of the punch, the 
section was approached with the punch held at an angle of 45° 
to the surface of the section. When the tip of the needle 
was in the appropriate location, it was fixed with gentle 
pressure to the surface of the section and then the punch was 
brought into a vertical position and pressed into the 
brain slice. Finally, the punch was rotated to free the 
sample from the surrounding tissue and withdrawn. After a 
successful withdrawal of the sample, a sharp edged hole
remained in the section (Figure 16) and the tissue disc was 
held within the needle. If tissue segments were retained in

the punched area, or if the entire sample was left behind,
f
the needle was replaced in its original position and the 
punching repeated. The tissue disc was pushed out of the 
punch into the bottom of the disposable polyallomer 
centrifuge tube and stored at -80° C without the addition 
of any fluid to increase the stability of the amines within 
the tissue. On the day of analysis, 75 jul of 0. 1M 
hydrochloric acid containing 12.5 yig of DHBA as an internal 
standard was added to each tube and the tissue homogenized by 
sonication for about 5 seconds in a sonication bath. The 
homogenate was centrifuged at 4°C and the supernatant 
injected on to the HPLC column and analysed for NA, ADR, DA, 
5-HT and 5-HIAA.
Protein Estimation:
The amount of brain tissue in the homogenate was 
estimated by its protein content. Since the protein content 
of the brain is fairly stable, the amount of protein in a 
brain extract is proportional to its tissue content. The 
protein pellet contained within the centrifuge tubes were 
stored at -80°C for protein determination by a modified 
comassie blue method of Bradford (1976) using Pierce reagents 
(Pierce, Chester, England, UK).
A standard curve of protein concentration versus 
absorbance was obtained by the reaction between known weights 
of bovine serum albumin (BSA-Sigma Chemical Co., Poole, 
Dorset) (2.5 - 100 jug) and Comassie Blue G250 Pierce protein 
assay reagent (Figure 17). The absorbance was read at 595 nm 
using an LKB Biochrom Ultrospec 4050 spectrophotometer.
8 2
100
80-
5
ABSORBANCE AT 595 nra
Regression Equation;-
Protein Concentrations 110.^17(Absorbance)-58.981 
Correlation Coefficients 0.959 
Standard Errors 10.03^
Figure 17. Standard curve of concentration of bovine 
serum albumin (BSA) versus absorbance at 595 nra 
immediately after reaction with Cooraassie Blue Q250
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The sample homogenate was dispersed In 200 jal of 0. IN 
NaOH and Incubated overnight at 4°C. The following morning, 
sample tubes were sonicated for 1-2 minutes. Duplicate 100 
jil samples were transferred into two separate tubes and each 
tube was diluted with 900 ul distilled water. 1 ml of the 
assay reagent was added to the diluted samples and the 
absorbance read immediately against the blank at 595 nm.
The protein concentration (jig/ml) in each tube was 
calculated by substitution of its absorbance into the 
regression equation of the standard curve (see Figure 17) . 
The protein content of the duplicate tubes were added 
together to give the total protein concentration of the 
original sample.
The total content of the individual amines in each 
sample was divided by the total amount of protein in that 
sample to give the concentration of each amine in the 
original tissue in pg/pg protein.
Turnover Estimation:
For the turnover estimation, the specific opiate 
agonists and the antagonist were limited to one in each 
receptor subtype studied. This is listed in Table 6.
The turnover studies described for pro-oestrous rats, 
where the whole hypothalamic amine concentrations were 
measured, was repeated to study the effects of opiates on 
specific hypothalamic nuclei. Here, the catecholamine 
synthesis was blocked for two intervals of 45 and 90 minutes.
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Contro 1 animals were not, treated with oc—MPT, on© sot of 
animals received oG-MPT at 13.45 hours. Another set of animals 
received oG-MPT at 13.00 hours. The turnover calculations were 
similar to the one previously described.
Drug Dose (mg/kg) Mode Receptor Subtype
Naloxone 
Morphine 
Tifluadom 
SKF 10,047
10
40
10
10
IP
ip
sc
sc
Opiate antagonist 
Mu agonist 
Kappa agonist 
Sigma agonist
Table 6. Names, doses, modes of injection and the receptor 
specificity of the drugs used.
Amine Analysis; High Performance Liquid Chromatography with 
Electrochemical Detection (HPLC-ECD)
As all the monoamines including 5-HT and 5-HIAA were of 
interest, this study employed the more recent method of 
direct injection of sample supernatant into the high 
performance liquid chromatography system with electrochemical 
detection (HPLC-ECD), without prior extraction procedures. 
This reduces sample preparation time and eliminates the need 
for evaluation and calculation of recovery rates, thus 
increasing analysis efficiency and also reducing the 
possibility of technical errors.
There are, however, certain disadvantages with this 
direct method, such as the resulting large solvent front. 
This does not allow the analysis of some of the metabolites
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of NA which elute along with the solvent front. However, 
these metabolites are not of interest in this study as NA 
turnover was measured by the oc-MPT depletion method. The 
second disadvantage is that the cell surface becomes coated 
with proteinaceous material very quickly reducing the 
sensitivity. This problem was alleviated by incorporating a 
precolumn into the HPLC system to remove residual 
microparticulate and/or dissolved proteinaceous material in 
the sample. In addition, the working electrode was 
frequently cleaned by alumina polishing or treated with 
chromium trioxide (200mg CrGs, 0.3ml H^O, 9.7ml H^SO^ for 30
seconds as described by Anton (1984) if responsiveness was 
severely impaired.
The simultaneous determination of NA, ADR, DA, 5-HT and 
5-HIAA make considerable demands on the chromatographic 
system, as it entails the separation of compounds of 
different polarities such as basic (NA, ADR, DA and 5-HT) and 
acidic (5-HIAA). HPLC in the reverse phase mode, including 
ion pair offers selective separation. The composition and 
conditions of the mobile phase are the main determinants of 
solute separation.
The main components of the HPLC system are schematically 
represented in Figure 18. The apparatus consisted of:
a) Column:
The column (Shandon Instruments, Runcorn, England) was 
packed with ODS (octadecyl si lane) hypersil (5 ji) packing 
material using a column packing device. The octadecyl
S
.71
 
IS
86
•lijcctloa h«.d 
with septus
/«t«p
detector call
TRIO
Simplified diagram depicting HPLC-2CD. 
The sample is injected using & micro­
syringe. The amines are separated by 
the column and detected electrochem- 
Ically, whereupon the "TRIO" displays 
and prints a chromatogram.
A
A bore are shown chromatograms which were plotted from a 
sample (left) and a standard (right). The computer is 
calibrated with the standard amine mixture, thereafter 
it identifies the internal standard (IS) in the sample 
and calculates the amounts of amines' present.
Constituents of mobile phase.
Citrlo aoid d»74d
Sodium acetate 4*dlg
Claoial acetic acid X.IJiml
Sodium EDTA 47flS
Sodium octane sulpbonate I2Qng
Tetra hydro furaa I2ml
Methanol 5Q®1
Made up to 1 litre with distilled 
water.
Figure 18. High Performance Liquid Chromatography with 
Electrochemical Detection
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hydrocarbon "tails" radiate from the silica particles,
effectively forming a polar stationary phase. This forms a
♦
column environment suitable for reverse phase chromatography.
An ion pairing agent (octane surphonic acid; HPLC grade,
Fisons) was used to render the amines more lipophilic, this
6
ensures their adequate column separation. The length of the 
column was 250mm long and 5mm in diameter. The column was 
protected by a precolumn which was hand-packed with the same 
material as was the column. The precolumn prevented the 
contaminated substances from the sample entering into the 
column itself thus increasing its life time. The precolumn 
often had to be cleaned by removing the top of the packing 
and replacing it with fresh ODS. This column was replaced by 
a shorter column (150 mm long and 4.6 mm wide; Beckman 
Instruments, England) to reduce the run time in the later 
part of the study. The packing material used was the same as 
in the other column. This also had a pre-column purchased 
from Beckman Instruments, England.
b) Pump:
A Gilson 302 pump capable of producing high pressure 
(up to 5000 psi) with a monometric module (Gilson, France) 
delivered the solvent through the column. The flow rate was 
set at 1.5 ml/minute during the analysis. The system was set 
to a low flow rate 0.15 ml/minute at other times.
c) Solvent:
An aqueous buffer constantly used consisted of 0.1 M 
sodium acetate, 0.1 M citric acid, 19 roM glacial acetic acid.
126 iim Na EDTA, 5% (v/v) methanol, 1.2% (v/v) tetrahydrofuran 
(THF) and 431 mM sodium octyl sulfate. This was adjusted to a
pH of 4.9 with 10M sodium hydroxide to ensure complete
ionisation of biogenic amine molecules. HPLC grade reagents 
and deionised water were used for the preparation of the 
solvent. The buffer was filtered under pressure through a 
mi 11ipore solvent clarification kit with 0.45 jam aqueous 
filters (Scotlab, Bellshill, Scotland) before use. This 
prevents any dust particles entering into the system. The 
solvent was then degassed with helium for 20-30 minutes. The 
occurrence of air bubbles could be eliminated (which 
increases the baseline noise) by this procedure. The 
solvent was recycled and renewed every 10-15 days.
d) Sample loading:
The sample was introduced on to the top of the pre­
column through an injector valve (Rheodyne "7125", 
California). The valve was then turned from 'load' position 
to 'inject' position thereby diverting the solvent through
the loop to carry the sample on to the pre-column. It was
flushed with deionised water in both positions before the 
next sample was injected.
e) Detector:
To detect and quantitatively measure the separated 
compounds, an electrochemical detector was used.
The potentiostat system (detector) consists of a carbon 
working electrode, a platinum wire auxiliary electrode and a 
silver/silver chloride reference electrode.
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The cell consists of a Plexiglass block divided in half 
by a 0.2 mm polytetra fluoroethylene (teflon) gasket. A flow 
cell with a volume of <lml, containing the glassy carbon 
working electrode, is formed by a slit (1.6cm x 0.5cm) cut in 
the gasket.
Electrochemical detection is based on the principle that 
compounds capable of oxidation or reduction in an electrical 
field result in the passage of current and the magnitude of 
this current is a measure of the quantity of compound 
oxidised or reduced. Each chemical reaction has a threshold 
voltage related to its Redox Potential and the potentiostat, 
a form of feedback voltage control, allows this voltage to be 
set for the particular compound to be measured. This 
introduces some measure of selectivity into the system. For 
catechol- and indoleamines a +ve potential of 0.65 V was 
used.
An electronic controller provides the operating 
potential (+0.65 V) with reference to an Ag/AgCl reference 
electrode (sensitivity InA, time constant 5 sec). When the 
signal passes across the working electrode it is oxidised 
thus giving up electrons to it and thereby generating an 
oxidation current. Provided the flow rate, temperature and 
working electrode area remain constant, the current detected 
is directly proportional to the concentration of the amine 
passing across the electrode. The potentiostat amplifier 
maintains the constant preset potential across the 
electrochemical detector and amplifies the nanoampere 
oxidation current to provide a proportional output voltage
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which is displayed on the recording- integrator',
f) Chromatogram:
As oxidisable bands of each compound pass the detector, 
the current (and resultant voltage) rises and falls, as a 
function of time to yield a 1iquid—chromatography, 
electrochemical chromatogram (Figure 18). The first peak on 
the chromatogram was the solvent front representing the 
oxidation of hydrochloric acid which has the shortest 
retention time and leaves the column first. This was 
followed by NA, ADR, IS, 5-HIAA, DA and finally 5-HT. As 5- 
HT remains in the column longest, it is susceptible to band 
broadening and hence the peak is short and broad compared to 
the other five. The system enables the detection of amines 
both at picogram and nanogram levels and within the range of 
amounts assayed the relationship between amount of amine and 
response amplitude is linear. Chromatograms were analysed by 
Trivector computing integrator (Scot lab, Bellshill, Scotland) 
and quantified using the peak area ratio of IS to analyte 
method.
Standards:
Stock solutions of noradrenaline bitartrate, adrenaline 
bitartrate, 3-hydroxy tyramine (dopamine) hydrochloride, 5- 
hydroxytryptamine creatinine sulphate complex, 5—hydroxy
indole-3-acetic acid and of internal standard, 3,4-dihydroxy 
benzyl amine hydrobromide were prepared in 0.1M HC1. They
Were stored at 4°C and renewed every four weeks. The
standard solution containing 2 ng/20 pi was made up every
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day by diluting the stock standards with 0.1M HC1 and 
for calibrating the system for amine analysis.
used
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pffects of intracerebroventricular administration of opiates 
pn Hypothalamic Monoamine Content, turnover and Plasma LH in
Short-term Castrated Rats
a) Hypothalamic Monoamine content 20 minutes post-infusion:
ng/gm wet weight of tissue
Treatment Receptor n
properties NA DA 5-HT 5-HIAA
Saline
opiate
9 3704+138 474+53 1511+101 1136+105
Naloxone
< C*! O/ i / 1*: <-*5 >
antagonist 8 3252+202 663+45* — —
Naloxone
< i ct) / 1 <: >
M ti 9 4323+195* 624+43 1715+251 1248+ 98
Morphine
< A O O /..1 cj / I-: cj >
jj-agonist 12 2888+212* 364+71 - -
Morphine
( 0 (") q / | .: (^| >
jj-agonist 10 3063+206* 374+50 1464+121 1108+101
Levorphano1
< A O 0>..i <3 / 1.: <3 >
ju-agonist 6 2545+181** 552+39 2161+259* 1151+ 85
Cyclazocine
< i cj / 1-*: c? >
k-agonist 5 2609+270** 363+45 2322+259* 631+ 96
SKF 10,047
< 1 O O/.t <3 / »-<: <3 >
O-agonist 7 3469+280 556+37 3089+337** 896+ 67
FK 33,824
C / I t: Q >
Met-enk 
analogue
9 3238+202 513+43 1692+152 927+148
Table 7. Values are Mean + SEM; Unpaired Student's t-test; 
Level of significance * p<0.05 and ** p<0.01. 'n' “ Number of
observations.
Morphine (400jjg and 800jug/kg) , levorphanol and
cyclazocine significantly decreased, and naloxone
significantly increased the NA content of the hypothalamus
compared to the controls. On the other hand, DA levels were 
not significantly altered by any of the opiate—agonists 
administered; only naloxone (30jig/kg) brought about a
significant elevation in DA concentrations. ADR levels were
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not significantly altered in' any of the groups studied. SKF 
10,047, eyelazocine and levorphanol caused a significant rise 
in 5-HT levels but neither morphine nor naloxone had a 
significant effect. Cyclazocine was the only opiate studied 
to cause 5-HIAA levels to decrease significantly. , FK 33,824 
had no significant effect on any of the amines measured.
b. Plasma LH levels 20 minutes post-infusion:
Plasma LH (ng/ml)
Treatment Receptor n
properties 0 min. 10 mins. 20 mins .
Saline _ 23 6.88+0.54 6.54+0.58 6.72+0.66
op i ate
Naloxone antagonist 9 6.94+0.94 7.78+0.84 8.90+1.18
< 3  < >) x Q y  W .Cf >
Naloxone ii ii 14 10.32+1.52 13.20+2.46 15.60+3.92
< / h: Q  >
Morphine li-agonist 12 6.35+1.53 4.56+0.59 4.22+0.50
< 4DOj.iq y U:cj )
Morphine li-agonist 15 6 .99 + 1.63 2.77+0.29* 2.51+0.3*
< BOOj..tg / l <: g.j >
Levorphano 1 p-agonist 6 7.38+1.49 4.81+0.96 4.85+0.99
( a  o o j > (?) y w.c) >
Cyclazocine k-agonist 5 7.62+0.66 5.73+0.77 7.29+0.85
< sr;<:>).» cj / k: <3 >
SKF 10,047 cf-agonist 7 9.90+2.90 6.45+0.66 6.64+0.56
< .1. 0 0 ).,ig / kQ >
FK 33,824 Met-enk 9 5.91+0.41 5.85+0.5 5.56+0.68
/ l.:g > analogue
Table 8. Values are Mean + SEM; Paired Student's t—test 
confirmed by two-way analysis of variance. Level of 
significance * p<0.05. 'n' — Number of observations.
Both at 10 and 20 minutes after the treatment with the 
various opiate agonists or the antagonist, naloxone, plasma 
LH concentrations were little altered. The higher dose of 
morphine was the only drug to cause a significant decrease in
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the plasma LH content. Both doses of naloxone slightly 
increased the LH levels; but, the rises were not significant.
c. Hypothalamic NA concentration and turnover two-hours 
post-infusion:
Treatment Receptor n k+SEM TR+SEM C+SEM
properties (per hour) (ng/g/hr) (ng/g)
Saline _ 23 0.42+0.01 1412+23 3361+21
opiate
Naloxone antagonist 15 0.44+0.01 1600+21 3677+19
< /  l >: <3 >
Morphine
C (ii) O  C> i.jl q  /  1*: q  >
ju-agonist 20 0.21 + 0.01* * * 561+31*** 2670+42**
Cyclazocine k-agonist 16 0.17+0.02*** 419+46*** 2540+64**
< ssoj..i<3 /  k g  >
SKF 10,047 cf-agonist 15 0.42+0.02 1342+71 3225+85
< 1 O  O  p  Q  S  <a >
Table 9. The rate constant (k+SEM), turnover (TR+SEM) and the 
initial concentration (C+SEM) of hypothalamic NA. Level of 
significance * P<0.05; ** p<0.01 and *** p<0.001. 'n' =
Number of observations.
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d. Hypothalamic DA concentration and turnover two—hours
post-infusion:
Treatment Receptor
properties
n k+SEM TR+SEM 
(per hour) (ng/g/hr) ;
C+SEM
(ng/g)
Saline
opiate
23 0.28+0.01 96+5 344+06
Naloxone
< d.> 0,1-1 <3 / I-*: <3) >
antagonist 15 0.15+0.02 51+8 340+10
Morphine
< In) O Cty-i Q / I*: Q >
ju-agonist 20 0.66+0.01*** 401+10*** 608+09***
Cyclazocine
< 30pg / K<a >
k-agonist 16 0.29+0.02 168+14 578+16***
SKF 10,047
< % OOug / I i: <3 >
o'-agonist 15 0.69+0.02*** 468+19*** 679+19***
Table 10. The rate constant (k+SEM), turnover (TR+SEM) and 
the Initial concentration (C+SEM) of hypothalamic DA . Level 
of significance * p<0.05; ** p<0.01 and *** p<0.001. 'n‘
Number of observations.
It was observed that the NA content of the hypothalamus 
and its turnover rate was very significantly decreased in 
both morphine and eyelazocine-treated animals. SKF 10,047 and 
naloxone, both, had no significant effect on either the NA 
content or its turnover. On the other hand, both morphine 
and SKF 10,047 brought about a highly significant rise in the 
hypothalamic DA content and its turnover. There was a highly 
significant rise in the rate constant in both these groups. 
Cyclazocine also caused a significant rise in the DA content 
of the hypothalamus, but there was no significant change 
observed in its turnover. Naloxone again did not 
significantly alter either the DA content or turnover.
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e. Hypothalamic 5 HT concentration and. turnover two—hours 
post- infusion:
Treatment
Receptor
properties n
5-HT
C+SEM
< n g / Q >
5-HIAA
C+SEM
< no s a >
5-HT 
 ^TR+SEM
-fc ± C3 >
Saline
opiate
5 1670+213 1458+190 93+13
Naloxone
(60pg / Q >
antagonist 5 2789+249* 2124+358 85 + 21
Morphine
< BOOjjg / I-*: Q >
ju-agonist 9 2911+111** 1177+172 63+08
Cyclazocine
< SOug / F: q >
k-agonist 6 1644+262 1720+159 44+04*
SKF 10,047
< 1 OOug / t-c eg >
o-agonist 5 1920+283 0988+ 60 56 + 05
Table 11. Values are Mean + SEM; unpaired Students' t-test; 
level of significance * p < 0.05; ** p < 0.01. 'n' = Number
of observations. C, Concentration; TR, Turnover.
The results are summarized in Table 11 and Figure 21. 
5-HT content in the hypothalamus was significantly elevated 
by both naloxone and morphine, but had no significant effect 
on its turnover rates. Cyclazocine brought about a 
significant decrease in the turnover of 5—HT, the content of 
which was not significantly altered. SKF 10,047 had no 
effect on either the content or turnover of 5-HT. There was 
no significant change observed in the hypothalamic 5—HIAA 
levels in any of the groups studied.
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f. Plasma. LH levels two-hours post-infusion:
Treatment Receptor n
Plasma LH (ng/ml)
properties 0 hour 1 hour 2 hours
Saline 
Naloxone
< 60|..ig / l-i: Q >
opiate
antagonist
14
5
6 .57+1.06 
6.73+0.41
5 . 03+0.72 
5 .56 + 0.82
4.32+0.67 
12.26+3.17
Morphine
< B  O  O  i..i Q / 1-.: cj >
ju-agonist 8 8.45+0.97 4.14+0.34* 4.74+0.56*
Cyclazocine k-agonist
< S O licj / ra >
6 9.15+1.22 4.65+0.46* 4.89+1.03*
SKF 10,047
< 1 OCy..iQ /  l-i: <;j >
b-agonist 5 8.05+1.03 8.16 + 1 . 22 4.44+0.96
Table 12. Values are Mean + SEM; Paired Student's t-test 
confirmed by two-way analysis of variance. Level of
significance * p<0.05. 'n' = Number of observations.
Both morphine and cyclazocine brought about a
significant decrease in circulating LH levels both at one 
hour and two hours after infusion. In contrast neither 
naloxone nor SKF 10,047 caused any significant alterations in 
circulating LH levels.
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g. Plasma LH levels two-hours post-infusion: Effect of o(-HPT 
for one hour.*
Treatment Receptor
Plasma LH (ng/ml)
properties 0 hour 1 hour 2 hours
Receive°C-MPT
Saline
Naloxone
< ACy ig / I-: cj >
Morphine
(HOOf.to / ■< Ol >
opiate
antagonist
5
8
6.43+0.27 
6.78+0.98
3.75+1.25 
5.94+1.21
2.91+0.31*** 
5.04+1.41
ji-agonist 6 7.01+0.74 4.72+0.75 2.61+0.34***
Cyc lazocine
/  I-.: <;j )
k-agonist 5 6.31+0.58 3.81+0.33 1.87+0.22**
SKF 10,047 o'-agonist 5 6.70+0.42 9.34+1.95 3.17+0.25***
( i  O  <;:> | . ( (r) /  I-.: rt) >
Table 13. Values are Mean+SEM. Paired Student's t-test
confirmed by two-way analysis of variance. Level of
significance * p<0.05, ** p<0.01 and *** p<0.001.
Number of observations.
' n' =
OC-MPT treatment one hour after the intraventricular 
infusion of various specific opiate receptor agonists caused 
& highly significant decrease in the levels of plasma LH. 
The control animals which received of-MPT also showed a very 
highly significant fall in their LH levels. Naloxone 
Prevents the fall normally induced by 0£-MPT.
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h. Plasma LH levels: Effect of oC-MPT for two hours:
Plasma LH (ng/ml)
Treatment Receptor n
properties 0 hour 1 hour 2 hours
receive^MPT
Saline _ 5 8.00+0.97 3.00+0.30* 1.70+0.27**
opiate
Naloxone antagonist 5 6.08+0.88 5.87+1.35 3.20+0.63
(60|ig y U:c3 >
Morphine fi-agonist 6 7.29+1.12 2.55+0.63* 4.69+1.11*
(0OOJICJ /  l-:cj >
Cyclazocine k-agonist 5 8.20+0.84 4.33+0.92* 3.07+0.83**
(3C>M<3 / W. <3 >
SKF 10,047 O’-agonist 5 7.13+0.85 5.36+1.39 5.17+1.23
( 1 OOj..«cj /  rj >
Table 14. Values are Mean+SEM; paired Student's t-test
conf irmed by two-way analysis of variance). Level of
significance * p<0.05, ** P<0.01 and *** p<0.001. 'n'
Number of observations.
It was observed that q£-MPT administration to both the 
control animals and those receiving morphine and cyclazocine 
caused a significant decrease in their plasma LH levels both 
at one hour and two hours post—treatment. However, 
circulating LH levels were not significantly changed in those 
animals treated with SKF 10,047 and with naloxone.
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Effectg gf Opiates on the Hypothalamic Monoamine 
Concentration and Turnover in Pro-oestrous Rats
a. Hypothalamic NA concentration and turnover:
Treatment
Saline ip 
Naloxone
< X C> rn Q / I-: <:j |i X (::i >
Morphine
C :l OiKQ / h: (j H i | :> >
Morphine
< ■<'•1 O m c:j / I ■: Q >
Levorphano1
< :l. <::> m  /  l-«: <3 y :l. |::> >
Cyc1azocine
< '.‘Hi m i . : j  /  In  q  11 1  j::j >
Ketocyc1azoc
< m  Q / I ■: q  y J. (:» )
FK 33,824
< 4|,ig / I*: <:j u 1 v t >
Saline sc 
Tifluadom
< 1 <:> m  <;j / l i: q  y tiu t:: >
SKF 10,047
< 1 Om<3 / !■: <j | sc >
Receptor
properties
n k+SEM 
per 30min
TR+SEM
ng/g/30min
C+SEM
ng/g
opiate
18 0 .20+0.01 0750+37 375 2+44
antagonist 28 0.39+0.01** 1955+54*** 5014+66**
p-agonist 10 0.58+0.04* * * 1949+161* 3361+106
p-agonist 15 0 .21+0.01 0492+31 2345 + 36* * *
ju-agonist 14 0.48+0.03* 1308+77 2724+49***
k-agonist 15 0.37+0.01** 1474+53** 3984+31
k-agonist 15 1.22+0.03*** 5265+148*** 4316+67
met-enk 
analogue
12 0.33+0.03 1189+128 3605+83
— 18 0.19+0.01 0713+45 3752+53
k-agonist 19 0.38+0.01** 1397+41** 3677+42
o'-agonist 20 0.31+0.01 1140+52 3678+49
Table 15. The rate (k+SEM), turnover(TR+SEM) and the initial 
concentration of NA (C+SEM) in the hypothalamus. Level of 
significance * p < 0.05, ** p < 0.01 and *** p < 0.001.
It was noted that the higher dose of morphine and 
levorphano1 very significantly decreased the hypothalamic NA 
concentration. No significant changes were observed in 
its turnover rates. Naloxone significantly increased both the 
concentration and the turnover of NA. Morphine (lOmg/kg), 
cyclazocine, ketocyclazocine and tifluadom had no significant 
effect on the hypothalamic NA concentration, but brought
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about a significant rise in its turnover rate. Neither SKF 
10,047 nor FK 33,824 significantly altered the concentration 
nor the turnover of hypothalamic NA.
b. Hypothalamic DA concentration and Turnover:
Treatment Receptor
properties
n k+SEM 
per 30min
TR+SEM
ng/g/30min
C+SEM
ng/g
Saline i.p .
op i ate
18 0.87+0.04 305+19 351+14
Naloxone
( I Oin. j / 1'.: 1 j it .i |:> >
antagonist 28 0.90+0.02 386+ 9 428+ 6
Morphine
( :l. <:> m I.J / 1 •: <;.:j it :l. >
ju-agonist 10 2.57+0.07* ** 1266+67*** 49 3+22
Morphine
< ■>'■1 C> m / 1*: Q  it 1 |..» >
ja-agonist 15 0.82+0.02 514+18* 6 26+14*
Levorphano1
< 1 Oiri. j / I-. Q it .1 |:> )
li-agonist 14 0.64+0.03 277+16 433+ 9
Cyclazocine
< rt / !-■: i.:j « .1. ■:> )
k-agonist 15 1.03+0.04 351+15 340+ 7
Ketocyc1azocine k-agonist
< r ,  (Tt <;.:j /  l-it >.:j H 1 >
15 0.90+0.03 297+10 33U+ b
FK 33,824
< '1 f /  ! ■: k.j || i. v t v .  >
met-enk 
analogue
12 1.18+0.02 439+10 372+ 4
Saline sc — 18 0.66+0.04 212+16 320+14
Tifluadom
< :l. C> fTt q  y  1-:. q  u t:it <::: )
k-agonist 19 0.52+0.02 225+ 9 433+ 8
SKF 10,047
< :L C> r n  ( j  / 11: <::j j| tut *::: >
o-agonist 20 0.31+0.01 135+ 6 437+ 6
Table 16. The rate (k+SEM), turnover (TR+SEM) and the initial 
concentration of DA (C+SEM) in the hypothalamus. Level of 
significance * p <  0.05, ** p <  O.O'l and *** p < 0.001. 'n' =
Number of observations.
The concentration, turnover and the rate constant of DA 
in the hypothalamus are summarized in Table 16 (Figure 25) . 
Except morphine, none of the other groups brought about any 
significant changes in their DA activity.
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c. Hypothalamic 5 HT Concentration and. Turnover:
Receptor 5-HT 5-HIAA 5-HT TR
Treatment properties n C+SEM
< n  q  /  q  >
C+SEM
( n  g /  Q  >
+SEM
< *X. R: ja ± <::» >
Saline ip
opiate
7 2122+164 1510+160 72 +  06
Naloxone
( :l. O  m  q  /  l< Q  l i p >
antagonist 6 2012+265 1214+290 56 +  10
Morphi ne
< i <::» m  q  /  q  >
U-agonist 5 1644+111 1177+172 71 +  10
Morphine
< A- O  m  <:;j / Q  |i 1 p  )
ju-agonist 6 4209+178*** 3259+142*** 78+04
Levorphano 1
( 1 O  m  q  / I-.: Q  ji J. fj >
ju-agonist 5 944+ 69*** 0788+ 94** 85 +  10
Cyclazocine
< “5 m  a  / I-*: o  II A p  )
k-agonist 7 2075+215 1481+ 53 79 + 09
Ketocyclazocine k-agonist
( H  fn cj / I :: <y (J J. p  >
6 1814+103 1531+ 58 87 + 07
FK 33,824
< Ai.\ Q  /  l->: Q  ; A -fc. >
Met-enk
analogue
5 2474+160 1503+213 62 + 09
Saline sc — 9 2869+246* 1693+187 59 +  04
Tif luadom
( 1 ©  rn q  /  I-.: q  ii ihj cu >
k-agonist 5 2469+200 2083+123 89+09*
SKF 10,047
< 1 O  fn q  /  U: q  |t >
tf-agonist 9 4321+224** 2518+219* 59 + 05
Table 17. Values are Mean+SEM; unpaired Students' t-test; 
level of significance * p  < 0.05; ** p < 0.01 and *** p < 
0.001. ' n' = Number of observations. C, Concentration, TR,
Turnover.
From the above table, it can be seen that, morphine 
(40mg/kg) , and SKF 10,047 caused a significant rise in the 
hypothalamic 5—HT and 5—HIAA levels, but had no significant 
effect on their turnover. The lower dose of morphine, 
FK 33,824 and naloxone, on the other hand, did not 
significantly alter the hypothalamic content of 5—HT, 5 HIAA
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or their turnover. An unusual observation was that 
levorphano1 brought about a significant decrease in the
levels of hypothalamic 5-HT and 5-HIAA. Saline
subcutaneously injected into the controls caused a 
significant elevation in the hypothalamic content of 5-HT
when compared to those controls which received saline
intraperitoneally (Gopalan, Brown & Gilmore, 1988).
Cyclazocine and ketocyclazocine did not have a significant 
effect on the levels of 5—HT and 5-HIAA and their turnover. 
Tifluadom was the only k-agonist to increase the hypothalamic 
turnover of 5-HT significantly.
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Ill
d. Plasma LH levels in Pro-oestrous Rats (with or without 
(fi-MPT) :
Plasma LH (ng/ml)
Treatment Receptor
properties OC-MPT oc-MPT °c-MPT
0 mins. 30 mins. 60 mins.
Saline ip _ 4.74+0.62 1.50+0.07*** 3.20+0.44
(27) (5) (10)
Naloxone opiate 11.34+2.04* * 1.33+0.09*** 6.97+0.65
< 1 O m g / k g i  lp) antagonist (32) (5) (5)
Morphine jj-agonist 2.76+0.38* — 2.10+0.32
( lOmg/ k: g n 1 p > (5) (5)
Morphine p-agonist 2.35+0.39** 1.66+0.17* 2.06+0.10*
< A O m g / k: eg * i p > (17) (5) (5)
Levorphano1 p-agonist 4.92+2.04 — 4.03+1.55
(lOmg/kgi ip) (20) (5)
Cyclazocine k-agonist 4.91+0.60 - 2.56+0.37
(Hmg / kg » i p > (17) (5)
Ketocyclazocine k-agonist 6.06+1.71 - 1.94+0.29*
( Smg / k: cj D ± p > (19) (5)
FK 33,824 Met-enk 1.82+1.68 - —
< 2pg / k: g R i •'✓•fc. > analogue (9)
FK 33,824 Met-enk 3.09+0.76 - 1.11+0.41
< 4pg / k: g R i v t > analogue (7) (5)
Saline sc - 3.89+0.38 1.40+0.2*** 2.39+0.43*
(20) (5) (5)
Tif luadom k-agonist 2.19+0.21** 1.70+0.10 1.78+0.07
< 1 Omg / k: g y wen > (22) (5) (5)
SKF 10,047 o'—agonist 4.04+0.54 2.00+0.13** 2.21+0.57
(10mg/kg|i wen > (22) (5) (5)
Table 18. Values are Mean + SEM; Unpaired Student's t-test 
confirmed by two-way analysis of variance. Level of 
significance * p<0.05 ** p<0.01 and *** pCO.OOl. (n)= Number 
of observations.
The plasma LH concentration was significantly decreased 
by both doses of morphine and tifluadom. This effect was 
significantly increased by naloxone. On the other hand, 
levorphano1, cyclazocine, ketocyclazocine, both doses of FK
33,824 and SKF 10,047 failed to cause any significant changes
112
levorphano1, cyclazocine, ketocyclazocine, both doses of FK
33,824 and SKF 10,047 failed to cause any significant changes 
in the levels of plasma LH. oC-MPT administered 30 minutes 
prior to decapitation brought about a significant decrease in 
the concentration of plasma LH in all groups studied except 
the tifluadom-treated group. o£-MPT administered one hour 
prior to decapitation showed a similar decrease in LH levels 
in the groups treated with morphine, ketocyclazocine and 
saline (sc) . Levorphanol was the only opiate which did not 
cause any significant changes in the plasma LH levels either 
in the control group or after oC^MPT treatment for one 
hour.
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Effects— of— Opiates on Monoamine Concentration and Turnover 
within the— Specific Hypothalamic regions in Pro—oestrous Rats
i) NA and DA concentration in the SCH, MPO, AHA, ME, ARN and 
VMH:
Area Saline
< c o n t r  c:> 1 >
Levorphano1
< f...i —  .a <3 <::> n  i ® t  >
Cyclazocine
< h: —  Q  «::> i < X nu -fc. >
Ketocyclazocine
< l-c — a g a n l  su-fc >
X O  m  Q  /  1,:q E3 m  eg /  l i: <::j S i m g  /  k  g
c 1 3  :j t: a i: v  :i C 3
SCH
NA 64.32+ 8.36 37.07+4.88* 64.40+ 6.91 40.8+4.15*
DA 6.79+ 1.21 12.44+3.02 21.49+ 5.87 09.48+2.4
MPO
NA 78.98+ 4.86 53.73+3.02** 91.29+ 7.83 80.05+9.32
DA 7.24+ 1.45 13.12+2.29 20.41+ 4.61 16.00+4.04
AHA
NA 72.10+ 8.70 41.46+2.75* 79.50+10.70 58.20+3.68
DA 5.26+ 0.62 10.83+2.43 11.77+ 4.49 11.77+4.49
ME
NA 108.40+15.30 52.68+5.96* 75 .50 + 11.70 68.30+9.12
DA 28.50+ 2.85 17.46+3.52** 62.00+11.80 17.18+5.02*
ARN
NA 98.77+ 8.36 48.65+3.00*** 72.18+ 7.99 73.10+7.34
DA 7.54+ 1.58 10.32+1.94* 15.94+ 2.75* 10.94+2.52*
VMH
NA 89.27+ 6.23 53.34+4.04*** 106.70+13.40 61.78+3.24**
DA 10.40+ 2.46 17.51+4.86 15.96+ 3.23 7.24+2.14
Table 19. Values are Mean + SEM (pg//*g) ; unpaired Student s 
t-test. Level of significance * p<0.05; ** p<0.01 and
* * * P < 0.001. Cr'3 = Number of observations.
Levorphano1 caused a significant decrease in the NA 
content of all six regions studied. DA content was
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significantly decreased only in the ME. Cyclazocine did not 
cause any significant changes in the NA concentration of any 
hypothalamic area studied; DA levels, however, were 
significantly increased in the ARN. Ketocyclazocine brought 
about a significant decrease in the NA concentration of the 
SCH and VMH. It also brought about a significant fall in the 
DA concentration of the ME.
ii) NA Concentration and Turnover:
Suprachiasmatic nucleus (SCH)
Treatment Receptor
properties
n k±SEM 
per 45min
TR±SEM
pg/)ug/45min
Conc+SEM
pg/>ig
Saline ip
opiate
24 0.48+0.02 30.45+1.34 63.43+1.98
Naloxone
< 1 Om<::j /  <:j y J. p
antagonist
>
24 0.65+0.02 46 .96 + 1 .69 72.24+1.62
Morphine)
< 40mg /  l< <y y 4. £
U-agonist
>
22 0.27+0.02 12.44+1.10* 46.10+0.88*
Saline sc - 22 0.50+0.01 30.47+1.04 o 0 .95 + 0 .96
Tifluadom
< 1  C > m <:j /  I i: cj y <id
k-agonist
>
22 0.28+0.01* 13.08+0.62** 46 .06 + 0.6**
SKF 10,047 cr^ -agonist 21 0.15+0.02** 07.53+0.93*** 48.91+1.03
( 1 O m i:;j ✓ Ii: <;j y ltd i
Table 20A. The rate constant (k+SEM), turnover(TR+SEM) and 
the initial concentration of NA (Conc+SEM) in the SCH. Level 
of significance * p < 0.05, ** p < 0.01 and *** p < 0.001. 
'n' = No. of observations.
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Medial Preoptic Area (MPO)
Treatment Receptor
properties
n K+SEM 
per 45min
TR±SEM
pg/)ug/45inin
Conc+SEM
pg/^ig
Saline ip 
Naloxone
< 1 Omg/kgn i p >
opiate
antagonist
24
24
0.34+0.01
0.45+0.01
25.06+1.00 
47.06+1.33**
73.70+1.42 
104.58+1.38**
Morphine
(40mg/kgi i (=> >
M-agonist 22 0 .21+0.01 11.13+0.80* 52.98+0.62**
Saline sc — 22 0.47+0.01 31.66+1.07 67.36+1.15
Tifluadom
< lOmg/kg p mta >
k-agonist 22 0.27+0.02 17.89+1.56 66.02+1.60
SKF 10,047
< 1 O f n gj / k: <3 p m c= >
o'-agonist 22 0.23+0.01** 16.82+0.97* 74.44+1.06
Table 20B. The rate (k+SEM), turnover (TR+SEM) and the
initial concentration of NA in the MPO. Level of
significance * p < 0.05 and ** p  < 0.01. 'n' = No. of
observations.
Anterior Hypothalamic Area (AHA)
Treatment Receptor
properties
n K+SEM 
per 45min
TR+SEM
pg/)^g/45min
Conc+SEM
pg/M2
Saline ip
opiate
24 0.26+0.02 18.97+1.54 72.97+1.49
Naloxone
< lOmg/kg| Ip)
antagonist 24 0.36+0.01 27.07+0.90 75.19+0.91
Morphine
<40mg/kg | Ip)
U-agonist 22 0.04+0.01* 01.82+0.39* 45.6 +0.6***
Saline sc - 22 0.18+0.01 13.02+1.00 71.52+1.11
Tifluadom
( lOmg/kg | «c >
k-agonist 22 0 .20+0.02 13.20+1.59 66.00+1.89
SKF 10,047
< 1 Omg/kg| bc)
o^agonist 22 0.31+0.02 25.50+1.87 82.27+2.07
t. --------------------------- -----
Table 20C. The rate constant (k+SEM), turnover (TR+SEM) and the
initial concentration of NA in the AHA. Level of
significance * p  < 0.05 and *** P  < 0.001. 'n' - Number of 
Observations.
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Median Eminence (ME)
Treatment Receptor
properties
n k+SEM 
per 45min
TR+SEM
pg/jig/45min
Conc+SEM
pg/MS
Saline ip
opiate
24 0.65+0.01 48.39+4.08 74.44+1.67
Naloxone
( 1 Omg /  k- a * ± (3 >
antagonist 24 0.50+0.01 41.13+1.19 82.27+1.26
Morphine
( 40mg/kg| lp)
p-agonist 22 0.31+0.02** 16.76+1.35 54.05+1.50
Saline sc — 22 0 .22+0.01 18.38+0.67 83.93+0.86
Tifluadom
< 1 Omg S  •< g | mic: >
k-agonist 22 0.43+0.01** 24.74+0.61 57.40+0.56***
SKF 10,047
(lOmg/kgi me:)
o'-agonist 22 0 .21+0.02 11.07+1.13 52.46+1.12***
Table 20D. The rate (k+SEM), turnover(TR+SEM) and 
concentration of NA (Mean+SEM) in the ME. 
significance ** p  < 0.01 and *** p  < 0 .001. 'n' 
observations.
Arcuate Nucleus (ARN)
the initial 
Level of 
= Number of
Treatment Receptor
properties
n K+SEM 
per 45min
TR+SEM
pg/pg/45min
1 Conc+SEM
pg/j^g
Saline ip
opiate
24 0.49+0.01 45.90+1.58 93.69+1.72
Naloxone
<1Omg/kgi 1p >
antagonist 24 0.53+0.01 55.43+1.71 104.58+2.13
Morphine
(40mg/kgi ± p> >
p-agonist 22 0.5 +0.01 34.36+0.89 68.72+1.03*
Saline sc - 22 0.41+0.01 36.54+1.10 89.12+1.33
Tifluadom
(lOmg/kgi me:)
k-agonist 22 0.60+0.02 42.49+1.44 70.81+1.49
SKF 10,047 o'-agonist 22 0.29+0.01 16.70+0.80** 57.40+0.73***
< t Omg /  kg | me: >
Table 20E. The rate constant (k+SEM), turnover (TR+SEM) and 
the initial concentration of NA in the ARN. Level of 
significance * p < 0.05, ** P < 0.01 and *** p < 0.001. n “ 
Number of observations.
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Ventromedial Nucleus (VMH)
Treatment Receptor
properties
n k+SEM 
per 45min
TR+SEM
pg/)ig/45min
Conc+SEM
pg/^g
Saline ip
opiate
24 0.55+0.01 55.27+1.23 100.45+1.23
Naloxone
( l O m g / k g n i p )
antagonist 24 0.39+0.02 42.03+2.47 107.77+2.86
Morphine
< •<'+ O i T1Q / k: a > ip)
>i-agonist 22 0 .10+0 .02*** 07.01+1.50*** 70.81+1.66**
Saline sc — 22 0.31+0.01*** 32.75+0.70** 105.64+0.68
Tifluadom
< :l. O m q / h: <a n m cr. >
k-agonist 22 0.14+0.01* 11.05+1.10*** 80.64+1.2***
SKF 10,047
< 1 O m < a  g me: >
o'-agonist 22 0.28+0.01 27.30+0.24 97.51+0.42
Table 20F. The rate constant (k+SEM), turnover(TR+SEM) and 
the initial concentration of NA in the VMH. Level of 
significance * p < 0.05, ** p  < 0.01 and *** p  < 0.001. ’n' =
Number of observations.
The NA content and its turnover in the six hypothalamic 
regions studied i.e., SCH, MPO, AHA, ME ARN and VMH are 
summarized in Table 20(A-F) and Figure (27a-f). Morphine 
caused a significant decrease in the NA content and turnover 
in the SCH, MPO, AHA and VMH. The NA content alone was 
significantly decreased in the ARN. Tifluadom significantly 
decreased the content and turnover of NA in both the SCH and 
VMH and decreased the NA content alone in the ME but had no 
significant effects in the MPO, AHA and ARN. SKF 10,047 
brought about a significant decrease in both the content and 
the turnover of NA in the ARN, but decreased turnover alone 
in the SCH and MPO and content alone in the ME. It did not 
cause any significant changes in either the AHA or the VMH. 
On the other hand, naloxone significantly increased both the
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concentration and the turnover of NA In the MPO. There were 
no significant changes observed in any other region studied.
iii) DA Concentration and .Turnover:
SCH
Treatment Receptor
properties
n K+SEM 
per 45min
TR+SEM
pg/jig/45min
Conc+SEM
pg/jug
Saline ip
opiate
24 1.01+0.02 7.10+0.25 7 . 03+0.20
Naloxone
< 1 O r> cy /  <3 || 1
antagonist
>
24 1.09+0.03 9.35+0.28 8.58+0.09
Morphine
< ■‘"•I <::» IT) /  11- Q  II J. |:a
p-agonist
>
22 0.89+0.03 7 . 27 + 0.22 8.17+0.29
Saline sc - 22 0.98+0.03 8.98+0.32 9.11+0.37
Tifluadom
( J. OfTicij s ' !•»; 1»U ci
k-agonist
>
22 1.01+0.04 13.87+0.67 13.74+0.61
SKF 10,047
< ;l O iti <3 /  In 13 H mi
o'-agonist
>
21 1.09+0.05 14.10+0.76 12 .94+0.74
Table 21A.The rate constant (k+SEM), turnover(TR+SEM) and the 
initial concentration of DA (cone +SEM) in the SCH. ‘n ‘ =
Number of observations.
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MPO
Treatment Receptor
properties
n K+SEM 
per 45min
TR+SEM
per/>ig/45min
Conc+SEM
pg/^ff
Saline ip
opiate
24 0.71+0.03 05.14+0.30 07.24+0.30
Naloxone
< 1 Omg /  kg | i pj )
antagonist 24 1.04+0.02 15.79+0.47*** 15.18+0.34***
Morphine
< 40mg / t< Q R 1 p >
/i-agonist 22 0.36+0.03 02.39+0.14 06.69+0.22
Saline sc — 22 0.65+0.04 03.74+0.09 05.75+0.24
Tifluadom
< 1 O m g / l«: g V ««c:: >
k-agonist 22 0.93+0.02 11.97+0.31*** 12.94+0.31***
SKF 10,047
< lOmg/kgr me >
tf-agonist 22 1.01+0 .02* 19.49+0.46***
u________
19.30+0.41***
Table 21B. The rate constant (k+SEM) , turnover (TR+SEM) and 
the initial concentration of DA (cone. +SEM) in the MPO. 
Level of significance * p < 0.05 and *** p < 0.001. 'n'
Number of observations.
AHA
Treatment Receptor
properties
n K+SEM 
per 45min
TR+SEM
pg/)ig/45min
Conc+SEM
pg/^g
Saline ip
opiate
24 0.69+0.02 3.60+0.06 5.26+0.13
Naloxone
(lOmg/kgi 1p >
antagonist 24 0.59+0.03 3.09+0.11 5.26+0.20
Morphine
(40mg/kg|ip)
jti-agonist 22 0.43+0.01* 3.37+0.08 7.92+0.12
Saline sc - 22 0.53+0.02 2.63+0.13 5.00+0.15
Tifluadom
< lOmg/kg R >
k-agonist 22 0.28+0.02 1.98+0.12 7.03+0.14*
SKF 10,047
( lOmg/kg y mcz >
o'-agonist 22 0.26+0.03 1.77+0.22 6.82+0.03
Table 21C. The rate constant (k+SEM) , turnover (TR+SEM) and 
the initial concentration of DA (cone. + SEM) in the AHA. 
Level of significance * P < 0.05. 'n' * Number of
observations.
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M E
Treatment Receptor
properties
n K+SEM 
per 45min
TR+SEM
pg/;ug/45min
Conc+SEM
pg/.pg
Saline ip
opiate
24 0.62+0.02 17.67+0.63 28.50+0.58
Naloxone
( l O m g / kg| ip)
antagonist 24 1.72+0.04*** 74.61+3.49** 43.38+1.77
Morphine
(40mg/kgii ± p» >
ji-agonist 22 0 .86+0.02 16.60+0.62 19.3 +0.49*
Saline sc — 22 0.7 +0.01 23.65+0.65 33.78+0.58
Tifluadom
< 1 © mg / kg | «*cr >
k-agonist 22 0.65+0.01 26.41+0.58 40.45+0.53
SKF 10,047
< 1 © tr\ Q / g n «c )
o'-agonist 22 1.05+0.05 40.40+2.88 38.47+2.14
Table 21D. The rate constant (k+SEM), turnover(TR+SEM) and 
the initial concentration of DA (cone + SEM) in the ME. 
Level of significance * p < 0.05, ** p < 0.01 and *** p  <
0.001. 'n' = Number of observations.
A R N
Treatment Receptor n K+SEM TR+SEM 1 Conc+SEM
poroperties per 45min pg/>ig/45min pg/jug
Saline ip - 24 0.73+0.03 05.5 +0.34 07.54+0.32
opiate
Naloxone antagonist 24 1.14+0.03 18.01+0.76** 15.80+0.56**
< 1 Omg /  kg| 1 p )
Morphine yi—agonist 22 1.06+0.03 14.41+0.75* 13.60+0.58
C 4dmg /  kg | ± p> >
Saline sc - 22 0.69+0.03 04.31+0.29 06.2*3+0.29
Tifluadom k—agonist 22 0.85+0.03 09.5 +0.40 11.13+0.35
( lOmg/kg D wc>
SKF 10,047 O'- agonist 22 1.05+0.04 15.78+0.21** 15.03+0.61**
<1Omg/kg|«c>
Table 21E. The rate constant (k+SEM), turnover (TR+SEM) and 
the initial concentration of DA (cone +SEM) in the ARN. 
Level of significance * p < 0.05 and ** p < 0 .01. 'n' *
Number of observations.
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VMH
Treatment Receptor n K+SEM TR+SEM Conc+SEM
properties per 45min pg/)ig/45min psr/lig
Saline ip -
opiate
24 0.91+0.02 08.54+0.32 09.39+0.27
Naloxone antagonist
< 1 o m <a ' ■< « 11 ip>
24 1.1 +0.03 11.42+0.52 10.38+0.38
Morphine ji-agonist
< A- O m <3 / I-: a B ± p> >
22 0.61+0.02* 05.38+0.20 08.85+0.19
Saline sc - 22 0.42+0.01*** 02.95+0.11*** 07.03+0.10
Tifluadom k-agonist
< 1 C>m<a S h:<a t «c )
22 0.69+0.03 07.33+0.32** 10.59+0.29*
SKF 10,047 cr-agonist
< 1 Omeg y !-■: q p me: >
22 0.95+0.04* 10.49+0.66* 11.02+0.54
Table 21F. The rate constant (k+SEM), turnover (TR+SEM) and 
the initial concentration of DA in the VMH. Level of 
significance * p < 0.05, ** p < 0.01 and *** p  < 0.001. 'n' = 
Number of observations.
The content and the turnover of DA studied in various 
specific hypothalamic regions are summarized in Tables 21(A- 
F) and Figures 27(a-f). The interesting observation made was 
that in the SCH there were not any significant changes in 
either the content or the turnover of DA after opiate 
treatment. Morphine brought about a significant decrease in 
the DA content of the ME. This opiate also caused a 
significant rise in DA turnover in the ARN. It failed to have 
a significant effect in the SCH, MPO, AHA and VMH. Tif luadom 
significantly increased both the content and turnover of DA 
in the MPO and VMH and the content alone in the AHA. This 
drug did not affect the DA content or its turnover in the 
SCH, ME. and ARN. SKF 10,047 caused a significant rise in 
both the content and the turnover of DA in the MPO and ARN;
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the turnover alone was Increased in the VMH. SKF 10,047 did 
not bring about any significant changes in either the DA 
concentration or its turnover in the SCH, AHA and ME. 
Naloxone, which was expected to reverse the effects of the 
opiates brought about a significant rise in the concentration 
and the turnover of DA in both the MPO and ARN and of the 
turnover alone in the ME; no significant changes were 
observed after naloxone treatment in DA concentration and 
turnover in the SCH, AHA and VMH.
iv) 5-HT Concentration and Turnover:
SCH
Receptor 5-HT 5-HIAA 5-HT
Treatment properties n Conc+SEM
< n  i::j / >
Conc+SEM TR+SEM
< >i. i«...» i i . > >
Saline ip
opiate
13 25.81+3.62 18.63+3.52 54 + 07
Naloxone
( x Off)(i) / l-i; (| i )
antagonist 13 18.18+4.63 13.81+2.90 91 + 12
Morphine
< 4 d m g  /  Q  R U. p  >
p-agonist 12 16.90+3.35 13.87+1.68 120+32
Levorphano1
< :l. O  m  q  / l-i; <:g |t :L p:> >
p-agonist 7 18.62+4.41 09.36+1.26 6b +17
Cyclazocine
< '.‘- i m  <j X  I-.; Q  R 1. (::> >
k-agonist 7 09.34+4.33* 32.66+7.23 157+51
Ketocyclazocine k-agonist
< “ "i m  u  / !■': Q  H ;L >
7 20.49+2.46 17.80+6.04 83 + 28
Saline sc - 12 41.03+4.98* 06.98+1.96* 26 + 11
Tifluadom
< 1 O  tn <;.) / l-i: q  r «u c:: >
k-agonist 12 17.98+2.12** 25.34+2.94* ** 166+44*
SKF 10,047
< 1 O  m  Q  /  11: eg (; u i i )
cf-agonist 12 16.68+2.95** 12.22+2.78 81+13*
Table 22A. Values are Mean+SEM; unpaired Students' t test; 
level of significance * P < 0.05; ** P < 0.01 and *** p < 
0.001 'n ' = Number of observations. Cone, Concentration,
TR, Turnover.
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MPO
5-HT 5-HIAA 5-HT TR
Treatment Receptor
properties
n Conc+SEM
pg/jig
Conc+SEM
pg/jjg
(% Ratio) 
±SEM
Saline ip
opiate
7 22.22+2.42 17.58+0.99 86 + 11
Naloxone
< lOmg/ Q il 1 r:> >
antagonist 6 21.83+6.76 18.49+5.61 156+73
Morphine
(40mg / <;j 8 a l-> >
U-agonist 6 18.05+3.68 13.86+1.23 91 + 18
Levorphano 1
< 1 Omg / IQ 8 1 F3 >
M-agonist 5 17.76+3.05 21.50+5.34 123+17
Cyclazocine
(3 m g / !-■: Q | 1 |:a >
k-agonist 7 27.00+3.15 23.43+2.16 92 + 13
Ketocyclazocine k-agonist
<Smg / kg | i pa >
6 20.92+5.40 32.79+7.45 188+23**
Saline sc - 9 16.91+2.59 12.34+1.62* 91 + 18
Tif luadom
< lOmg / I-*: g g «k«:: >
k-agonist 5 16.62+2.85 14.94+2.30 99 + 18
SKF 10, 047
< 1 Omg / kg g m<” >
tf-agonist 9 21.81+4.13 14.62+3.62 83+16
Table 22B. Values are means + SEM; unpaired Students’ t-test; 
level of significance * p < 0.05; ** p < 0.01 and *** p <
0.001. ’n' =Number of observations.
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AHA
5-HT
,i______
5-HIAA 5-HT TR
Treatment Receptor
properties
n Conc+SEM
pg/jig
Conc+SEM
pg/Mg
(% Ratio) 
+SEM
Saline ip
opiate
7 32.47+4.46 24.29+2.80 85 + 14
Naloxone
< 1 Omg /  kg II i |:> >
antagonist 6 23 . 92+3.58 25.95+2.42 125+21
Morphine
(40mg /  \< g S P> >
^-agonist 6 31.68+3.58 28.80+2.13 96 + 07
Levorphano 1
(lOmg/kg g ip)
M-agonist 5 29.35+5.06 22.52+3.43 79 + 07
Cyc lazocine
< Smg / l< g s i p )
k-agonist 7 16.53+3.12* 24.94+2.63 118+31
Ketocyclazocine k-agonist
< 5mg / g S i p )
6 26 .21 + 2.33 28.55+4.05 111+14
Saline sc - 9 48.21+4.19* 23.07+3.15 48+06*
Tif luadom
(lOmg/kg |  n c  )
k-agonist 5 21.42+2.30* * 25.80+1.93 130+14***
SKF 10,047
(lOmg/kg p v&cz >
d^agonist 9 29.87+3.27* 38.25+5.12* 130+13*
Table 21C. Values are means + SEM; unpaired Students' t-test ;
level of significance * P < 0.05; ** p < 0.01 and *  *  *  p  <
0.001. 'n' = Number of observations.
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5-HT 5-HIAA 5-HT T1
Treatment Receptor
properties
n Conc+SEM
pg/lig
Conc+SEM
pg/Msr
(% Rati( 
+SEM
Saline ip
opiate
7 37.92+4.21 17.10+2.06 116+54
Naloxone
( i Omg / k: g s i p >
antagonist 6 24.34+5.30 15.68+1.43 65 + 13
Morphine
< ■a o (t> g / i.: g n A | :> >
jd-agonist 6 25.98+6.05 19.83+4.41 78+10
Levorphano 1
(lOmg/kg n i p )
ju-agonist 5 16.08+1.34* 18.33+6.91 174+66
Cyc lazocine
Omg/kgi i p >
k-agonist 7 22.74+5.83 20.70+4.66 126+40
Ketocyclazocine k-agonist
Omg/kgi lp)
6 20.75+4.66* 26.45+7.94 157+69
Saline sc - 9 24.87+3.32 13.18+2.44 56 + 08
Tif luadom
llOmg/kg| *» tr >
k-agonist 5 23.89+4.54 14.27+3.70 69 + 20
SKF 10,047
< 1 Omg /  k:g * mcz )
O'-agonist 9 20.62+3.80 18.56+2.91 99 + 13
Table 22D. Values are means + SEM; unpaired Students' t-test; 
level of significance * p < 0.05. 'n' = Number of
observations.
127
ARN
5-HT 5-HIAA 5-HT TR
Treatment Receptor
properties
n Conc+SEM
pg/Mg
Conc+SEM
pg/tig
(% Ratio) 
+SEM
Saline ip
opiate
7 26.46+2.05 16.87+3.79 68+17
Naloxone
( 1 O m q / l< Ii F'-> >
antagonist 6 20.16+5 .66 18.31+3.59 121+26
Morphine
( /+ O m ( j / I-.: :l. |:> >
ji-agonist 6 22.74+4.11 19.78+3.24 98+14
Levorphano 1
( 1 O m CJ y I-: <3 |i I |rj >
/i-agonist 5 26.32+0.88 20.01+4.06 81 + 23
Cyclazocine
(Sim<3 / <3 I :l. (:> >
k-agonist 7 16.79+4.65 32.69+6.1 203+26* *
Ketocyclazocine k-agonist
(SimQ / I-: Q |i i. |i:» )
6 25.47+4.46 28.15+4.44 141+34
Saline sc - 9 23.37+3.66 22.91+2.53 148+32
Tif luadom
< lOmg / ♦-»: q   ^i»uc:: >
k-agonist 5 27.40+4.12 18.98+2.32 81 + 17
SKF 10,047
( 1 O m eg / q  k h c  )
O'-agonist 9 19.71+1.99 13.75+1.41* 71+05
Table 22E. Values are means + SEM; . unpaired Students’ t- 
test; level of significance * p < 0.05 and ** p < 0.01. 'n' = 
Number of observations.
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VMH
r—
5-HT 5-HIAA 5-HT TRTreatment Receptor
properties
n Conc+SEM
P £ r / j i g
Conc+SEM
P S T / i i g
(% Ratio) 
+SEM
Saline ip
opiate
7 34.78+4.03 18.40+2.09 54+04
Naloxone
< ;l. <::> m  Q  /  !•>: <y n i p )
antagonist 6 31.30+4.17 19.99+4.36 75 + 15
Morphine
( <::> fn q  /  g  I  1 p> >
ju-agonist 6 25.96+3.39 27.25+2.29* 135+32*
: Levorphano 1
1 ( :L <::> m  q  /  l< t;.j a i |::> >
,u-agonist 5 27.75+4.54 23.96+4.61 86 + 13
1 Cyclazocine
( S  fn Q  /  !-■: Q  || ±  p> >
k-agonist 7 39.13+5.99 28.97+4.86 75 + 06
Ketocyclazocine k-agonist
< H  fn Q  /  (•■: c j (  i  p  )
6 27.78+5.78 29.58+6.27 175+65
Saline sc — 9 34.07+2.82 20.66+2.03 64+07
Tif luadom
< 1 O m g  /  «  B w c :  >
k-agonist 5 25.60+4.71 24.64+3.04 126+30
SKF 10,047
< 1 O fn q / !•>: tg B dttc )
C-agonist 9 36.82+5.09 28.72+5.88 75 + 06
Table 22F. Values are means + SEM; unpaired Students' t-test; 
level of significance * p < 0.05. 'n' = Number of
observations .
The 5-HT content and turnover in specific hypothalamic 
nuclei are summarized in Tables 22 (A—F) and Figures 27 (a— 
f) . Tif luadom and SKF 10,047 brought about a significant 
decrease in the 5—HT content and an increase in the turnover 
in the SCH. Tif luadom also brought about a very significant 
rise in 5-HIAA levels in this region. Cyclazocine was the 
only other opiate to significantly decrease the 5—HT content 
of the SCH. However, there were no significant changes 
observed in its turnover. Saline, injected subcutaneously
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into the controls, caused a significant rise in the 5-HT 
content but a significant decrease in 5-HIAA levels in the SCH 
compared to those controls which received saline 
intraperitonea1ly.
None of the treatments caused any significant changes in 
the 5—HT content of the MPO. However, in this region the 
turnover of 5-HT was very significantly increased by 
ketocyclazocine. The controls which received saline 
subcutaneously, again had significantly reduced levels of 
5-HIAA in the MPO although the content and turnover of 5-HT 
were not significantly altered.
Within the AHA, cyclazocine, tifluadom and SKF 10,047 
all caused a significant decrease in 5-HT content. Both 
tifluadom and SKF 10,047 caused an increase in 5-HT turnover 
in the AHA. However, SKF 10,047 brought about a significant 
increase in 5-HIAA levels in this region. Those controls 
which received saline subcutaneously had an increase in the 
5-HT content and a decrease in turnover of 5-HT in the AHA.
The turnover of 5-HT in the ME was significantly 
increased by SKF 10,047; its content was decreased by 
levorphano1. Ketocyclazocine caused a significant fall in 
the content of 5-HT in the ME; no significant changes were 
observed in either the 5—HIAA content or in the 5—HT turnover 
in this region.
The 5-HT content of the ARN was not significantly 
altered by any of the drugs administered. However, 5-HT 
turnover was significantly increased by cyclazocine, and 5 
HIAA levels were significantly reduced by SKF 10,047.
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Within the VMH, morphine caused a significant rise in
the content of 5—HIAA and 5—HT turnover. The content of 5—HT 
in this region was not significantly altered in any of the 
groups studied.
It was interesting to note that naloxone did not cause
any significant changes in either the levels or turnover of
5-HT and 5—HIAA in the six specific hypothalamic regions
studied.
v) Plasma LH levels in Pro-oestrous Rats (with or without 
00-MPT) :
Plasma LH (ng/ml)
Treatment Receptor
properties oC-MPT OC-MPT oC-MPT
0 mins. 45 mins. 90 mins.
Saline ip _ 4.74+0.62 1.36+0.09*** 1.72+0.ll***
opiate (27) (6) (5)
Naloxone antagonist 11.34+2.04** 1.47+0.04*** 1.64+0.08***
(lOmg/kgi i p ) (32) (6) (5)
Morphine ju-agonist 2.35+0.39** 1.43+0.21 1.45+0.45*
!40mg /  kg | ± p> > (5) (5) (5)
Saline sc — 3.89+0.38 1.56+0.06*** 1 .44+0.11***
(20) (5) (5)
Tlf luadom k-agonist 2.19+0.21** 1.48+0.15* 1.41+0.14*
HOmg/kg p *uc:: > (22) (5) (5)
SKF 10,047 ct-agonist 4.04+0.54 1.45+0.19*** 1.54+0.17**
< 1 Omg / kg | wc: > (22) (5) (5)
Table 23. Values are Mean + SEM; unpaired Student's t-test 
confirmed by two-way analysis of variance. Level of
significance * p<0.05 , ** p<0.01 and *** p<0.001.
(n) = Number of observations.
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The plasma LH levels were significantly decreased 
compared to the saline-injected controls by both morphine and 
tifluadom. In contrast naloxone significantly increased the 
levels of LH. SKF 10,047 did not significantly alter LH 
concentration in the plasma from those in the controls. 
Treatment with cC-MPT for both 45 minutes and 90 minutes 
caused an overall fall in LH content in the plasma.
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Numerous peptidergic and monoaminergic neural elements 
present in the hypothalamus influence pituitary gonadotrophic 
function. However, there is very little information
available about how these various structures are
interconnected. Among the different peptides isolated and 
characterized, the opioids represent a significant group. 
They are widely distributed within the CNS and their very 
high concentration within the hypothalamus (Stojilkovic et 
al., 1987) suggests that they may be important in 
neuroendocrine regulation (see Kalra, 1986). The precise 
mechanism of action i.e., whether opiates act directly on the 
release of hypothalamic GnRH or interfere with other 
modulatory transmitters is a subject of current research.
It has been shown that opiates do not directly alter the 
release of LH from the anterior pituitary (see Grossman & 
Rees, 1983; Bicknell, 1985) instead they appear to inhibit 
gonadotrophin secretion by preventing the discharge of GnRH 
at the hypothalamic level (Ching, 1983; see Kalra, 1983). 
The effect of opiates on GnRH secretion is controversial. In 
vitro studies have shown that exposure of GnRH terminals to 
opiates and opioid peptides causes little change in basal 
GnRH release into the medium (Rotsztejn et al., 1978; Drouva 
et al., 1981). These observations are not in agreement with 
numerous in vivo studies, where GnRH levels promptly decline 
(Ching, 1983) after opiate administration. However, a large 
body of evidence suggests that the effects of opioids on GnRH 
neurones are indirect and are probably mediated via opioid 
interaction with monoaminergic neurones (Adler & Crowley,
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1984; Looking land 6c Moore, 1985; Miller, Clifton 6c Steiner,
1985) .
There is a great deal of evidence to indicate that the 
physiological effects of opioid peptides are exerted through 
their interaction with specific binding sites present in the 
brain identified as the opioid receptors (Cox, 1982; Wood, 
1982; Lutz et al . , 1985; Schoff elmeer, Hogenboom 6c Mulder,
1987; Zukin et al., 1988) . Different classes such as mu, 
delta, kappa and sigma receptor types have been described 
(Iyengar, Kim 6c Wood, 1986; Wood, 1980) . Additionally, each 
of the endogenous opioids apparently binds to more than one 
opioid receptor type (Cox, 1982, Stojilkovic et al., 1987). 
Therefore, in order to understand further the influence of 
the endogenous opioid peptides on the neuroendocrine control 
of LH secretion, it is important to define what effect 
activation of each of the opioid receptor types has on this 
hormone. Though this issue has been addressed (Leadem 6c 
Kalra, 1985; Pfeiffer et al., 1983), it is only recently that 
agonists have been synthesized that exhibit sufficient 
binding selectivity to distinguish between several major 
opioid receptor sites. James and Goldstein (1984) developed a 
method of assessing this selectivity and have surveyed a 
number of opioid agonists. They define a selective opioid as 
any ligand that exhibits binding to its preferred receptor 
type by at least 100-fold over the other opioid receptor 
types.
The present study was undertaken to investigate the 
effects of specific opioid receptor agonists and antagonist
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on the hypothalamic monoaminergic systems in regulating LH 
release in the rat.
The Effects of Opiates on Monoamine Content. Turnover and
Plasma LH levels in short-term Orchidectomized Rata
The present study provides firm evidence that drugs 
acting on central opioid receptors alter amine content and 
turnover in the hypothalamus. Opiates have previously been 
reported to alter catecholamine and indoleamine turnover in 
the rat brain (Akabori & Barraclough, 1986, Clark et al., 
1988; Deyo, Swift & Miller, 1979; Yarbrough, Buxbaum and
Sanders-Bush, 1973; Johnson & Crowley, 1984). The results
reported here suggest that morphine decreases hypothalamic NA 
levels immediately after infusion. This effect is seen up to 
the maximum interval studied (i.e., two hours post-infusion), 
at which time the turnover of this amine is also decreased. 
The evidence, as provided by this study, suggests that 
morphine inhibits the synthesis of NA, in addition to 
reducing its rate of release. Furthermore, it is proposed 
that these effects are mediated by two different receptors, 
mui and mus;. Mui receptors have been characterized as causing 
a profound membrane hyperpolarisation on binding opiates 
(Williams & North, 1984)j Mu^ receptors are coupled to
adenylate cyclase and mediate mu effects other than those
acting through the mui receptor (Pasternak, 1986). 
Additionally, a decrease in intracellular levels of cyclic 
adenosine monophosphate (cAMP), as mediated by the mua 
receptor, could alter neurone biochemistry leading to a
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reduction in the initial tissue content of NA. The existence 
of both mui and mua receptors on noradrenergic axon terminals 
within the area studied would be sufficient to explain the 
observed effects of morphine.
None of the opiates tested in this study had any 
significant effect on hypothalamic DA concentrations at 20 
minutes post—infusion. However. both the content and 
turnover of hypothalamic DA were very significantly increased 
two hours following morphine administration. Acute 
administration of morphine has been reported to increase 
hypothalamic DA concentrations (deWeid et al., 1974), but to 
have either no effect or merely cause a slight increase in 
the whole brain DA concentration (Gauchy et al., 1973; deWeid 
et al., 1974) in the rat. DA is the most likely prolactin
release inhibitory factor (PIF) (Tuomisto and Mannisto,
1985), the increase in prolactin secretion which occurs after 
morphine treatment is hence incompatible with elevated DA 
re lease.
Little information is available on the effects of 
morphine on 5-HT levels in the hypothalamus (see Meites et 
al., 1979) although acute morphine administration has been 
reported to increase 5-HT turnover in the whole brain of rats 
(Haubrich & Blake, 1973; Yarbrough, Baxbaum & Sanders-Bush, 
1971). In the present study, while morphine did not cause 
any significant changes in the hypothalamic 5-HT content at 
20 minutes post-treatment, a significant increase in 5-HT 
levels was seen after an interval of two hours.
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Treatment
Plasma LH 
10 min/20 min
Monoamine Content 
(20minutes post-infusion)
NA DA 5-HT 5-HIAA
Saline
Naloxone 
(30jug/kg)
Naloxone
(60jug/kg)
Morphine
(400)ig/kg)
Morphine
(800jug/kg)
Levorphanol
(400>ig/kg)
Cyclazocine 
(50pg/kg)
SKF 10,047 
(100jug/kg)
FK 33,824
0/0
0/0
0/0
- / -
0/0
0/0
0/0
0/0
0
0
0
Table 24. Plasma LH levels and hypothalamic monoamine content 
at 20 minutes post-infusion. (+ - Increase; - = decrease; 0= 
No change).
The majority of the data available suggest that mu 
receptors are specifically involved in the control of 
gonadotrophin secretion (Schluz et al., 1981; Pfeiffer et 
al., 1983; Panerai et al., 1985). However, it is also 
possible that other types of receptors (kappa and delta) 
might also participate in such control (Kato et al., 1982; 
Iyengar et al., 1986; Leadem & Kalra, 1985, 1987). Further,
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an Interaction between hypothalamic GnRH neurones and kappa 
receptors has been Implicated by the work of Marko (1982) .
The effects of cyclazocine on hypothalamic monoamine 
levels were in some respects similar to those of morphine, 
but cyclazocine had no effect on DA turnover rate, although 
the content of DA was significantly increased. This opiate 
also brought about a rise in hypothalamic 5-HT levels at 20 
minutes following infusion. It has been suggested that 
cyclazocine is not a pure kappa receptor agonist, but also 
has partial agonist/antagonist activity at other opioid 
receptor types (Wood, 1983). Furthermore, cyclazocine has 
been shown to possess a high affinity for the mu receptor 
(Zukin & Zukin, 1981). The action of this opiate is dose- 
dependent. At higher doses the antagonist activity 
predominates and at lower doses it acts as an agonist (Wood 
et al., 1982) . The dose used in this study (50jug/kg) would 
suggest an agonistic action of cyclazocine.
The effects of SKF 10,047 (N-allylnor-phenazocine), a 
prototype sigma receptor agonist, differed from those of 
morphine and cyclazocine in that it had no significant effect 
on either hypothalamic NA levels or turnover. Although the 
5-HT content of the hypothalamus was initially raised (i.e., 
20 minutes post-infusion), this was not maintained at two 
hours. Both hypothalamic DA content and turnover were 
significantly increased after SKF 10,047 infusion, a similar 
effect to that seen in the morphine-treated group (Wood et 
al., 1982). The drug used in this study was DL SKF 10,047; 
the D isomer is a potent sigma—agonist, whereas the L isomer
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is a potent mu-antagonist (Compton et al . , 1987). The effects 
of this drug are thus also of a mixed agonist-antagonist 
type. The rise in DA content and turnover in the 
hypothalamus is suggestive of sigma-agonist activity, whereas 
the absence of changes in hypothalamic NA activity (similar 
to naloxone) seems to be a mu-antagonist effect. SKF 10,047 
has likewise been shown to possess antagonistic properties 
at both mu and kappa receptor sites, but displays a powerful 
sigma agonism (Compton et al., 1987). Mu and kappa effects
on DA turnover have been demonstrated in this study, 
characterized by a significant increase in the rate of amine 
release and synthesis. If SKF 10,047 had antagonised 
endogenous mu and kappa activity, a stimulatory effect on NA 
and 5-HT turnover would have been witnessed. It therefore 
appears that the antagonist effects of the drug are small or 
may be suppressed by some other factors involved in this 
regulation.
The mode of action of SKF 10,047 remains obscure. 
However, the sigma-agonist phencyclidine (PCP) has been shown 
to inhibit the uptake of DA by synaptic transmitter storage 
vesicles (Ary & Komiskey, 1979). Such an action in vivo 
would decrease intraneuronal amine oxidation, decreasing axon 
terminal levels of neurotransmitter. It is possible that SKF 
10,047, acting via the sigma receptor, may exert similar 
effects within noradrenergic and serotoninergic neurones. 
Although the deficit would tend to be compensated by 
subsequent synthesis, a depleted storage capacity could 
render this ineffectual. Hence, it is possible that SKF
10,047 may exert its effects on NA and 5-HT levels via such a 
mechanism.
The most powerful stimulatory effect on DA turnover 
observed in this study was that exerted by SKF 10,047. A 
marked increase in both the amine depletion irate and the 
initial tissue concentrations resulted in a five—fold 
increase in turnover. The qualitative differences in the 
actions of morphine, for example, and SKF 10,047, cannot be 
determined by measurements of turnover. Other studies have 
revealed that the behavioural manifestations of SKF 10,047 
treatment (Martin, 1983) are very similar to those exhibited 
by the administration of centrally active DA agonists
(Seeman, 1980). Although SKF 10,047 increased DA turnover in 
a manner indistinguishable from that of morphine, it is 
suggested that SKF 10,047 does not act to dissociate DA 
synthesis from release (Martin, 1983). Hence, the large 
turnover would correspond to an increased rate of secretion 
of DA from nerve terminals.
Naloxone, which largely acts as a mu antagonist (Folders 
et al., 1963), is also known to bind to other opioid 
receptors with varying affinity (Martin et al., 1976; 
Pfeiffer & Herz, 1982). This antagonist, although causing an 
initial rise in the hypothalamic NA content, i.e., at 20
minutes after administration, did not have a persistent
effect. There were no changes observed in the content or 
turnover rates of NA or DA in the hypothalamus at two hours 
post-treatment. However, naloxone did bring about a rise in
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Treatment Plasma LH 
lhr/2hrs
Amine Content/Turnover 
(2 hours post-infusion)
NA DA 5-HT
Cont/TR Cont/TR Cont/TR
Saline
Naloxone 0/0
(60pg/kg)
Morphine -/-
(800yg/kg)
Cyclazocine —/—
(50jug/kg)
SKF 10,047 0/0
(lOOpg/kg)
0/0
- / -
- / -
0/0
0/0 
+/ + 
+/0 
+/ +
+/0
+/0
0/ -
0/0
Table 25. Plasma LH levels and monoamine content and turnover 
two hours post—infusion. ( + = Increase, — = Decrease; 0 = No
change).
the 5-HT content of this region. Morphine had a similar 
effect on the hypothalamic 5-HT content. The effect of the 
antagonist naloxone was thus unexpected, and contradicts the 
findings of previous workers (see Martin, 1983). The present 
results would imply that naloxone may have activated a 
stimulatory opioidergic input to the hypothalamic 5-HT 
neurones. The existence of such an input has been postulated 
by others, who have demonstrated the stimulation of 
LH release by icv morphine (Motta & Martini, 1982; Piva 
et al., 1986). Furthermore, naloxone may elicit
morphine-like analgesia when administered icv (Dickensen, Le
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Bars & Besson, 1981). These observations preclude a precise 
interpretation of the mode of action of naloxone in this 
investigation. Nevertheless, many central and peripheral 
axon terminals have inhibitory autoreceptors (e.g. alphas— 
adrenoceptors); if opioidergic neurones are no exception 
naloxone may in certain situations cause a disinhibition of 
these neurones leading to effects indistinguishable from 
those of opioid administration.
Morphine has been found to lower LH levels in intact 
male rats (Cicero et al., 1979; see Cicero, 1980). Naloxone 
administration sharply increases serum LH levels (Cicero et 
al., 1979; Kalra & Simpkins, 1981; Van Vugt et al., 1981, 
Piva, et al., 1986), suggesting an inhibitory role of 
endogenous opioids on the hypothalamic-pituitary-LH axis. 
However, in the present study, it was found that naloxone 
failed to cause any significant changes in circulating LH 
levels and the effect of SKF 10,047 was similar. The effects 
of naloxone seen during the present study could perhaps be 
related to the steroidal manipulation created in this 
particular experimental model. The animals were treated with 
the opiates or their antagonist, naloxone, between 18-20 
hours post-castration. It could be predicted therefore, that 
in spite of removing gonadal steroid production by 
castration, the diminishing residual levels of testosterone 
could explain why the effects of naloxone differed from those 
recorded by others. Morphine has been shown to mimic the 
effects of testosterone in exerting its inhibitory action on 
LH release at the hypothalamic level (Miller et al., 1986). 
The highly significant changes observed in hypothalamic
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catecholaminergic activity at two hours after treatment with 
morphine would also imply that the traces of testosterone 
might have enhanced its activity and decreased the 
antagonistic effect of naloxone. Only future studies at 
differing intervals post-castration would provide more 
evidence towards this hypothesis. Further, long-term 
gonadectomy has been shown to alter the number of opioid 
receptors in the CNS (Cicero et al., 1987). However, there 
are no reports suggesting a change in the number of opioid 
receptors in the short-term castrated rat. It could be 
assumed therefore, that such a change in number occurring 
immediately after castration could result in a decreased 
antagonistic activity of naloxone.
The stimulatory role of NA in the control of LH release 
is well documented (Adler et al., 1983; Kalra & Gallo, 1983;
see Kalra, 1986). This was further confirmed by the present 
findings; the decrease in hypothalamic NA content and 
turnover observed after morphine and cyclazocine 
administration most likely caused the significant fall seen 
ini LH levels. Furthermore, the drugs which failed to cause 
any significant changes in noradrenergic turnover within the 
hypothalamus also did not alter circulating LH levels in the 
animals. Thus in the naloxone- and SKF 10,047-treated animals 
In which there was no significant alteration in the 
hypothalamic NA content or turnover, there was also no change 
In circulating LH levels.
OC-MPT, an inhibitor.of tyrosine hydroxylase, used to 
study catecholaminergic activity in the hypothalamus, itself
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br<?u^ t  about a significant decrease in LH levels in the 
controls and in the morphine- and eyelazocine-treated groups.
Plasma LH
Treatment Control 0C-MPT for 1 hour O^MPT for 2 hrs
lhr/2hrs lhr/2hrs lhr/2hrs
Saline 0/0 0/- -/-
Naloxone 0/0 0/0 0/0
(60yg/kg)
Morphine -/- 0/- -/-
(800jjg/kg)
Cyclazocine -/- 0/- -/-
(50^g/kg)
SKF 10,047 0/0 0/- 0/0
Table 26. Effects of oO~MPT on plasma LH levels one and two 
hours post-infusion. - - Decrease 0 « No change.
However, oC-MPT treatment to the groups which had earlier 
received naloxone did not led to an alteration in their LH 
levels. Although SKF 10,047 caused a significant decrease in 
circulating LH one hour after <£-MPT treatment, no similar 
change was seen two hours after oC-MPT administration. The 
acute depletion of NA caused by the injection of OC-MPT could 
be responsible for the reduction seen in LH levels (Herdon et 
al., 1984). The effects of naloxone and SKF 10,047 on 
circulating LH would indicate that these two drugs might 
somehow sustain noradrenergic activity, thus, not affecting 
their LH levels. If DA was involved in the c£-MPT- mediated
I
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decrease in plasma LH, then one would have expected LH levels 
i also to decrease in the SKF 10,047—treated animals. This is 
because this drug caused a very high increase in the 
hypothalamic content of DA similar to that brought about by 
morphine and cyclazocine. However, it is difficult to predict 
what effect the increased DA activity observed in the opiate- 
treated groups had on LH release. Both a stimulatory and an 
inhibitory action for DA have been claimed by other 
investigators (James et al., 1987; Gallo, 1980).
In this study, although changes in NA content and 
turnover could be correlated with changes observed in LH 
levels, the same was not true for DA. While the increased 
hypothalamic DA content and turnover seen in the morphine- 
and cyclazocine-treated groups would be suggestive of an 
inhibitory role for DA on LH release, SKF 10,047 which 
significantly increased the turnover of DA, brought about no 
alterations in LH levels to the animals treated with it. 
j Rotsztejn et al., (1978) observed that although morphine and 
other endogenous opioid peptides had no effect on basal GnRH 
secretion, these agents significantly suppressed the DA- 
induced stimulation of GnRH release from hypothalamic slices 
in vitro. Consequently, these investigators suggested that 
the interaction between opiates and DA may occur 
postsynaptical ly at the, level of the GnRH nerve endings. 
There is little evidence to show that opiates affect the 
response of GnRH neurones to DA or adrenergic agonists in 
vivo (Kalra & Gallo, 1983; Kalra & Simpkins, 1981). 
Although DA was found to excite GnRH release from the ME of 
male rats in vitro (Negro-Vilar & Ojeda, 1978; Negro-Vilar,
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Ojeda & McCann, 1979; Schneider & McCann, 1969), lev 
injection produced little stimulation of GnRH—induced LH 
release in vivo (Kalra & Kalra, 1983). Another body of 
evidence suggests that opiates acting at the level of the ME 
do not affect GnRH release directly, but rather interfere 
with the response of neurosecretory nerve endings to DA 
stimulation (Gallo, 1980). The stimulatory action of DA on in 
vitro GnRH release could be inhibited by DA antagonists, 
such as pimozide and haloperidol (see Seeman & Guttman, 1987; 
Barnett, 1986). Attempts have been made to correlate changes 
in LH secretion induced by steroid feedback mechanisms with 
changes in DA activity (Gallo, 1980, Simpkins, Kalra & Kalra, 
1980, 1983). Gunnet, Lookingland & Moore (1986) have reported 
that DA levels were increased in the MPO, DMN and median zona 
incerta following castration. Testosterone replacement
brought DA levels back to normal. Two weeks following
orchidectomy, the DA turnover in the MPO was decreased. 
Subsequent administration of testosterone to these animals, 
in doses that reduce LH levels to intact values, increased 
the DA turnover. The present findings that morphine and
cyclazocine increased DA turnover may be compared to those 
showing increased DA turnover in the MPO after testosterone
administration, as both morphine and testosterone exert
similar effects on LH in the castrated rat (see Cicero,
1980). However, Simpkins et al., (1980, 1983) reported that
local injections of testosterone into the MPO of castrated 
rats failed to modify LH secretion. Thus, the effects of 
increased dopaminergic activity on LH release is not clear.
i
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The observed decrease in hypothalamic 5-HT turnover by 
treatment with cyclazocine seen in the present study would 
suggest a stimulatory effect of 5-HT on LH release (Walker,
1983) . Apart from a direct action on kappa receptors, it is 
likely that the effect of cyclazocine on 5-HT turnover is at 
least partly mediated by the action of this drug at other 
opioid receptor sites. Specifically, cyclazocine has been 
shown to possess a high affinity for the mu receptor where it 
acts as a competitive antagonist (Martin, 1983). For this 
reason, the drug-induced diminution of 5-HT turnover observed 
in this study may partly be due to the blockade of 
stimulatory opioidergic innervation (Johnson & Crowley,
1984). SKF 10,047 also caused a fall in 5-HT turnover 
although it failed to reach significant levels.
The effects of opiates and their antagonist, naloxone, 
on both monoamine activity and LH levels could be, at least 
partly, explained by the existing steroidal feed-back 
mechanism and its manipulation by castration and opiate 
administration. The gonadal steroids exert powerful negative 
feedback effects on LH secretion. Part of this influence is 
exerted via the hypothalamus and probably includes an 
opioidergic component (Schulz et al., 1981; Gabriel et al.,
1983; Bhanot & Wilkinson, 1984). As reported earlier, 
morphine administration can mimic both the acute and chronic 
effects of this steroid on the hypothalamic-pituitary-LH axis 
of the castrated male rat (Cicero et al., 1979, 1980; Van
Vugt et al., 1982). The parallel actions of morphine and
steroids suggest a common mechanism of action (Miller et al.,
1986). Low concentrations of testosterone (400—600pg/ml 
serum), which fail to inhibit LH release in orchidectomized 
rats, were maximally effective when these rats concurrently 
received continuous opiate stimulation by morphine (Gabriel 
et al., 1983). It has been found that the effects of
endogenous and exogenous opiates on LH release disappear
coincident with the removal of gonadal steroid feedback at 7 
days post-castration (Bhanot & Wilkinson, 1983). Naloxone is 
no longer able to stimulate LH secretion in these animals. 
These findings suggest the endogenous opioid peptide neurones 
may not only affect GnRH release, but may also influence 
neurosecretory events modulated by steroids to promote GnRH 
accumulation in the ME nerve terminals (Kalra & Kalra, 1983).
In conclusion, it was found that opiates modulate 
hypothalamic monoaminergic activity in the short-term
orchidectomized rats. The reduced LH levels caused by
morphine and cyclazocine could be related to their causing a 
decreased hypothalamic NA turnover. The rise in DA turnover 
brought about by SKF 10,047 failed to alter LH levels. 
Surprisingly, naloxone had no significant effect on either 
the amine turnover or LH release.
i
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The effects of Opiates on Hypothalamic Monoaminergic activity 
and LH levels Prior to the Pre-ovulatory LH surge in the Rat
In the present study. It was found that naloxone 
treatment prior to the pre-ovulatory LH surge (12.30 hours on 
the afternoon of pro-oestrus) led to an increase in basal LH 
levels. This stimulatory action of naloxone on LH release in 
female rats has been widely reported (Gabriel, Simpkins & 
Kalra, 1983; Piva et al., 1985; Allen & Kalra, 1986; 
Petraglia et al., 1986). Recently, it has been demonstrated 
that with prolonged naloxone treatment it is possible to 
evoke a premature surge of LH on the day of dioestrous II 
when the LH levels are basal (Allen & Kalra, 1986). This 
naloxone-induced surge resembles the normal preovulatory LH 
surge observed on the afternoon of pro-oestrus. This also 
implies the involvement of inhibitory opioid regulation of 
preovulatory LH surge in rats.
The results presented here indicate that hypothalamic 
noradrenergic activity is greatly increased by naloxone 
administration. Many others have also reported a stimulatory 
action of naloxone on NA content and/or turnover within the 
hypothalamus during the afternoon of pro-oestrus (Akabori & 
Barraclough, 1986). Earlier studies have shown that 
injections of NA into the third ventricle elicit LH release 
in ovariectomized steroid-primed rats (Krieg & Sawyer, 1976). 
The stimulatory action of naloxone on hypothalamic NA content 
and turnover, as reported in this investigation, is further 
strengthened by the results of previous pharmacological
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studies showing that naloxone-induced LH release is prevented 
by inhibitors of noradrenergic and/or adrenergic synthesis 
(Kalra, 1981; Kalra & Crowley, 1982; Kalra & Simpkins, 1981; 
Van Vugt et al., 1981).
The catecholaminergic systems that are activated by 
naloxone may, in turn, enhance the release of GnRH (Kalra, 
Crowley & Kalra, 1987; Simpkins et al., 1980; Wilkes & Yen,
1981). This is well supported by the findings of Blank & 
Roberts (1982), who reported that GnRH antagonists could 
block naloxone-induced elevation of serum LH in immature 
female rats. Furthermore, Leadem et al., (1985) reported that 
naloxone infusion within minutes increased the release of 
GnRH from the MBH—POA in vitro. Both in vivo and in vitro 
studies have convincingly demonstrated that stimulation of LH 
release by NA may be the result of hypersecretion of GnRH 
into the hypophyseal portal system (Krieg & Ching, 1982; 
Negro-Vilar & Ojeda, 1978; Negro-Vilar et al., 1979). There 
is further evidence indicating an increased release of
endogenous NA during the afternoon of pro-oestrus into the ME
region which is in close proximity with GnRH terminals 
(McNeill & Sladek, 1978; Ajika,* 1979) . The rise in NA in the 
ME region is correlated with the initiation of the LH surge. 
The release of GnRH into portal blood is increased several 
fold by electrical stimulation of the ME, POA and SCH, areas 
which are known to contain the high concentration of GnRH-
containing cell bodies and fibres (POA-SCH) and nerve
terminals (ME). Stimulation of the AHA, which is separated 
by less than 1mm from the POA, results in only a very slight 
increase in GnRH release into the portal blood. Furthermore,
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stimulation of the hippocampus and amygdala does not bring 
about any GnRH release into the portal blood (see Fink,
1986) .
Further investigations into the effects of naloxone on 
amines in specific hypothalamic regions showed that naloxone 
significantly increased the content and turnover of NA in the 
MPO alone. This is supported by the findings of Honma & 
Wuttke (1980) who have concluded that the stimulatory action 
of NA on GnRH release is via its action within the MPO.
Ranee et al., (1981) suggest that increased
catecholaminergic activity within the ME is important in 
initiating the preovulatory LH surge. Further, they have 
demonstrated the existence of a clear temporal relationship 
between increased ME catecholamine turnover and a rise in 
serum gonadotrophins between 12.00 and 14.00 hours on the 
afternoon of pro-oestrus. Ranee and his co-workers also 
propose that NA may act within the entire POA-SCH
tuberoinfundibular system including the ME in influencing the 
preovulatory gonadotrophin surge. In support of this claim 
they demonstrated that NA turnover rates were increased, not 
only in the MPO, but also in the ME, SCH and ARN between 
15.00 and 17.00 hours on the afternoon of pro-oestrus, at
which time LH levels are1 continuing to rise (Barraclough et
al., 1979). Increased NA turnover in crucial sites along the 
POA-tuberal pathway has been reported by many others (Crowley 
et al., 1978; Wise, Ranee & Barraclough, 1981).
In an elegant study, Kalra (1981) reported that
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intracranial implantation of naloxone in regions outside the 
hypothalamus failed to elicit LH release. However, implants 
containing naloxone, or intracerebral injection of naloxone 
anywhere in the narrow medial zone within the MPO and 
extending caudally to the ME-ARN, readily stimulated LH 
secretion. Morphine pretreatment blocked these local effects 
of the naloxone implants. Furthermore, naloxone implants 
into the VMH & DMN, where GnRH perikarya and axons have been 
visualized (Kelly, Ronnekleiv & Eskay, 1982; King et al., 
1982; Witkin, Paden & Silverman, 1982), were ineffective in 
stimulating LH release. The strict regional specificity of 
the action of naloxone, together with the fact that morphine 
blocked the local excitatory effect of naloxone on GnRH 
secretion, indicate that opioid receptors which influence LH 
secretion may be confined to a narrow neural zone in the POA- 
tuberal pathway.
In the present study, lOmg/kg morphine was seen to 
increase turnover of NA within the hypothalamus. This effect 
of morphine was unexpected. However, Pang, Zimmerman & Sawyer
(1977), observed that a dose of lOmg/kg morphine, 
administered subcutaneously to normal female rats during the 
critical period of the day of pro-oestrus, enhanced the pre­
ovulatory surge of LH. These authours also found that only a 
dose of morphine 6 times higher (i.e., 60mg/kg) was capable 
of depressing the LH peak on the day of pro-oestrus. In 
addition, small doses of morphine administered to immature 
gonadotrophin-treated rats apparently increased pituitary LH 
output (Hu 1se & Coleman, 1983) . In the present study, using 
lOmg/kg morphine, however, LH levels were significantly
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decreased In spite of their increased NA turnover within the 
hypothalamus. It should be noted here that in these animals, 
the hypothalamic DA turnover was also greatly increased. It 
Is suggested, therefore, that increased dopaminergic activity 
may be inhibitory to LH release. On the other hand, the
higher dose (40 mg/kg) of morphine caused a significant
decrease in the hypothalamic NA content. Circulating LH 
levels were also decreased in these animals. Due to the
somewhat ambiguous results obtained with the lower dose of 
morphine, only the higher dose was used to estimate 
monoaminergic activity within specific hypothalamic regions. 
Among the isolated hypothalamic areas, morphine (40mg/kg) was 
seen to reduce NA turnover in the SCH, MPO, AHA and VMH. 
Furthermore, the reduction seen in the ME was not significant 
because of the huge standard errors. These could have arisen 
from the technique of removing semi lunar punches to isolate 
this region, and thus inconsistencies in the amount of tissue 
collected (Figure 16). The opiate-induced decrease in NA 
content/turnover has been widely reported (Dyer & Grossman, 
1988; Dyer et al, 1988). Diez-Guerra et al., (1986) also 
demonstrated that morphine could inhibit electrically 
stimulated NA release from slices of rat MPO in vitro. 
Similarly, Akabori & Barraclough (1986) have shown that 
morphine decreases noradrenergic activity within the MPO and 
ME of ovariectomized, oestrogen-primed rats. Morphine
administration has also been shown to decrease NA levels in 
the whole brain and hypothalamus of rats (deWeid et al., 
1974; van Ree et al., 1976).
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The characteristic effects of all the kappa receptor 
agonists investigated on the whole hypothalamus were 
increased NA turnover. The differential effects of the mu 
and kappa opiate agonists on the NA content of the whole 
hypothalamus are however consistent with recent results which 
have demonstrated that mu, but not kappa agonists, suppress 
LH release after their icv infusion into the long-term 
ovariectomized rat (Pfeiffer et al., 1987).
Specific Hypothalamic Regions
Treatment W.H.
(mg/kg) SCH MPO AHA ME ARN VMH
Nal (10) + 0 + 0 0 0 0
Morp(40) 0 - - - 0 0 -
Tif1(10) + 0 0 0 0 -
SKF(IO) 0 - - 0 0 - 0
Table 27. Effects of opiates and their antagonist, naloxone,
on NA turnover in the whole hypothalamus (W.H.) and in
specif ic regions within the hypothalamus of pro-oestrous
rats. (+ = Increasei; - = Decrease and 0 = No effect)
Within the specific hypothalamic areas it was surprising 
to find that none of these agonists caused a significant rise 
In either NA content or turnover. The highly selective kappa 
agonist, tifluadom (Burkard, 1984), caused a significant 
decrease in NA turnover in the SCH and VMH. These results, 
therefore, contradict those that were obtained from the 
studies upon the whole hypothalamus. Using the entire
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hypothalamic homogenate to study aminergic activity in the 
region has certain drawbacks (Palkovits & Brownstein,
1983; Kilts & Anderson, 1986). Firstly, it is not possible to 
localize the effects of a particular drug and secondly, its
effects might differ in specific areas. Only further studies
in areas not included in this study may explain these 
differential effects caused by the kappa agonists.
The sigma agonist, SKF 10,047, had no significant effect 
either upon plasma LH levels or on NA turnver within the
whole hypothalamus. This finding is similar to that observed 
in the short-term orchidectomized rats. However, when 
specific regions within the hypothalamus were examined in 
pro-oestrous rats, SKF 10,047 did bring about a significant 
decrease in NA turnover within the SCH, MPO and VMH.
The synthetic met-enkepha1 in analogue, FK 33,824, has 
been shown to cause a decrease in LH levels in various 
experimental models (Bhanot & Wilkinson, 1982; Hill, Marbach 
& Scherrer, 1980; Kato et al., 1982; Leadem & Kalra, 1985)
which does not cross the blood-brain barrier (Bhanot &. 
Wilkinson, 1982; Hill, 1980). Peripheral administration of 
this drug reduces circulating LH levels, suggesting its 
action is within the ME which lies outside the blood-brain 
barrier (Bhanot & Wilkinson, 1982). Central administration of 
this drug has also been found to be effective in decreasing 
LH levels (Kato et al., 1982). However, in the present study, 
icv administration of FK 33,824 (both 2 jig and 4 pg/kg) had 
no significant effect upon plasma LH levels. Also, both the 
NA and DA content within the brain were unaffected by FK
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33,824. The action of this opiate on specific hypothalamic
regions were not studied as the injury from the icv mode of 
injection could have interfered with the punch technique.
Specific Hypothalamic Regions
Treatment W.H.
(mg/kg) SCH MPO AHA ME ARN VMI
Nal (10) 0 0 + 0 + + 0
Morp(40) + 0 0 0 0 + 0
Tif1(10) 0 0 + 0 0 0 +
SKF(10) 0 0 + 0 0 + +
Table 28 Effects of opiates and their antagonist, na loxc
on DA turnover in the whole hypothalamus (W.H.) and
specific regions within the hypothalamus of pro-oestrous 
rats. (+ = Increase; - = Decrease and 0 = No change).
Only the opiate morphine brought about a significant 
increase in the whole hypohalamic turnover of DA in the pro- 
oestrous rat. Its antagonist, naloxone, had no significant 
effect on this. These findings are similar to those observed 
in the short-term castrated rats.
When specific hypothalamic regions were studied, 
morphine caused a significant decrease in DA content within 
the ME, similar to the findings of Akabori & Barraclough
(1986). Naloxone caused an increase in turnover of DA in 
the same region. Both naloxone and morphine were seen to 
bring about a significant increase in DA turnover in the ARN.
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This finding was unexpected, and may be due to an increase in 
mu receptor levels in the pro—oestrous rats as reported by 
Casulari et al., (1987). The dose of naloxone given may have 
failed to overcome the increased activity of the endogenous 
opioid peptides.
Tifluadom, SKF 10,047 and naloxone all caused an 
increase in DA turnover in the MPO region. This could be due 
to both kappa and sigma agonists acting as antagonists in the 
MPO region probably exerting this effect via a different 
receptor type, most likely the mu receptors. Similar effects 
were seen in the short-term orchidectomized rats, where the 
antagonist properties of the sigma agonist predominated, and 
neither SKF 10,047 nor naloxone had any effect on 
hypothalamic NA and 5-HT turnover.
The increase in DA turnover observed after 
administration of the opiates was also seen when the 
antagonist naloxone was given. This would suggest an 
increased opioidergic activity within the hypothalamus during 
the afternoon of pro-oestrus. Indeed, a large body of 
evidence exists in favour of this hypothesis. On the 
afternoon of pra-oestrus there is an increase in 
concentration of brain mu receptors (Casulari et al., 1986), 
and an elevation of beta-endorphin in the portal plasma 
(Sarkar & Yen, 1985). The levels of leu-enkephalin and 
dynorphin have been found to be significantly higher in the 
hypothalamus and anterior pituitary on the afternoon of pro­
oestrus (Suda et al., 1986). In the SCH, ME and ARN beta-
endorphin concentrations were seen to be increased
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significantly during the same period (Barden et al., 1981; 
Knuth et al., 1983; Hulse et al., 1984). These reports 
indicate an increase in intrinsic opioidergic tone during the 
afternoon of pro-oestrus. This increased tone may overcome 
the effects of the administered naloxone. This conclusion is 
further supported by the present findings regarding the 
effects of opiates on 5-HT turnover. One or more of the 
opiate agonists caused a significant increase in 5—HT 
turnover in all the hypothalamic regions studied, but 5-HT 
turnover was not significantly affected by naloxone.
The present study confirms the stimulatory activity of 
NA on LH release. Recently, Dyer & Grossman (1988) have 
reported that the opioid peptides regulate noradrenergic 
transmission in the MPO thereby influencing the neurones 
controlling the release of LH. The richly innervated region 
of the MPO, receiving inputs from the ventral noradrenergic 
neurones, seems to be the major site regulating the release 
of LH (Dyer & Grossman, 1988). In the present study, it was 
found that naloxone increased the turnover of NA in the MPO 
and this was correlated with an increase in plasma LH 
levels. The opposite effect was seen when morphine was 
administered. These findings support the theory that the 
action of mu receptors is limited to the MPO-tuberal pathway 
(Kalra, 1981). This is further supported by the fact that 
kappa and sigma agonists did not produce the same effect in 
the MPO. SKF 10,047, although decreasing NA turnover in the 
MPO failed to affect LH levels. Tifluadom, on the other hand, 
decreased LH levels without affecting NA turnover in the MPO,
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but reduced noradrenergic activity in the VMH and SCH.
The reports so far available are not consistent with 
regard to the effects of DA on LH secretion. Rotsztejn et 
al. , (1978) reported that DA induced the release of GnRH from
fragments of MBH in vitro. However, Kalra (1985) was unable 
to bring about GnRH release by DA in intact pro-oestrous rat 
whether or not they had been pretreated with morphine. In the 
present study, both agonists and antagonist drugs increased 
DA turnover, but they differed in their effects on LH 
levels further supporting the conclusion that DA turnover 
may not significantly influence LH release.
Specific Hypothalamic Regions
Treatment W.H.
(mg/kg) SCH MPO AHA ME ARN VM
Nal (10) 0 0 0 0 0 0 0
Morp(40) 0 0 0 0 0 0 +
Tif1(10) + + 0 + 0 0 0
SKF(10) 0 + 0 + + 0 0
Table 29. Effects of opiates and naloxone on 5-HT turnover in . 
the whole hypothalamus (W.H.) and in specific regions within 
the hypothalamus in pro-oestrous rats. (+ - Increase; - =
Decrease and 0 = No effect).
An inhibitory action of 5-HT on LH secretion has been 
widely reported (Yarbrough, Buxbaum & Sanders-Bush, 1973; 
Kamberi, Mical & Porter, 1970; Pilotte & Porter, 1979). The
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daily periodicity in LH levels has been shown to be 
associated with neuronal activity in the SCH where there is a 
rich concentration of 5—HT neurones (see Consolazione et al., 
1982) . In the present study, both tifluadom and SKF 10,047 
increased 5-HT turnover in the SCH and AHA. However, only 
tifluadom brought about a significant decrease in circulating 
LH levels. Morphine did not have any significant effect on 5- 
HT turnover in the SCH, but increased this in the VMH. 
Furthermore, naloxone did not have any significant effect on 
5-HT turnover in any of the regions studied. It can therefore 
be concluded that 5-HT neurotransmission may be mediated by 
opioid receptors other than those of the mu type. Studies 
using pure kappa and sigma antagonists when such drugs become 
available, would further elucidate the exact role of 5-HT in 
the regulation of LH release.
Thus, in conclusion, the mu agonist morphine decreased 
NA turnover in the SCH, MPO, AHA & VMH. Naloxone increased 
NA turnover in the MPO alone suggesting that NA turnover in 
the MPO region is mediated by mu receptors. Since kappa and 
sigma agonists also decreased NA turnover in the regions 
studied it is concluded that there exists a heterogenous 
group of receptors mediating this. None of the opiates had 
any significant effect on NA turnover in the ME which is the 
final neuronal pathway. This would therefore indicate that 
the opiate-mediated effects on NA turnover occur at higher 
leveIs.
Since both opiate agonists and naloxone increase DA
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turnover but do not have consistent effects on circulating LH 
levels it could be concluded that changes in DA turnover do 
not play a major role in the regulation of LH release.
Both kappa and sigma agonists significantly, increased 5- 
HT turnover in the SCH and AHA. This effect was not seen
after treatment with the mu agonist morphine, nor with
naloxone. Thus it may be concluded that increased 5-HT
turnover may be mediated by opioid receptors other than those
of the mu type.
i
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The use of high-performance liquid chromatography with electrochem ical 
detection to exam ine the effects of opiates on rat brain catecholam ine
levels
By D. P. G i l m o r e  and  C. G o p a l a n . Institute o f Physiology, University o f Glasgow,
Glasgow G 12 8QQ
C urrently we are em ploying high-perform ance liquid chrom atography w ith electro­
chemical detection (h.p.l.c.-e.c.d .) to  exam ine how opiates m ight a lter gonadotrophin 
release in the ra t  through the ir effects on brain am ine levels. B oth pro-oestrous 
female and short-term  castra ted  male ra ts  are being utilized. The la tte r are operated 
upon under ether anaesthesia. V arying doses of m orphine sulphate and its antagonist, 
naloxone, are being adm inistered to  groups of anim als either i.p., or stereotaxically 
into the brain  ventricles under Saffan (alphaxolone 0-9%, w /v ; alphadolone acetate 
((•3%, w /v ) anaesthesia (2-3 m l/ra t  given i.p .). A t pre-determ ined intervals the ra ts  
are killed by decapita tion  and the brains rem oved on ice. H ypothalam ic and cortical 
extracts are prepared as previously described (Gopalan, Meek & Gilmore, 1987), and 
applied directly  to a h.p.l.c. column. F o r each sample we are able sim ultaneously to 
measure the conten t of noradrenaline, adrenaline, dopam ine, serotonin and 5- 
hydroxyindole acetic acid. The concentration of each amine present in the tissue is 
determined by a  T rivector chrom atography com puting in tegrator using peak area as 
the basis for calculation. The run  tim e for each sample is usually 1 h. The traces from 
up to 16 injected samples can be stored in the  mem ory of the in tegrator and recalled 
for d isplay  a t any tim e during or after the analysis. Differences in hypothalam ic 
amine concentrations between the experim ental groups and the controls is providing 
information on the  role of the  am inergic system s in the regulation of gonadotrophin 
secretion.
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The effect of specific adrenergic agents on hypothalamic catecholamine 
levels during the pre-ovulatory LH surge in the rat
Chaya Gopalan, Dominic R. Meek and Desmond P. Gilmore
Institute o f  Physiology, University o f  Glasgow, Glasgow G12 8QQ, Scotland, UK
The brain catecho lam inerg ic  system  appears to  play an 
important role in regu lating  th e  p re -ovu la to ry  LH surge. 
P h arm aco log ical su p p re s s io n  o f  th ese  cen tra l n e u ro ­
transm itters prior to the  “ c ritica l” period  on the day o f  
pro-oestrus consequen tly  resu lts  in b lockade o f th e  LH surge 
and ovu lation  [1, 2], R ecently  we have investiga ted  the 
effect o f  in trav en tricu la r in fusions o f  various ad ren o cep to r 
agonists and an tagon ists on ovu lation  in the  cycling fem ale 
rat [3].
T he p resen t study was carried  o u t to ob tain  m ore  
inform ation ab o u t the  participation  o f the  ca techo lam ines in 
the in itiation  o f  the  p re-ovu la to ry  LH surge. V arious 
pharmacological agen ts acting on  specific ad renerg ic  recep tor 
subtypes w ere ad m in iste red  (by i.p. in jection) to  rats on the 
' day o f  p ro -oestrus. E ffects o f  these  p ro ced u res on hypo­
thalamic ad renaline  (A D R ) and n o rad ren a lin e  (N A ) levels 
were th en  m easu red  by high p e rfo rm an ce  liquid c h ro m a to ­
graphy with e lectrochem ica l d e tec tio n  (H P L C -E D ).
M a te r ia ls  and  m eth o d s: F em ale  Sprague-D aw ley rats 
(Tuck and Sons, B attlesbridge, E ssex) w eighing 250-300 g 
were m ain ta ined  u n d e r co n d itio n s o f  con tro lled  tem p era tu re  
(21 ±  1°C) and 12 h light: 12 h d a rk n ess (lights on 06:00 -  
18:00). Food  and w ater w ere available ad  libitum. Vaginal 
smears w ere m o n ito red  each m o rn in g  and only those  rats 
showing th ree  o r m o re  con secu tiv e  4-day o estro u s cycles 
were se lec ted , on the  day o f  p ro -o es tru s , for use in th is study.
R ats w ere given p en to b a rb ito n e  so d ium  (PB ), 35 m g/kg , 
at 13:30 on the  a fte rn o o n  o f  p ro -o es tru s to block the  p re ­
ovulatory  LH surge. T o d e te rm in e  the  effects o f  stim ula to ry  
adrenerg ic  agen ts, th ese  w ere ad m in iste red  in e ith e r 1 ml o f 
0.9% saline or 5% glucose be tw een  13:30 and 14:30. A d re n ­
ergic blocking agen ts w ere given at 13:30 in 1 ml o f 5% 
glucose to p ro -o es tro u s rats no t p reviously  trea ted  w ith PB. 
T he d rugs ad m in iste red  w ere c lon id ine  (an « 2-adrenerg ic  
ag on ist), y o h im bine  (an « 2-adrenerg ic  an tag o n ist), salbu- 
tam ol and feno tero l (/32-ad renerg ic  agonists) and 1CI 118, 
551 (w hich is (2RS, 3 R S )-3 -iso p ro p y lam in o -l-(7 -m eth y l- 
indan-4-yloxy) bu tan-2-o l) (a /32-adrenerg ic  an tag o n ist). 
C on tro ls  received  e ith e r 0.9% saline or 5% glucose (1 m l).
T he  an im als w ere decap ita ted  b e tw een  14:30 and 16:00. 
The b rains w ere rapidly rem o v ed  and th e  h ypo thalam us
surgically iso lated  on ice in 0.1 M HC1 conta in ing  3 ,4 -d ihy ­
d ro x y -  b e n z y la m in e  (D H B A ) as an in te rnal standard . 
A lthough  ca techo lam ines are know n to be sub ject to ox id a ­
tive deg rad a tio n , they  have been  found  to be stable for at 
least 12 h at room  tem p e ra tu re  in 0.1 M HC1 [4], T he 
hypothalam ic sam ples w ere cen trifuged  and the  su p ern a tan ts  
sto red  at — 25°C until assayed.
Tw enty  /xl a liquots o f  the  su p e rn a tan t w ere injected on to  a 
rev erse  phase H PLC  co lu m n  w ith an e lectrochem ical 
d e tec to r and th e  co n cen tra tio n  o f  A D R  and N A  presen t 
sim u ltaneously  m easu red . T he m obile  phase used  was 
c itra te -aceta te  bu ffer w ith 5% (v /v ) m eth an o l, 2% (v /v ) 
te trah y d ro fu ran  and 100 mg/1 sod ium  octyl su lphate .
R e su lts  and  d isc u ss io n : T he resu lts  are su m m arized  in 
Table 1. /32-adrenerg ic  agonists are know n to ov erco m e the 
p en to b arb ito n e  block to ovu lation  [3], O ur resu lts  indicate 
that the  /32-agonists feno tero l and salbu tam ol both  increase 
the  A D R  co n ten t o f the  hypo thalam us w hereas the 
an tagonist ICI 118, 551 low ers it. P reviously , exogenously  
ad m in iste red  A D R  has been  show n to be m ore  po ten t than  
NA in evok ing  ovulation  in the p ro -oestrous rat [5], O ur 
findings would also support the  view recently  put forw ard [6] 
that en d o g en o u s A D R  plays a m ajor role in con tro lling  the 
p re-ovulato ry  LH surge.
T he « 2-adrenerg ic  agonist clonidine has previously been 
found  bo th  to p rev en t ovulation  [3] and to inhibit LH release 
w hen g iven to ovariectom ized  unprim ed  rats [7], A lthough 
our resu lts  d e m o n s tra ted  that clonid ine causes a highly 
significant decrease  in the  hypothalam ic A D R  co n ten t, it is 
also seen  to  bring ab o u t a significant increase in N A  levels in 
th is sam e brain region. It is probable that the  fo rm er effect is 
responsib le  for the  inh ib ito ry  action  o f  clonid ine on o v u la ­
tion and LH release.
T he u;2-an tagonist yoh im bine  has been  show n to have no 
clear-cu t effect on ovu lation  [3], T his is u n d erstandab le  as 
o u r resu lts  have indicated  that a lthough  this d rug signifi­
cantly reduces the hypothalam ic A D R  co n ten t, it does not 
significantly a lte r NA levels in this region.
In sum m ary , o u r findings w ould support the previously 
postu lated  roles for bo th  A D R  and NA in the ev en ts  leading 
to the  p re-ovulatory  LH surge in the  p ro -o estro u s rat.
Table I: N oradrenaline an d  adrenaline content in the hypothalam us (n g /g  wet weight o f  tissues; m eans ±  S T M )
A d ren e rg ic  D ose N o. o f
T re a tm e n t re cep to r type (m g /k g ) rats N o rad re n a lin e A d ren a lin e
G lu co se  (5% ) — 9 1062 ±  130 276 ± 85
G lu co se  (5% ) +  PB - 6 678 ±  9G 30 ± 26a
N o rm al Saline  +  PB - 8 1160 ±  110 173 ± 86
C lo n id in e f  -T PB « 2-agon is t 20 6 1575 ±  120b 6 ± 4 C
Y o h im b in e « 2-agonist 20 5 1166 ±  119 37 ± 13“
S a lb u ta m o l +  PB /f2-agon ist 20 5 851 ±  271 767 ±  1 12C
f e n o te ro l  +  PB /32-agon ist 20 5 1212 ±  165^ 526 ±  1.04*-'
1C 1 1 18. 551 /32-agon ist 20 6 1012 ±  124 17 ± 15a
•D issolved in saline (other drugs dissolved in 5% glucose). In comparison with 5% glucose, p <  ; "P. 05; in comparison with 
saline + PB, p <  : b0.()5, C0.()I; in comparison with 5% glucose +  PB, p <  : d0.()5, <'().()I
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The a p ft if  of opiates on the hypothalamic aminergic content during 
the pre-ovulatory LH surge in the rat
C. Gopalan, C.H. Brown and D.P. Gilmore
Institute o f  Physiology, University o f  Glasgow, Glasgow G12 8QQ, Scotland, U K
T here is now  a g enera l co n sen su s th a t b o th  catecho lam ines 
and in d o leam in es play an im p o rtan t ro le  in th e  p re-ovu la to ry  
release o f lu te in iz ing  h o rm o n e  re leasing  h o rm o n e  (L H R H ) 
[1], P harm acolog ical su p press ion  o f  cen tra l n e u ro tra n sm is­
sion prio r to  th e  critical period  on  p ro -o estru s has co nsist­
ently re su lted  in b lockade  o f  th e  p re -o v u la to ry  L H  surge and 
ovulation  [2].
M o rph ine  has long b een  k n ow n to  inh ib it gonad o tro p h in  
release [3 — 5] by its action  up o n  th e  cen tra l n e rv o u s  system . 
F u rth e rm o re , pep tiderg ic  n e u ro n es  con ta in ing  th e  e n d o ­
genous op io ids /3 -endorph in , en k ep h a lin  and  dy n o rp h in  h ave  
been iden tified  in close p rox im ity  to  th e  L H R H  n e u ro n es  in 
the p reoptic  a rea  o f  th e  ra t h y p o th a lam u s [6]. It has now  
been estab lish ed  th a t several d iffe ren t classes o f opiate 
recep tor sub types ex is t w ith in  th e  m am m alian  b rain . T he 
presen t study  was u n d e rta k en  to  investiga te  how  specific 
opiate recep to r agon ists and  an tag o n ists  (see T able 1) m ight 
alter m o n o am in e  co n cen tra tio n s  in th e  ra t h y p o thalam us and 
thus affect th e  p re -o v u la to ry  L H R H  and  L H  surges. H igh 
perfo rm ance  liquid ch ro m ato g rap h y  w ith e lectrochem ica l 
de tection  (H P L C -E C D ) was em ployed  to  m easu re  am ine  
levels in  th e  h y p o thalam us.
Materials and methods: F em ale  Sprague-D aw ley ra ts 
(200—250 g) w ere  p u rchased  from  T uck  and  Sons, Battles- 
bridge, Essex and h o u sed  in  a te m p e ra tu re  (21 ±  1°C) and  
ligh t-con tro lled  ro o m  (lights on  06:00 — 18:00). Food  and 
w ater w ere  supplied  ad  libitum. D aily vaginal sm ears w ere 
taken  and  only ra ts w hich had  show n at least tw o co n secu tive
4-day cycles w ere  u sed  in th is  study . T h e  ra ts w ere  in jected  
w ith th e  specific recep to r agonist o r an tag o n ist d isso lved  in 
1 m l o f  physiological saline at 12:30 on  th e  a fte rn o o n  o f p ro ­
o estru s  (prior to  th e  p re -o v u la to ry  L H  su rg e). A fter an 
in te rv a l o f 2 h , th e  an im als w ere  d ecap ita ted  and th e  b rains 
rapidly rem o v e d  on  ice. H ypotha lam ic  ex trac ts  w ere  p rep ar­
ed as p rev iously  desc rib ed  [7],
20 fx 1 sam ples o f th e  su p e rn a tan t w ere  in jected  on  to  a 
rev erse  phase H P L C  co lu m n  and  th e  co n cen tra tio n s o f  n o ra ­
d ren alin e  (N A ), ad ren a lin e  (A D R ), d o p am in e  (D A ), se ro ­
to n in  (5-H T ) and its m e tab o lite  5 -hydroxy indo le  acetic acid 
(5 -H IA A ) w ere  sim u ltan eo u sly  m easu red . T h e  so lv en t u sed  
was a c itra te -ace ta te  b u ffer w ith 5% (v /v ) m eth a n o l, 1.2%
(v /v ) te trah y d ro fu ran  and  100 mg/1 sod ium  octyl su lphon- 
ate . T h e  flow ra te  was se t at 1.5 m l/m in .
Results and discussion: T he resu lts  are su m m arized  in 
T able  1. It is apparen t th a t a lthough  th e  low er dose  o f  m o r­
ph ine, a m u  recep to r agonist, raised  D A  levels in th e  hypo­
th a lam u s, it d id  n o t significantly a lte r levels o f  the  o th e r 
am in es p resen t in th is region. In co n trast, th e  h igher dose  o f 
m o rp h in e  and lev o rp h an o l, an o th e r m u  recep to r agonist, 
significantly low ered th e  hypothalam ic co n ten t o f bo th  N A  
and  5-H T while th e  m u  recep to r an tagon ist na loxone  signifi­
cantly increased  hypothalam ic N A  levels. Both cyclazocine 
and  ketocyclazocine (kappa recep to r agonists) b ro u g h t about 
very significant increases in th e  hypothalam ic indoleam ine 
co n te n t, bu t only th e  la tte r significantly affected  N A  levels in 
th is  reg ion . A n o th e r kappa recep to r agonist, tifluadom , was 
th e  only opiate to  significantly low er A D R  levels in the 
h y p o thalam us, w hile at the  sam e tim e it caused th e  D A  
co n ten t to  be significantly e levated . SK F 10,047 (a sigm a 
agonist) significantly raised  levels o f  D A , 5-HT and  5-HIA A.
T he en d o g en o u s opioids have been  show n to m odu la te  
th e  action  o f a variety  o f n eu ro tran sm itte rs  in the  central 
n e rv o u s  system , in particu lar, th e  biogenic am ines N A , D A  
and 5-H T [8]. N A  is know n to play an excitatory  role in 
L H R H  and LH  release, and by decreasing the  hyothalam ic 
co n te n t o f  th is n e u ro tra n sm itte r  m o rph ine  is able to  block 
ovu la tio n  in p ro -o estro u s ra ts [9]. In th is study , we no ted  
th at th e  decrease  in hypothalam ic N A  that occurred  after 
m o rp h in e  and levorphano l trea tm e n t could be reversed  by 
na loxone . On th e  o th e r h and , kappa and sigm a receptor 
agonists failed to  reduce  hypothalam ic NA levels; k e to ­
cyclazocine ev en  significantly  raised  these.
A cute  adm in istra tio n  o f m o rp h in e  (10 m g/kg) has been 
show n to  increase  th e  brain  tu rn o v e r  o f D A  [10]. O ur studies 
using a sim ilar dose  o f  th is opiate b rough t about a significant 
e levation  in D A  levels.
5-HT has b een  rep o rted  to  have a perm issive action on the 
p re -ovu la to ry  gonad o tro p h in  surge in rat. N u m ero u s studies 
indicate that m o rp h in e  can affect the actions o f 5-HT on 
gon ad o tro p h in  release. It has been  suggested  that the  e n d o ­
genous opioid pep tides s tim u la te  5-HT tu rn o v er in the  p re ­
optic area  o f  th e  hypothalam us [11]. Such a theory  is sup-
Treatm ent
I Physiological 
saline 
M orphine 
M orphine 
N aloxone 
Levorphanol 
Cyclazocine 
kKfetocyclazocine 
Physiological 
saline3 
SKF 10,0473 
Tifluadom3
Table 1: Biogenic amine concentrations in the rat hypothalamus (ng/ g wet weight o f  tissue; means ±  SEM )
D A  5-H T
9
5
13
8
10
10
10
10
9
Opiate receptor 
type
Dose
(m g/kg) N A A D R
M u-agonist
M u-agonist
M u-antagonist
M u-agonist
Kappa-agonist
Kappa-agonist
Sigma agonist 
Kappa agonist
5-H IA A
1455 ± 86 27 ± 6 188 ±  13 782 ± 62 643 ± 69
10 1856 ±  185 70 ±  26 309 ±  40** 996 ± 68 714 ±  105
50 1078 ± 69** 13 ± 3 257 ±  29 416 ±
41** 377 ± 32**
10 1830 ±  132* 25 ± 6 226 ±  28 763 ± 75 446 ±  106
10 1114 ± 70* 15 ± 2 234 ±  21 543 ± 44* 567 ± 74
5 1650 ± 62 22 ± 3 212 ±  15 1258 ± 130** 898 ± 32**
5 1752 ± 80* 21 ± 2 221 ±  24 1099 ± 62** 928 ± 31**
1444 ± 93 23 ± 3 174 ±  10 1048 ± 79 650 ± 66
10 1514 ± 63 29 ± 7 275 ±  13** 1530 ± 92** 941 ± 74*
10 1517 ± 64 8 ± 3* 237 ±  18* 907 ± 74 765 ± 45
“Administered subcutaneously; all others administered intraperitoneally. n =  number o f  animals in each treatment group. In comparison with the control 
value, p <  ; *0.05; **0.01 (unpaired t test).
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p o rted  by th e  e ffec ts o b se rv ed  o n  h y p o th a lam ic  in d o le a m in e  
lev e ls  a fte r  th e  a d m in is tra tio n  o f  cyclazoc ine , ke tocyclazo- 
c ine  an d  S K F  10,047.
O n e  u n e x p e c te d  fin d in g  o f  th e  s tu d y  w as th a t h y p o ­
th a lam ic  5-H T  leve ls w ere  sign ifican tly  h ig h e r in  th e  c o n tro ls  
in jec ted  su b c u tan e o u sly  th a n  in th o se  g iv en  saline  in tra - 
p e rito n ea lly . S u b c u tan e o u s  in jec tio n s a re  likely  to  re su lt in 
so m e  d isc o m fo rt an d  fo r th is  re a so n  th ey  w ere  alw ays 
a d m in is te re d  to  ra ts  w hich  h ad  first b e en  p laced u n d e r  light 
e th e r  an aesth es ia . H o w ev e r, e th e r  in h a la tio n  is k n o w n  to 
cau se  m ild  s tre ss  and  stre ss  its e lf  has b e en  sh o w n  to  lead  to  
an  in crease  in  b ra in  5 -H T  leve ls [12].
A lth o u g h , at p re se n t, little  in fo rm a tio n  is availab le  on  th e  
e ffec ts  o f  specific o p ia te  re ce p to r ag o n is ts  o n  b iogen ic  am in e  
c o n c e n tra tio n s  in  th e  b ra in , s tu d ie s  on  L H  leve ls d u rin g  th e  
p re -o v u la to ry  su rg e  in d ica te  th a t a c tiv a tio n  o f  m u , kappa and  
sigm a re ce p to rs  in h ib it L H  re lease  [12, 13]. T h is in h ib itio n  
m ay  in v o lv e  th e  p a rtic ip a tio n  o f  N A , D A  and  5-H T  c o n ta in ­
ing n e u ro n a l sy s te m s w hich  a re  a ffec ted  by ex o g en o u s  
op iates.
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